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Preamble
It is essential that the medical profession play a central role in
critically evaluating the evidence related to drugs, devices,
and procedures for the detection, management, or prevention
of disease. Properly applied, rigorous, expert analysis of the
available data documenting absolute and relative benefits and
risks of these therapies and procedures can improve
outcomes and reduce costs of care by focusing resources
on the most effective strategies. One important use of such
data is the production of clinical practice guidelines that, in
turn, can provide a foundation for a variety of other
applications such as performance measures, appropriate
use criteria, clinical decision support tools, and quality
improvement tools.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly en-
gaged in the production of guidelines in the area of cardiovas-
cular disease since 1980. The ACCF/AHA Task Force on
Practice Guidelines is charged with developing, updating, and
revising practice guidelines for cardiovascular diseases and
procedures, and the Task Force directs and oversees this effort.
Writing committees are charged with assessing the evidence as
an independent group of authors to develop, update, or revise
recommendations for clinical practice.
Experts in the subject under consideration have been selected
from both organizations to examine subject-specific data and
write guidelines in partnership with representatives from other
medical practitioner and specialty groups. Writing committees
are specifically charged to perform a formal literature review,
weigh the strength of evidence for or against particular treat-
ments or procedures, and include estimates of expected health
outcomes where data exist. Patient-specific modifiers, comor-
bidities, and issues of patient preference that may influence the
choice of tests or therapies are considered. When available,
information from studies on cost is considered, but data on
efficacy and clinical outcomes constitute the primary basis for
recommendations in these guidelines.
The ACCF/AHA Task Force on Practice Guidelines makes
every effort to avoid actual, potential, or perceived conflicts
of interest that may arise as a result of industry relationships
or personal interests among the writing committee. Specifi-
cally, all members of the writing committee, as well as peer
reviewers of the document, are asked to disclose all current
relationships and those 24 months prior to initiation of the
writing effort that may be perceived as relevant. All guideline
recommendations require a confidential vote by the writing
committee and must be approved by a consensus of the
members voting. Members who were recused from voting are
noted on the title page of this document. Members must
recuse themselves from voting on any recommendation
where their relationships with industry (RWI) apply. If a
writing committee member develops a new relationship with
industry during his/her tenure, he/she is required to notify
guideline staff in writing. These statements are reviewed by
the Task Force on Practice Guidelines and all members during
each conference call and/or meeting of the writing committee,
updated as changes occur, and ultimately published as an
appendix to the document. For detailed information regarding
guideline policies and procedures, please refer to the methodol-
ogy manual for ACCF/AHA Guideline Writing Committees.1
RWI and other entities pertinent to this guideline for authors and
peer reviewers are disclosed in Appendixes 1 and 2, respec-
tively. Disclosure information for the ACCF/AHA Task Force
on Practice Guidelines is also available online at (http://www.acc.
org/about/overview/ ClinicalDocumentsTaskForces.cfm).
These practice guidelines are intended to assist healthcare
providers in clinical decision making by describing a range of
generally acceptable approaches for diagnosis, management,
and prevention of specific diseases or conditions. Clinicians
should consider the quality and availability of expertise in the
area where care is provided. These guidelines attempt to
define practices that meet the needs of most patients in most
circumstances. The recommendations reflect a consensus
after a thorough review of the available current scientific
evidence and are intended to improve patient care. The Task
Force recognizes that situations arise where additional data
are needed to better inform patient care; these areas will be
identified within each respective guideline when appropriate.
Patient adherence to prescribed and agreed upon medical
regimens and lifestyles is an important aspect of treatment.
Prescribed courses of treatment in accordance with these recom-
mendations are effective only if they are followed. Because lack
of patient understanding and adherence may adversely affect
outcomes, physicians and other healthcare providers should
make every effort to engage the patient’s active participation in
prescribed medical regimens and lifestyles.
If these guidelines are used as the basis for regulatory or
payer decisions, the goal should be improvement in quality of
care and aligned with the patient’s best interest. The ultimate
judgment regarding care of a particular patient must be made
by the healthcare provider and the patient in light of all of the
circumstances presented by that patient. Consequently, there
are circumstances in which deviations from these guidelines
are appropriate.
The guidelines will be reviewed annually by the ACCF/
AHA Task Force on Practice Guidelines and considered
current unless they are updated, revised, or withdrawn
from distribution.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
Sidney C. Smith, Jr, MD, FACC, FAHA
Immediate Past Chair, ACCF/AHA Task Force on
Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Review
The writing committee conducted a comprehensive search of
the medical and scientific literature through the use of
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PubMed/MEDLINE. Searches were limited to publications
written in the English language. Compiled reports were
reviewed and additional articles were provided by committee
members. Specifically targeted searches were conducted on
the following subtopics: acute aortic dissection, ankylosing
spondylitis, aortic dissection and litigation, aortic neoplasm,
aortic tumors, Behc¸et disease, bicuspid aortic valve, calcified
aorta, chronic dissection, coarctation of the aorta, D-dimer,
dissecting aneurysm, Ehlers-Danlos syndrome, endovascular
and aortic aneurysms, medial degeneration, porcelain aorta,
giant cell arteritis, imaging and thoracic aortic disease,
inflammatory disease, intramural hematoma, Loeys-Dietz
syndrome, Marfan syndrome, Noonan syndrome, penetrating
aortic ulcer, polycystic kidney disease, thoracic and aortic
aneurysms, thoracic aortic disease and patient care, thoracic
aortic disease and surgery, thoracic aorta and Kawasaki
disease, Takayasu arteritis, thoracoabdominal and aorta or
aortic disease, and Turner syndrome. More than 850 refer-
ences were reviewed, with 830 used as the primary evidence
base for the final guideline. The ACCF/AHA Task Force on
Practice Guidelines methodology processes were followed to
write the text and recommendations. In general, published
manuscripts appearing in journals listed in Index Medicus
were used as the evidence base. Published abstracts were used
only for emerging information but were not used in the
formulation of recommendations.
The committee reviewed and ranked evidence supporting
current recommendations with the weight of evidence ranked
as Level A if the data were derived from multiple randomized
clinical trials or meta-analyses. The committee ranked avail-
able evidence as Level B when data were derived from a
single randomized trial or nonrandomized studies. Evidence
was ranked as Level C when the primary source of the
recommendation was consensus opinion, case studies, or
standard of care. In the narrative portions of these guidelines,
evidence is generally presented in chronological order of
development. Studies are identified as observational, retro-
spective, prospective, or randomized. For certain conditions
for which inadequate data are available, recommendations are
based on expert consensus and clinical experience and are
ranked as Level C. An analogous example is the use of
penicillin for pneumococcal pneumonia, where there are no
randomized trials and treatment is based on clinical experi-
ence. When recommendations at Level C are supported by
historical clinical data, appropriate references (including
clinical reviews) are cited if available. For issues where
sparse data are available, a survey of current practice among
the clinicians on the writing committee formed the basis for
Level C recommendations and no references are cited. The
schema for classification of recommendations and level of
evidence is summarized in Table 1, which also illustrates how
the grading system provides an estimate of the size of the
treatment effect and an estimate of the certainty of the
treatment effect.
To provide clinicians with a comprehensive set of data,
whenever possible, the exact event rates in various treatment
arms of clinical trials are presented to permit calculation of
the absolute risk difference (ARD), number needed to harm
(NNH); the relative treatment effects are described either as
odds ratio (OR), relative risk (RR), or hazard ratio (HR)
depending on the format in the original publication. Along
with all other point statistics, confidence intervals (CIs) for
those statistics are added when available.
The writing committee recognized that the evidence base
for this guideline is less robust in terms of randomized
clinical trials than prior ACCF/AHA guidelines, particularly
those focused on coronary artery disease (CAD) and heart
failure. As the reader will discern, much of the evidence base
for this topic consists of cohort studies and retrospective
reviews, which largely emanate from centers with a special-
ized interest in specific types of thoracic aortic disease. The
writing committee attempted to focus on providing the
practitioner with recommendations for evaluation and treat-
ment wherever possible and where controversy exists, iden-
tified as such in the text.
The writing committee acknowledges the expertise of the
highly experienced and effective practice guidelines staff of
the ACCF and AHA. The writing committee chair also
acknowledges the commitment and dedication of the diverse
writing committee members who were able to put aside issues
of specialty “turf” and focus on providing the medical
community with a guideline aimed at optimal patient care.
1.2. Organization of the Writing Committee
The guideline was written by a committee comprised of
experts in cardiovascular medicine, surgery, radiology, and
nursing. For many of the previous ACCF/AHA practice
guidelines, writing expertise has been available within these 2
organizations. Because of the broad scope and diversity of
thoracic aortic diseases, as well as the specialists who treat
such patients, the ACCF and AHA sought greater involve-
ment from many specialty organizations. Most, but not all,
specialty organizations that represent the major stakeholders
caring for patients with thoracic aortic diseases provided
writing committee members and financial support of the
project, and they are recognized as marquee level partners
with the ACCF and AHA. These organizations included the
American Association for Thoracic Surgery (AATS), Amer-
ican College of Radiology (ACR), American Stroke Associ-
ation (ASA), Society of Cardiovascular Anesthesiologists
(SCA), Society for Cardiovascular Angiography and Inter-
ventions (SCAI), Society of Interventional Radiology (SIR),
Society of Thoracic Surgeons (STS), and Society for Vascu-
lar Medicine (SVM). The American College of Emergency
Physicians (ACEP) and the American College of Physicians
(ACP) were also represented on the writing committee.
Where additional expertise was needed, the scientific coun-
cils of the AHA were contacted for writing committee
representatives. Representation was provided or facilitated by
the Councils on Cardiovascular Nursing, Cardiovascular
Surgery and Anesthesia, Cardiovascular Radiology and Inter-
vention, and Clinical Cardiology, Council for High Blood
Pressure Research, and Stroke Council.
1.3. Document Review and Approval
This document was reviewed by 3 outside reviewers nomi-
nated by the ACCF and 2 outside reviewers nominated by the
AHA, as well as 1 or 2 reviewers from each of the following
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organizations: the AATS, ACP, ACEP, ACR, ASA, SCA,
SCAI, SIR, STS, and the SVM. It was also reviewed by 6
individual content reviewers—2 content reviewers from the
ACCF Catherization Committee and 1 content reviewer from
the ACCF Interventional Council. All reviewer RWI infor-
mation was collected and distributed to the writing committee
and is published in this document (see Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACCF and the AHA and the AATS,
ACEP, ACR, ASA, SCA, SCAI, SIR, STS, and SVM and
was endorsed by the North American Society for Cardiovas-
cular Imaging.
1.4. Scope of the Guideline
The term “thoracic aortic disease” encompasses a broad range
of degenerative, structural, acquired, genetic-based, and trau-
matic disease states and presentations. According to the
Centers for Disease Control and Prevention death certificate
data, diseases of the aorta and its branches account for 43 000
to 47 000 deaths annually in the United States.2 The precise
number of deaths attributable to thoracic aortic diseases is
unclear. However, autopsy studies suggest that the presenta-
tion of thoracic aortic disease is often death due to aortic
dissection (AoD) and rupture, and these deaths account for
twice as many deaths as attributed to ruptured abdominal
aortic aneurysms (AAAs).3 The diagnosis of acute thoracic
AoD or rupture is often difficult and delayed, and errors in
diagnosis may account for deaths otherwise attributed to
cardiac arrhythmia, myocardial infarction (MI), pulmonary
embolism, or mesenteric ischemia.
The University HealthSystem Consortium (UHC) is an
alliance of more than 100 academic medical centers and
Table 1. Applying Classification of Recommendations and Level of Evidence
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior
myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak.
Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may
be a very clear clinical consensus that a particular test or therapy is useful or effective.
†In 2003, the ACCF/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline
recommendations have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from
the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will
increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
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affiliate hospitals. UHC’s Clinical DataBase/Resource Man-
ager allows comparison of patient-level risk-adjusted out-
comes for performance improvement. The UHC provided the
writing committee with a summary of recent information
based on ICD-9 codes for thoracic aortic disease–related
hospitalizations from the Clinical DataBase/Resource Man-
ager (Tables 2A and 2B). This data table demonstrates a high
number of hospital discharges (more than 135 000) for
thoracic, abdominal, thoracoabdominal, and “unspecified”
aortic aneurysms in the 5-year period between 2002 and
2007. Subcategories include those with dissection, those with
rupture, and those with neither. In the most recent 1-year
period assessed (fourth quarter 2006 through third quarter
2007), there were nearly 9000 cases representing all patients
with thoracic aortic disease discharged from UHC hospitals.
Although these data are unavailable for the entire United
States, they provide important estimates of the magnitude of
the prevalence of thoracic aortic disease. Additional informa-
tion regarding the patient admission source, particularly those
with acute presentations, is pertinent to the discussion regard-
ing interinstitutional transfer (see Section 17.2).
Most patients with significant thoracic aortic disease will
be directed to specialized practitioners and institutions. How-
ever, the importance of early recognition and prompt treatment
and/or referral for various thoracic aortic diseases by all health-
care professionals provides the rationale for this document. This
guideline will attempt to provide the practitioner with a suffi-
cient description of background information, diagnostic modal-
ities, and treatment strategies so that appropriate care of these
patients can be facilitated and better understood. The goal of this
Table 2A. ICD-9 Procedure Codes For Aortic Aneurysms
Aortic Aneurysm
Category Dissection Ruptured
No Mention of
Rupture
Thoracic 441.01 441.1 441.2
Abdominal 441.02 441.3 441.4
Thoracoabdominal 441.03 441.6 441.7
Aortic (unspecified) 441.00 441.5 441.9
Table courtesy of UHC Clinical DataBase/Resource Manager.
Table 2B. Number of Discharges by Year by Category of Aortic Aneurysm Among Academic Medical Centers Reporting Data to the
UHC Clinical Database*
Aortic Aneurysm
Category 2002q4–2003q3 2003q4–2004q3 2004q4–2005q3 2005q4–2006q3 2006q4–2007q3
5-Year
Total
Category %
Distribution
% of All
Categories
Thoracic 25.9
Dissection 1607 1683 2028 2321 2355 9994 28.5
Ruptured 187 225 219 234 251 1116 3.2
No mention of
rupture
3086 4026 4953 5730 6156 23 954 68.3
Subtotal 4880 5934 7200 8285 8762 35 064
Abdominal 62.7
Dissection 553 630 747 867 867 3664 4.3
Ruptured 651 657 720 734 702 3464 4.1
No mention of
rupture
12 075 13 280 15 882 17 818 18 683 77 738 91.6
Subtotal 13 279 14 567 17 349 19 419 20 252 84 866
Thoracoabdominal 8.3
Dissection 583 587 674 755 834 3433 30.5
Ruptured 150 129 110 157 127 673 6.0
No mention of
rupture
1091 1183 1472 1621 1773 7140 63.5
Subtotal 1824 1899 2256 2533 2734 11 246
Aortic (unspecified) 3.0
Dissection 223 310 326 343 339 1541 37.6
Ruptured 9 3 15 9 9 45 1.1
No mention of
rupture
310 385 505 612 701 2513 61.3
Subtotal 542 698 846 964 1049 4099
Total No. of cases 20 525 23 098 27 651 31 201 32 797 135 275
Total No. of
inpatient
discharges
2 679 334 2 777 880 3 018 141 3 222 542 3 297 834 14 995 731
UHC indicates University HealthSystem Consortium.
*Note: Year-to-year increases are due in part to changes in number of reporting hospitals.
Table courtesy of UHC Clinical DataBase/Resource Manager.
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guideline is to improve the health outcomes and quality of life
for all patients with thoracic aortic disease.
Other practice guidelines developed by ACCF and AHA
address the management of patients with cardiac and
vascular diseases. The ACCF/AHA guidelines on periph-
eral arterial disease4 include recommendations for lower
extremity, renal, mesenteric, and abdominal aortic dis-
eases. Data standards on this topic are currently in devel-
opment, as is a practice guideline on extracranial carotid
and vertebral artery diseases. The ACCF/AHA guidelines
are published in the Journal of the American College of
Cardiology and Circulation and are available on both the
ACC (www.acc.org) and AHA (my.americanheart.org)
Web sites.
This guideline includes diseases involving any or all parts
of the thoracic aorta with the exception of aortic valve
diseases5 and includes the abdominal aorta when contiguous
thoracic aortic diseases are present. Specific disease states are
described in the following sections, and the reader is referred
to the glossary of terminology in Section 1.5 and Appendix 3
for abbreviations used throughout the guideline.
The reader will note that several topics or referenced areas
may appear more than once throughout the guideline. This
will appear to be redundant to those who choose to read the
entire document, but the writing committee believed that
because of the multidisciplinary nature of and organizational
involvement in this project, individuals representing specific
disciplines may choose to read and extract portions of the
document for their own use. Inclusion of the narrative text
and references was thought to be appropriate to facilitate a
more complete understanding for these disciplines and indi-
viduals. Accordingly, the organization of the guideline is
meant to be less of a textbook presentation of the various
topics but rather a more clinically oriented document appli-
cable to a variety of disciplines.
1.4.1. Critical Issues
As the writing committee developed this guideline, several
critical issues emerged:
● Thoracic aortic diseases are usually asymptomatic and not
easily detectable until an acute and often catastrophic
complication occurs. Imaging of the thoracic aorta with
computed tomographic imaging (CT), magnetic resonance
imaging (MR), or in some cases, echocardiographic exam-
ination is the only method to detect thoracic aortic diseases
and determine risk for future complications (see Section 4).
● Radiologic imaging technologies have improved in terms
of accuracy of detection of thoracic aortic disease. How-
ever, as the use of these technologies has increased, so also
has the potential risk associated with repeated radiation
exposure, as well as contrast medium–related toxicity.
Whether these technologies should be used repeatedly as a
widespread screening tool is discussed in Section 4. In
addition, the writing committee formulated recommenda-
tions on a standard reporting format for thoracic aortic
findings as discussed in Section 4.5.
● Imaging for asymptomatic patients at high risk based on
history or associated diseases is expensive and not always
covered by payers.
● For many thoracic aortic diseases, results of treatment for
stable, often asymptomatic, but high-risk conditions are far
better than the results of treatment required for acute and
often catastrophic disease presentations. Thus, the identifi-
cation and treatment of patients at risk for acute and
catastrophic disease presentations (eg, thoracic AoD, tho-
racic aneurysm rupture) prior to such an occurrence are
paramount to eliminating the high morbidity and mortality
associated with acute presentations (see Section 8.1).
● A subset of patients with acute AoD are subject to missed
or delayed detection of this catastrophic disease state.
Many present with atypical symptoms and findings, mak-
ing diagnosis even more difficult (see Sections 8.1.4 and
8.6). This issue has come under greater medical-legal
scrutiny, and specific cases have been widely discussed in
the public domain. Widespread awareness of the varied and
complex nature of thoracic aortic disease presentations has
been lacking, especially for acute AoD. Risk factors and
clinical presentation clues are noted in Section 8.1.4. The
collaboration and cosponsorship of multiple medical special-
ties in the writing of this guideline will provide unique
opportunities for widespread dissemination of knowledge to
raise the level of awareness among all medical specialties.
● There is rapidly accumulating evidence that genetic alter-
ations or mutations predispose some individuals to aortic
diseases (see Section 5). Therefore, identification of the
genetic alterations leading to these aortic diseases has the
potential for early identification of individuals at risk. In
addition, biochemical abnormalities involved in the pro-
gression of aortic disease are being identified through
studies of patients’ aortic samples and animal models of the
disease.6,7 The biochemical alterations identified in the
aortic tissue have the potential to serve as biomarkers for
aortic disease. Understanding the molecular pathogenesis
may lead to targeted therapy to prevent aortic disease.
Medical and gene-based treatments are beginning to show
promise for reducing or delaying catastrophic complica-
tions of thoracic aortic diseases (see Section 9.2).
● As noted in Section 18, there are several areas where
greater resources for research and both short- and long-
term outcomes registries are needed.
1.5. Glossary of Terms and Abbreviations Used
Throughout Guideline
Aneurysm (or true aneurysm): a permanent localized dila-
tation of an artery, having at least a 50% increase in
diameter compared with the expected normal diameter of
the artery in question. Although all 3 layers (intima, media,
and adventitia) may be present, the intima and media in
large aneurysms may be so attenuated that in some sections
of the wall they are undetectable.
Pseudoaneurysm (or false aneurysm): contains blood re-
sulting from disruption of the arterial wall with extravasa-
tion of blood contained by periarterial connective tissue
and not by the arterial wall layers (see Section 8.4). Such
an extravascular hematoma that freely communicates with
the intravascular space is also known as a pulsating
hematoma.8–10
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Ectasia: arterial dilatation less than 150% of normal arterial
diameter.
Arteriomegaly: diffuse arterial dilatation involving several
arterial segments with an increase in diameter greater than
50% by comparison to the expected normal arterial
diameter.
Thoracoabdominal aneurysm (TAA): aneurysm involving
the thoracic and abdominal aorta (see Section 9.2.2.3).
Abdominal aortic aneurysm (AAA): aneurysm involving
the infradiaphragmatic abdominal aorta.
Aortic dissection (AoD): disruption of the media layer of the
aorta with bleeding within and along the wall of the aorta.
Dissection may, and often does, occur without an aneu-
rysm being present. An aneurysm may, and often does,
occur without dissection. The term “dissecting aortic an-
eurysm” is often used incorrectly and should be reserved
only for those cases where a dissection occurs in an
aneurysmal aorta (see Section 8.1).
2. The Thoracic Aorta
2.1. The Normal Aorta
The thoracic aorta is divided into 4 parts: the aortic root
(which includes the aortic valve annulus, the aortic valve
cusps, and the sinuses of Valsalva); the ascending aorta
(which includes the tubular portion of the ascending aorta
beginning at the sinotubular junction and extending to the
brachiocephalic artery origin); the aortic arch (which begins
at the origin of the brachiocephalic artery and is the origin of
the head and neck arteries, coursing in front of the trachea and
to the left of the esophagus and the trachea); and the
descending aorta (which begins at the isthmus between the
origin of the left subclavian artery and the ligamentum
arteriosum and courses anterior to the vertebral column, and
then through the diaphragm into the abdomen).
The normal human adult aortic wall is composed of 3
layers, listed from the blood flow surface outward (Figure 1):
Intima: endothelial layer on a basement membrane with
minimal ground substance and connective tissue.
Media: bounded by an internal elastic lamina, a fenestrated
sheet of elastic fibers; layers of elastic fibers arranged
concentrically with interposed smooth muscle cells;
bounded by an external elastic lamina, another fenestrated
sheet of elastic fibers.
Adventitia: resilient layer of collagen containing the vasa
vasorum and nerves. Some of the vasa vasorum can
penetrate into the outer third of the media.
2.2. Normal Thoracic Aortic Diameter
In 1991, the Society for Vascular Surgery created a table
(Table 3) describing the normal diameter of the adult thoracic
aorta based on CT and chest x-ray.12
Since then, it has been recognized that the “normal aortic
diameter” is influenced by a number of factors, including
patient age, sex, and body size; location of aortic measure-
ment; method of measurement; and the robustness and type of
imaging methods used. Hannuksela et al13 noted that diameter
increased by 0.12 to 0.29 mm/y at each level measured by CT
for 41 men and 36 women aged 18 to 82 years (Figure 2).
Aortic diameter for men was larger than that for women, but
the difference decreased with age. Body mass index also
affected aortic diameter by 0.27 mm (0.14 to 0.44 mm) per
unit of body mass index.13
Aortic diameter gradually tapers downstream from the
sinuses of Valsalva. Hager et al14 examined 46 men and 24
Figure 1. Aortic pathology associated with tho-
racic aortic aneurysm involving the ascending
aorta. All panels are identically oriented with the
adventitia at the top and the intima at the bottom.
H&E staining of aortic sections from a control (a)
and a patient (b) with a TAA demonstrates medial
degeneration with the fragmentation of elastic
fibers, accumulation of proteoglycans, and regions
of smooth muscle cell loss. Movat staining of aor-
tic sections from control (c) and patient with an
aneurysm (d) shows fragmentation of elastic fibers
(stained black), loss of smooth muscle cells (cells
stained red and nuclei stained violet), and accu-
mulation of proteoglycans (stained blue) in the
medial layer. 40 magnification; scale bars repre-
sent 500 mcg. H&E indicates hematoxylin and
eosin; and TAA, thoracic aortic aneurysm. Modi-
fied from Milewicz et al.11
Table 3. Normal Adult Thoracic Aortic Diameters
Thoracic Aorta
Range of Reported
Mean (cm)
Reported
SD (cm)
Assessment
Method
Root (female) 3.50 to 3.72 0.38 CT
Root (male) 3.63 to 3.91 0.38 CT
Ascending
(female, male)
2.86 NA CXR
Mid-descending
(female)
2.45 to 2.64 0.31 CT
Mid-descending
(male)
2.39 to 2.98 0.31 CT
Diaphragmatic
(female)
2.40 to 2.44 0.32 CT
Diaphragmatic
(male)
2.43 to 2.69 0.27 to 0.40 CT, arteriography
CT indicates computed tomographic imaging; CXR, chest x-ray; and NA, not
applicable. Reprinted with permission from Johnston et al.12
Hiratzka et al 2010 Guidelines on Thoracic Aortic Disease e275
D
ow
nloaded from
 http://ahajournals.org by on August 16, 2018
women without cardiovascular disease (age range 1 to 89
years; mean age 50.2 years) using helical CT (Figure 3). For
these patients, there was no correlation with weight, height, or
body surface area, but aortic diameter increased with age and
was larger for men than for women.14
Two-dimensional echocardiography has been used to de-
fine the “normal” range for aortic diameter at the sinuses of
Valsalva in different age categories (and stratified by body
surface area).15 Adjusting for 2 of the key determinants of
aortic diameter allows a more precise characterization of
aortic size in otherwise healthy individuals15 (Figure 4).
Again, age and sex affected aortic root diameter, but the
influence of sex was neutralized when diameter was indexed
to body surface area (Table 4).
These tables and definitions help define the presence or
absence of a thoracic aortic aneurysm and help define the
threshold for considering further treatment for such patients.
However, patients with certain genetic syndromes and abnormal
tissue morphology may in fact have a normal aortic diameter at
the time of acute AoD rupture (see Section 5.1.2). Another
challenge relates to abnormal morphology of one aortic segment
compared with another. For example, if the diameter of the
ascending aorta exceeds the diameter of the aorta at the level of
the sinuses Valsalva, even if both are within normal range, then
the ascending aorta is considered to be enlarged. To adjust for
body habitus variation, the use of aortic diameter indexed to
height has been reported to better indicate surgical timing than
might be recommended from aortic diameter alone for an
otherwise asymptomatic patient with Marfan syndrome or bi-
cuspid aortic valve.16 Whenever possible, the writing committee
has inserted aortic diameter thresholds for further action,
whether the action is for continued surveillance or for endovas-
cular or surgical intervention.
3. Thoracic Aortic Histopathology
3.1. Atherosclerosis
Atherosclerosis is characterized by intimal lesions called
atheromata, or atheromatous or fibrofatty plaques, which
protrude into the arterial lumen and weaken the underlying
media often associated with calcification. With aging, pres-
ence of risk factors, and genetic predisposition, this
progresses to complicated lesions with surface defects, hem-
orrhage, and/or thrombosis. A 1995 consensus document
from the AHA defines the types and histologic classes of
atherosclerosis17 (Figure 5).
Thoracic aortic atherosclerosis is less common than abdominal
aortic atherosclerosis, but the clinical importance is great. Clinical
presentations and problems associated with aortic atherosclerosis
and atheroma are discussed extensively in Section 11.
3.2. Aneurysms and Dissections
The pathology associated with thoracic aortic aneurysms and
dissections was initially termed cystic medial necrosis but
this term is a misnomer; the disease is not associated with
necrosis of the aorta or with cyst formation. Aortic aneurysm
histopathology, more accurately termed medial degeneration,
is characterized by disruption and loss of elastic fibers and
increased deposition of proteoglycans (Figure 1). Typically,
there are areas of loss of smooth muscle cells in the aortic
media, but whether there is a total loss of smooth muscle cells
in the aortic wall is not clear. There can be atherosclerosis
lesions present, but again, these changes are typically super-
imposed on medial degenerative disease. Although medial
degeneration was initially described as a noninflammatory
Figure 2. Normal diameter and upper limit of ascending and
descending aorta related to age. Reprinted with permission from
Hannuksela et al.13
Figure 3. Mean aortic diameters (in cm) at various
levels measured by helical CT in 70 adults. Thin
lines represent 2 SDs, representing 95% refer-
ence area. CT indicates computed tomographic
imaging; and SD, standard deviation. Reprinted
with permission from Hager et al.14
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disease, recent literature supports the presence of inflamma-
tory cell infiltration in this disease.18,19
The biochemical pathways and proteins involved with medial
degeneration have not been clearly delineated. However, multi-
ple studies have found increased immunostaining for a subset of
matrix metalloproteinases (MMPs) in the media of thoracic
aortic aneurysms, particularly MMP-2 and MMP-9.20–23 Immu-
nostaining of aortic media from patients with Marfan syndrome
has demonstrated increases in MMP-2 and MMP-9, which were
associated with smooth muscle cells at the borders of areas of
medial degeneration and on the surface of disrupted elastic
fibers. Elevated MMP-2 and MMP-9 immunostaining has been
demonstrated in ascending aneurysms from patients with either
tricuspid or bicuspid aortic valves21,23 and inconsistently in
ascending aortic tissue from patients with tricuspid aortic
valves.22 These 2 MMPs are known to have elastolytic activity.
Variable expression of MMPs and tissue inhibitors of MMPs has
also been demonstrated in aortic tissue of patients with Marfan
syndrome versus patients without Marfan syndrome.24 Although
accumulation of proteoglycans in the aortic media is another
consistent finding in thoracic aortic aneurysms, no studies have
determined why this accumulation occurs or whether these are
causative in nature.
Medial degeneration is also associated with focal loss of
vascular smooth muscle cells. Although there are regions of
smooth muscle cell loss, morphometric analysis of aortic tissue
has suggested that hyperplastic cellular remodeling of the media
in ascending thoracic aortic aneurysms may be an initial adap-
tive response to minimize increased wall stress resulting from
vascular dilatation.25 More recent studies of the aortic pathology
associated with myosin heavy chain 11, smooth muscle
(MYH11), and actin, alpha 2, smooth muscle aorta (ACTA2)
mutations leading to ascending aortic aneurysms demonstrate a
hyperplastic response by smooth muscle cells in the aortic
media. The aortic media in aneurysm tissue taken from patients
harboring mutations in these genes demonstrated focal hyper-
plasia associated with smooth muscle cells that were remarkable
for a lack of structured orientation parallel to the lumen of the
aorta, but instead, the smooth muscle cells were oriented
randomly with respect to one another.26,27
3.3. Vasculitis and Inflammatory Diseases
A variety of inflammatory vasculitides may also result in
thoracic aortic disease. These include giant cell arteritis
(GCA), Takayasu arteritis, and Behc¸et disease (see Section
7). The pathophysiology of GCA shares important features
with Takayasu arteritis.28 T-cell clonal expansion suggests a
specific antigenic response, which currently remains unelu-
cidated. The inflammatory response, which begins in the
Figure 4. Sinus of Valsalva diameter, by
body surface area. Left, The 95% normal
confidence limits for aortic root diameter
at the sinuses of Valsalva in relation to
body surface area in adults 40 years of
age. Right, The 95% normal confidence
limits for the proximal ascending aortic
diameter in relation to body surface area
in adults 40 years of age. SEE indicates
standard error of the estimate. Reprinted
with permission from Roman et al.15
Table 4. Sex Differences in Aortic Root Dimensions in Adults
Aortic Root
Absolute
Values (cm) Men P Value Women
Indexed
Values (cm/m2) Men P Value Women
Annulus 2.60.3 0.001 2.30.2 1.30.1 NS 1.30.1
Sinuses of Valsalva 3.40.3 0.001 3.00.3 1.70.2 NS 1.80.2
Sinotubular junction 2.90.3 0.001 2.60.3 1.50.2 NS 1.50.2
Proximal ascending aorta 3.00.4 0.001 2.70.4 1.50.2 NS 1.60.3
NS indicates not significant.
Adapted from Roman et al.15
Hiratzka et al 2010 Guidelines on Thoracic Aortic Disease e277
D
ow
nloaded from
 http://ahajournals.org by on August 16, 2018
adventitial layer, is marked by augmented cytokine and MMP
production causing granuloma formation. Granuloma forma-
tion both shields the vessel from the inciting antigen and
causes vessel destruction.29 Behc¸et disease is a vasculitis
affecting both arteries and veins, of all sizes.
4. Imaging Modalities
4.1. Recommendations for Aortic Imaging
Techniques to Determine the Presence and
Progression of Thoracic Aortic Disease
Class I
1. Measurements of aortic diameter should be taken at
reproducible anatomic landmarks, perpendicular to
the axis of blood flow, and reported in a clear and
consistent format (see Table 5). (Level of Evidence: C)
2. For measurements taken by computed tomographic
imaging or magnetic resonance imaging, the exter-
nal diameter should be measured perpendicular to
the axis of blood flow. For aortic root measurements,
the widest diameter, typically at the mid-sinus level,
should be used. (Level of Evidence: C)
3. For measurements taken by echocardiography, the
internal diameter should be measured perpendicular
to the axis of blood flow. For aortic root measure-
ments, the widest diameter, typically at the mid-
sinus level, should be used. (Level of Evidence: C)
4. Abnormalities of aortic morphology should be rec-
ognized and reported separately even when aortic
diameters are within normal limits. (Level of Evi-
dence: C)
5. The finding of aortic dissection, aneurysm, trau-
matic injury and/or aortic rupture should be imme-
diately communicated to the referring physician.
(Level of Evidence: C)
6. Techniques to minimize episodic and cumulative radi-
ation exposure should be utilized whenever possi-
ble.30,31 (Level of Evidence: B)
Class IIa
1. If clinical information is available, it can be useful to
relate aortic diameter to the patient’s age and body
size. (Level of Evidence: C)
Definitive identification or exclusion of thoracic aortic dis-
ease or one of its anatomic variants requires dedicated aortic
Figure 5. Atherosclerotic lesions. Flow
diagram in center column indicates path-
ways in evolution and progression of
human atherosclerotic lesions. Roman
numerals indicate histologically character-
istic types of lesions defined at the left of
the flow diagram. The direction of the
arrows indicates the sequence in which
characteristic morphologies may change.
From Type I to Type IV, changes in lesion
morphology occur primarily because of
increasing accumulation of lipid. The loop
between Types V and VI illustrates how
lesions increase in thickness when throm-
botic deposits form on their surfaces.
Thrombotic deposits may form repeatedly
over varied time spans in the same loca-
tion and may be the principal mechanism
for gradual occlusion of medium-sized
arteries. Adapted from Stary et al.17
Table 5. Essential Elements of Aortic Imaging Reports
1. The location at which the aorta is abnormal (see Section 2).
2. The maximum diameter of any dilatation, measured from the external
wall of the aorta, perpendicular to the axis of flow, and the length of the
aorta that is abnormal.
3. For patients with presumed or documented genetic syndromes at risk for
aortic root disease measurements of aortic valve, sinuses of Valsalva,
sinotubular junction, and ascending aorta.
4. The presence of internal filling defects consistent with thrombus or
atheroma.
5. The presence of IMH, PAU, and calcification.
6. Extension of aortic abnormality into branch vessels, including dissection
and aneurysm, and secondary evidence of end-organ injury (eg, renal or
bowel hypoperfusion).
7. Evidence of aortic rupture, including periaortic and mediastinal
hematoma, pericardial and pleural fluid, and contrast extravasation from
the aortic lumen.
8. When a prior examination is available, direct image to image comparison
to determine if there has been any increase in diameter.
IMH indicates intramural hematoma; and PAU, penetrating atherosclerotic
ulcer.
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imaging. Selection of the most appropriate imaging study
may depend on patient-related factors (ie, hemodynamic
stability, renal function, contrast allergy) and institutional
capabilities (ie, rapid availability of individual imaging mo-
dalities, state of the technology, and imaging specialist
expertise). Consideration should be given to patients with
borderline abnormal renal function (serum creatinine greater
than 1.8 to 2.0 mg/dL)—specifically, the tradeoffs between
the use of iodinated intravenous contrast for CT and the
possibility of contrast-induced nephropathy, and gadolinium
agents used with MR and the risk of nephrogenic systemic
fibrosis.32
Radiation exposure should be minimized.31,33–36 The risk of
radiation-induced malignancy is the greatest in neonates,
children, and young adults.31 Generally, above the age of 30
to 35 years, the probability of radiation-induced malignancy
decreases substantially.30,31 For patients who require repeated
imaging to follow an aortic abnormality, MR may be pre-
ferred to CT. MR may require sedation due to longer
examination times and tendency for claustrophobia.
CT as opposed to echocardiography can best identify
thoracic aortic disease, as well as other disease processes that
can mimic aortic disease, including pulmonary embolism,
pericardial disease, and hiatal hernia. After intervention or
open surgery, CT is preferred to detect asymptomatic post-
procedural leaks or pseudoaneurysms because of the presence
of metallic closure devices and clips.
We recommend that external aortic diameter be reported
for CT or MR derived size measurements. This is important
because lumen size may not accurately reflect the external
aortic diameter in the setting of intraluminal clot, aortic wall
inflammation, or AoD. A recent refinement in the CT
measurement of aortic size examines the vessel size using a
centerline of flow, which reduces the error of tangential
measurement and allows true short-axis measurement of
aortic diameter. In contrast to tomographic methods, echo-
cardiography-derived sizes are reported as internal diameter
size. In the ascending aorta, where mural thrombus in
aneurysms is unusual, the discrepancy between the internal
and external aortic diameters is less than it is in the descend-
ing or abdominal aorta, where mural thrombus is common.
Standardization of aortic diameter measurements is important
to the planning of endovascular treatment of an aneurysm,
where the diameter of the aorta in the seal zone must be
matched to the diameter of an endograft. Here, the choice of
internal or external diameter is specified by the manufacturer
of the endograft.
4.2. Chest X-Ray
Routine chest x-ray may occasionally detect abnormalities of
aortic contour or size that require definitive aortic imaging.
Chest x-ray often serves as a part of the evaluation of patients
with potential acute AoD, primarily to identify other causes
of patient’s symptoms, but also as a screening test to identify
findings due to a dilated aorta or bleeding. However, chest
x-ray is inadequately sensitive to definitively exclude the
presence of AoD in all except the lowest-risk patients and
therefore rarely excludes the disease. Pooled data from 10
studies places the predictive sensitivity of a widened medi-
astinum or an abnormal aortic contour associated with sig-
nificant thoracic aortic disease at 64% and 71%, respective-
ly.37 In the same analysis, however, including all abnormal
radiographic findings increased the sensitivity to 90%, sug-
gesting that a completely normal chest x-ray does lower the
likelihood of AoD and may provide meaningful clinical
information in very low-risk patients.37 The presence of a
widened mediastinum or other radiographic findings sugges-
tive of thoracic aortic disease increases the likelihood of
AoD, particularly among patients who lack a clear alternative
source for their symptoms. In a blinded prospective study of
216 patients who underwent evaluation for acute thoracic
aortic disease, the specificity of chest x-ray for aortic pathol-
ogy was 86%.38
For patients with chest trauma, chest x-ray is a poor
screening test for the diagnosis of aortic injury.39–41 A
sharply demarcated normal mediastinal contour is sometimes
used to exclude mediastinal hematoma (suggesting a wide
mediastinum, abnormal mediastinal contour, left apical cap,
loss of the aortic knob, depression of the left main bronchus,
and deviation of an indwelling esophageal tube). However,
these signs of hemomediastinum are more often false positive
than true positive for aortic injury.40 Figure 6 illustrates the
normal appearance of the thoracic aorta, and its components,
on a posteroanterior chest x-ray.
4.3. Computed Tomographic Imaging
CT scanning has been used for more than 2 decades to
identify acute AoD and to diagnose and measure other
thoracic aortic diseases42 (see Section 5.1). Advantages in-
clude near universal availability—the ability to image the
entire aorta, including lumen, wall, and periaortic regions; to
identify anatomic variants and branch vessel involvement;
and to distinguish among types of acute aortic syndromes (ie,
intramural hematoma [IMH], penetrating atherosclerotic ulcer
[PAU], and acute AoD)—and the short time required to com-
plete the imaging process and the 3-dimensional data. Electro-
Figure 6. Chest x-ray of a normal thoracic aorta. Arrows indi-
cate arch, and arrowheads show ascending and descending
aorta.
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cardiogram (ECG)-gated techniques have made it possible to
generate motion-free images of the aortic root and coronary
arteries, similar to coronary CT angiographic imaging.
Reports of newer-generation multidetector helical CT
scanners show sensitivities of up to 100% and specificities of
98% to 99%.43–46 Data from the International Registry of
Acute Aortic Dissection (IRAD) show that for patients with
aortic dissection, CT was the initially used diagnostic modal-
ity in 61% of patients and transthoracic echocardiography
(TTE) and/or transesophageal echocardiography (TEE) was
used first in 33% of patients. Whether this was because the
first test was insufficient to diagnose dissection or because
additional information about cardiac and aortic valve function
was required is unclear.47
The sequence for CT performed in the potential setting of
acute AoD generally would include a noncontrast study to
detect subtle changes of IMH (Figure 7), followed by a
contrast study to delineate the presence and extent of the
dissection flap, identify regions of potential malperfusion,
and demonstrate contrast leak indicating rupture. Imaging of
the vascular tree from the thoracic inlet to the pelvis,
including the iliac and femoral arteries, provides sufficient
information to plan surgical or endovascular treatment, if
needed. Prompt interpretation and communication of findings
to the appropriate treating physicians are essential in the acute
setting.
For trauma patients, the sensitivity, specificity, and accu-
racy of contrast-enhanced multidetector CT for traumatic
aortic injury are 96%, 99%, and 99%, respectively.48–50 The
negative predictive value of contrast-enhanced CT ap-
proaches 100% in many studies, most with in-hospital
follow-up of negative CT examinations36,48,51,52 (Figure 8).
An outcome study of 278 patients undergoing contrast-
enhanced CT for blunt chest trauma revealed 6 patients with
aorta/great vessel injury and confirmed the 100% negative
predictive value in the remaining patients using an extensive
review of medical databases with a median follow-up of 20.5
months.53
Regarding other thoracic aortic diseases, CT has been
shown to have a 92% accuracy for diagnosing abnormalities
of the thoracic aorta, in a series of examinations that included
33 thoracic aneurysms, 3 ruptured thoracic aortic aneurysms,
Figure 7. Axial CT images demonstrating the value of noncon-
trast images. Top, Precontrast image demonstrates a high-
attenuation aortic hematoma indicating an acute aortic event.
Bottom, Images obtained with intravenous contrast material
demonstrate the contrast-filled aortic lumen and the hematoma
as a relatively lower attenuation band. CT indicates computed
tomographic imaging.
Figure 8. Traumatic aortic rupture secondary to a motor vehicle
crash. Top, Axial CT image demonstrates a traumatic injury with
pseudoaneurysm (T) in the proximal descending thoracic aorta,
numerous bilateral rib fractures, and small bilateral pleural effu-
sions, with no significant mediastinal hematoma. Bottom, Still
image through the thorax further demonstrates the extent of the
aortic trauma. The full cine video for the bottom panel is avail-
able in the online-only Data Supplement at http://circ.ahajournals.
org/cgi/content/full/CIR.0b13e3181d4739e/DC1. CT indicates com-
puted tomographic imaging.
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6 PAUs, 5 AoDs, and 2 pseudoaneurysms. In addition, CT
correctly predicted the need for hypothermic circulatory
arrest during surgical repair in 94% of patients.54 For con-
genital and inflammatory conditions of the thoracic aorta, the
literature is primarily descriptive, and accuracy data are not
available.
4.3.1. Computed Tomographic Imaging Technique
Although nonhelical CT scanners are capable of diagnosing
thoracic aortic disease, the technique used is axial step-and-
shoot technology. Inherent limitations include slow scan
speed, relatively poor spatial resolution given thicker colli-
mation used to extend the needed craniocaudal coverage, and
inherently a noncontiguous dataset. Any patient motion, even
minimal, between the acquisition of each image or cluster of
images creates a stair-step artifact on multiplanar and
3-dimensional renderings. Helical CT scanners of 4 and
greater detector rows consistently provide volumetric acqui-
sitions of the thoracic aorta. Scanners with 16 and greater
detector rows provide isotropic resolution in the x, y, and z
axes, which allows the datasets to be reconstructed in the
optimum imaging plane best suited to any individual vessel.
Technical parameters recommended for image reconstruc-
tion are slices of 3-mm or less thickness with a reconstruction
interval of 50% or less than the slice thickness at 50% or
greater overlap, tube rotation of 1 second or less, and 120 to
140 kVp.55 ECG gating is particularly useful for ascending
aortic disease, eliminating motion artifact at the aortic root
that can simulate an AoD (Figure 9), and allowing evaluation
of aortic valve morphology and function, as well as evalua-
tion of the proximal coronary arteries. If appropriately ac-
quired, an aorta CT and a complete CT coronary angiogram
can be obtained in 1 CT acquisition. For AoD, the scan
coverage should start above the aortic arch and extend at least
to the aortoiliac bifurcation, and probably the groin. This is
important to determine both branch vessel involvement, such
as lesion extension into the abdominal aorta and iliac arteries
and characterization and diagnosis of malperfusion syn-
drome, and to evaluate access for percutaneous repair when
transluminal therapy is being considered. (For further infor-
mation on technique parameters and anatomic coverage, see
the online-only Data Supplement.)
The CT angiographic acquisition uses intravenous contrast
delivered at rate of 3 to 5 mL/s by a power injector and
usually followed by a saline bolus. The total volume of
contrast used should be kept as low as possible, to no greater
than 150 mL.
Although axial sections remain the mainstay of interpreta-
tion, 2- and 3-dimensional reconstructions, such as maximum
intensity projection, multiplanar and curved multiplanar ref-
ormations, and volume rendering, may augment interpreta-
tion and improve communication of the findings.54 To our
knowledge, it has not been scientifically shown that the use of
these tools increases diagnostic accuracy or diagnostic con-
fidence among specialists. For example, in 1 study multipla-
nar reconstructions when added to axial images alone
changed the interpretation in only 1 case.54 However,
3-dimensional reconstruction is likely to play an important
role in the planning of surgical or endovascular approaches.
4.4. Magnetic Resonance Imaging
MR has been shown to be very accurate in the diagnosis of
thoracic aortic disease, with sensitivities and specificities that
are equivalent to or may exceed those for CT and TEE.44,58–62
Like CT, MR provides a multiplanar evaluation of the
Figure 9. Mimic of aortic dissection created by
motion of the aortic root. Top left, Image at the
level of the right pulmonary artery demon-
strates a normal descending thoracic aorta and
pseudodissection of the ascending aorta due
to motion artifact that occurs on non–ECG-
gated CT examinations (arrow). Top right,
Image at the aortic root shows a double con-
tour to the aortic root that may simulate a dis-
section flap (arrow). Bottom, Still image through
the thoracic aorta further delineates the extent
of the motion artifact. The full cine video is
available in the online-only Data Supplement at
http://circ.ahajournals.org/cgi/content/full/
CIR.0b013e3181d4739e/DC1. CT indicates
computed tomographic imaging; and ECG,
electrocardiogram.
Hiratzka et al 2010 Guidelines on Thoracic Aortic Disease e281
D
ow
nloaded from
 http://ahajournals.org by on August 16, 2018
thoracic aorta, and the examination can be extended in
coverage to include the length of the aorta and branch vessels,
from skull base to the toes. Advantages of MR include the
ability to identify anatomic variants of AoD (IMH and PAU),
assess branch artery involvement, and diagnose aortic valve
pathology and left ventricular dysfunction without exposing
the patient to either radiation or iodinated contrast. Disadvan-
tages include prolonged duration of imaging acquisition
during which the patient is inaccessible to care providers;
inability to use gadolinium contrast in patients with renal
insufficiency; contraindication in patients with claustropho-
bia, metallic implants, or pacemakers; and lack of widespread
availability on an emergency basis. Although time-resolved
MR techniques are improving, MR often cannot clearly
characterize the relationship of an intimal flap and aortic root
structures, specifically the coronary arteries. Likely as a result
of these considerations, data from IRAD found that MR was
the least-used imaging study, used in only 1% of patients as
the initial diagnostic study.63 For traumatic injury and con-
genital and inflammatory conditions of the thoracic aorta, the
literature is primarily descriptive, and accuracy data are not
available.
4.4.1. Magnetic Resonance Imaging Technique
A comprehensive MR examination of the thoracic aorta may
include many components, including black blood imaging,
may include basic spin-echo sequences, noncontrast white
blood imaging, contrast-enhanced MR angiography using
gadolinium based agents, and phase-contrast imaging. MR of
the thoracic aorta in the acute setting can be shortened to meet
urgent patient assessment needs. The use of each is described
more specifically later. MR examinations have become faster,
with advances in gradient hardware that have significantly
reduced repetition times, resulting in ultrafast MR angiogra-
phy techniques. However, MR examinations remain 2 to 4
times longer than CT examinations. MR terminology across
imaging vendors is less consistent than that of CT; therefore,
imaging sequences are described later as general types of
sequences without vendor-specific details.58,59
4.4.2. Black Blood Imaging
Black blood imaging, using spin-echo sequences, is used to
evaluate aortic anatomy and morphology (such as aortic size
and shape), and the aortic wall for hematoma or other causes
of thickening such as vasculitis. They may be repeated after
the administration of gadolinium-based contrast agents to
identify wall enhancement. These sequences should use ECG
gating at end-diastole and may be performed with or without
double inversion recovery techniques that null the signal from
blood. These sequences generate 2-dimensional images that
can be obtained in the axial, sagittal, and coronal planes, as
well as the oblique sagittal or “candy cane” view. T1-
weighted gradient echo sequences may be used in place of
black blood images and are usually performed both before
and after contrast administration. They can be obtained in the
axial, sagittal, and coronal planes.
4.4.3. Noncontrast White Blood Imaging
This is performed using either basic gradient echo sequences
or the more advanced balanced steady-state free precession
techniques (SSFP) that are T2*weighted and generate images
with subsecond temporal resolution. Signal is generated from
blood, making it appear white in the absence of contrast.
SSFP techniques use ultrashort repetition times that require
MR scanners with high-performance gradients. For the latter,
an in-plane resolution of approximately 2.01.5 mm2 can be
obtained using a repetition time of 3.2 ms, TE of 1.6 ms, flip
angle of 60 to 70 degrees, and a 256256 matrix. SSFP
techniques can be performed to generate 2-dimensional,
3-dimensional, and cine images; the 2-dimensional images
are usually performed in the axial, sagittal, and coronal planes
in an interleaved manner and use ECG gating with triggering
at end-diastole to generate images in less than 500 ms that do
not require breath holding. Cine SSFP sequences require 7- to
9-second breath holding and are usually only performed at
specific anatomic locations of interested, as determined by
the findings on the previously generated images. For patients
who cannot hold their breath, cine SSFP sequences can be
performed without using ECG gating or breath holding but
with substantially lower spatial and temporal resolution.
4.4.4. Contrast-Enhanced Magnetic
Resonance Angiography
For the thoracic aorta, contrast-enhanced MR angiography is
usually performed with ECG gating. Although this increases
acquisition time, it provides motion-free images of the aortic
root and ascending aorta. For patients without a contraindi-
cation to receiving a gadolinium-based contrast agent,
contrast-enhanced MR angiography is often the sequence of
choice from which most of the diagnostic information is
obtained. Contrast-enhanced MR angiography images are
obtained as a 3-dimensional volumetric dataset, which can be
manipulated and viewed in much the same manner as CT
scan datasets. Advances in MR, particularly gradient strength,
have markedly reduced the acquisition times of contrast-
enhanced MR angiography possible to subsecond acquisition
times. This temporally resolved subsecond contrast-enhanced
MR angiography is particularly useful in critically ill patients
or patients who cannot hold their breath, where motion
artifact can degrade other sequences that take longer to
acquire, with the tradeoff being a reduction of in-plane
resolution.
4.4.5. Phase Contrast Imaging
These sequences are usually performed to evaluate gradients
across an area of stenosis, across an intimal or cardiac valve.
Image contrast is produced by differences in velocity.
Images are obtained using ECG gating or triggering.
Two-dimensional images are generated that center on the
area of concern. Peak flow and velocity measurements may
be calculated, and time–flow and time–velocity curves are
generated.
4.5. Standards for Reporting of the Thoracic
Aorta on Computed Tomography and Magnetic
Resonance Imaging
Viewing and measuring are best accomplished at a picture
archiving and communications system workstation or an
independent computer workstation, in which the aorta can be
rotated into the best orientation to review each segment of the
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aorta and the aortic branches. This minimizes the chance of
inadvertently confusing normal structures for vascular abnor-
mality (Figure 10).
The writing committee believes that specific qualitative
and quantitative elements are important to include in reports
(Table 5).
Diameter measurements taken from axial images are in-
herently incorrect unless the artery being measured is per-
fectly aligned in cross section on the image (Figure 11). It is
preferable to make diameter measurements perpendicular to
the longitudinal or flow axis of the aorta to correct for the
variable geometry of the aorta. Suggested standard anatomic
locations are noted in Figure 12. The use of standardized
measurements helps minimize errant reports of significant
aneurysm growth due to technique or interreader variability
in measuring technique.
4.6. Angiography
Angiography provides accurate information about the site of
dissection, branch artery involvement, and communication of
the true and false lumens.60,61 Additionally, angiographic and
catheter-based techniques allow for evaluation and treatment
of coronary artery62 and aortic branch (visceral and limb
artery) disease, as well as assessment of aortic valve and left
ventricular function.60,63
Disadvantages of angiography compared with other less
invasive modalities include 1) not being universally available
because it requires the presence of an experienced physician
to perform the study; 2) being an invasive procedure that is
time consuming and requires exposure to iodinated contrast;
3) having poor ability to diagnose IMH given a lack of
luminal disruption; 4) potentially producing false negative
results when a thrombosed false lumen prevents adequate
Figure 10. Left brachiocephalic vein mimics an intramural
hematoma on CT. Axial CT image demonstrates a low-
attenuation crescent of material anterior to the innominate
artery. CT indicates computed tomographic imaging.
Figure 11. Markedly tortuous aorta with thora-
coabdominal aortic aneurysm demonstrated on
(A) 3-dimensional shaded surface display ren-
dering. B and C represent incorrect measure-
ment of the aorta on standard coronal and
axial images respectively, while D is an image
of the aorta perpendicular to the centerline or
axis of the aorta, with the arrow demonstrating
the correct location for diameter measurement,
which in this case was 7.8 cm.
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opacification to identify the dissection; and 5) reported
sensitivities and specificities of angiography for the evalua-
tion of acute AoD that are slightly lower than those for the
other less invasive modalities.42,64,65 Thus, CT, MR, and TEE
have replaced catheter-based angiography as the first-line
diagnostic tests to establish the presence of the acute aortic
syndrome.60,63,66,67 Multidetector CT has also largely replaced
angiography for the anatomic studies required for treatment
planning and monitoring of aortic disease.68
4.7. Echocardiography
The aorta and its major branches can be visualized with
echocardiography using a variety of imaging fields as well as
methods of ultrasound. The suprasternal view is best for
visualizing the aortic arch, whereas the aortic root and
ascending aorta are best seen in the left (and sometimes right)
parasternal projection. When involvement of the innominate
artery, left subclavian artery, or left common carotid artery is
suspected, orthogonal and longitudinal scanning planes are
helpful. Imaging of the descending thoracic aorta is less
easily accomplished with echocardiography compared with
other imaging modalities. Abdominal scan planes can be used
to visualize the caudal descending aorta.
In general, TEE is superior to TTE for assessment of the
thoracic aorta. Through the use of multiplane image acquisi-
tion, 3-dimensional Doppler TEE is safe and can be per-
formed at the bedside, with a low risk of complications (less
than 1% overall, less than 0.03% for esophageal perforation),
most of which are related to conscious sedation.69,70 Recon-
struction of the aorta can be performed. Intraoperative use of
TEE is noted in Sections 14.2.3 and 14.2.4.
4.7.1. Echocardiographic Criteria for Thoracic
Aortic Aneurysms
The echocardiographic diagnosis of thoracic aortic aneu-
rysms is determined on demonstration of aortic enlargement
relative to the expected aortic diameter, based on age- and
body size–adjusted nomograms (Figures 2, 3, 4, and 13). For
other aortic segments, such nomograms have not been devel-
oped, so aortic dilatation is diagnosed when the aorta exceeds
a generally agreed to standard diameter (Table 3) or when a
given aortic segment is larger than contiguous aortic seg-
ment(s) of apparently normal size. Beyond establishing the
presence of aortic enlargement, echocardiography may reveal
associated cardiac pathology that suggests the underlying
etiology of the aortic disease (eg, bicuspid aortic valve).
4.7.2. Echocardiographic Criteria for Aortic Dissection
The echocardiographic diagnosis of an AoD requires the
identification of a dissection flap separating true and false
lumens (Figure 14). However, one of the major limitations of
both TTE and TEE is the frequent appearance of artifacts that
mimic a dissection flap (Figure 15). These usually arise from
a mirror image or reverberation artifact that appears as a
mobile linear echodensity overlying the aortic lumen. It is
therefore essential that the echocardiographer make certain to
distinguish true dissection flaps from such artifacts. The first
step is to confirm the presence of the dissection flap from
several angles and from several transducer locations. The
second step is to confirm that the dissection flap has a motion
independent of surrounding structures and that the apparent
flap is contained within the aortic lumen (ie, does not pass
through the aortic wall in any view). The third step is to use
Figure 12. Normal anatomy of the thoracoabdominal aorta with
standard anatomic landmarks for reporting aortic diameter as
illustrated on a volume-rendered CT image of the thoracic aorta.
CT indicates computed tomographic imaging. Anatomic loca-
tions: 1, Aortic sinuses of Valsalva; 2, Sinotubular junction; 3,
Mid ascending aorta (midpoint in length between Nos. 2 and 4);
4, Proximal aortic arch (aorta at the origin of the innominate
artery); 5, Mid aortic arch (between left common carotid and
subclavian arteries); 6, Proximal descending thoracic aorta
(begins at the isthmus, approximately 2 cm distal to left subcla-
vian artery); 7, Mid descending aorta (midpoint in length
between Nos. 6 and 8); 8, Aorta at diaphragm (2 cm above the
celiac axis origin); 9, Abdominal aorta at the celiac axis origin.
CT indicates computed tomographic imaging.
Figure 13. Transthoracic echocardiogram of a patient with
Marfan syndrome with mitral valve prolapse and 4-cm ascend-
ing aortic aneurysm.
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color-flow Doppler to demonstrate differential flow on the 2
sides of the dissection flap. Often one can visualize 1 or more
sites of intimal tears, with color-flow Doppler demonstrating
sites of flow between the 2 lumens. The true lumen typically
exhibits expansion during systole and collapse during diastole.
Additional signs of the true lumen include little or no
spontaneous echocardiographic contrast, systolic jets directed
away from the lumen, and forward flow during systole. The
false lumen often exhibits diastolic expansion, evidence of
spontaneous contrast, complete or partial thrombosis, and
reversed, delayed, or absent blood flow. Imaging criteria for
distinguishing the true and false lumens have also been
described for intravascular ultrasound71 and CT.72 Features
that characterize the false lumen of an acute dissection
include the wedgelike angle (the “beak sign”) where the
dissection flap meets the aortic wall, the presence of strand-
like structures (“cobwebs”) in the lumen, and the lack of a
laminar structure in the outer wall of the lumen.
Associated echocardiographic findings of clinical impor-
tance include identification of a pericardial effusion. Indeed,
it is often possible to see a layer of echogenic material within
the pericardial fluid that is indicative of hemopericardium.
Echocardiography can provide important information about
right and left ventricular function and myocardial ischemia
based on assessment of left ventricular segmental wall mo-
tion. On TEE, one can identify the ostia of the 2 coronary
arteries and detect involvement by the dissection flap. Echo-
cardiography also identifies the presence of aortic regurgita-
tion and permits grading of its severity. On TEE, the
mechanisms of acute aortic regurgitation can be defined, and
these data can be used to guide the surgeon’s efforts to spare
the valve at the time of aortic repair.
4.7.2.1. Diagnostic Accuracy of Echocardiography for
Aortic Dissection
TTE has a sensitivity of 77% to 80% and a specificity of 93%
to 96% for identification of proximal AoD. For distal AoD,
the sensitivity of TTE is lower. TEE improves the diagnostic
accuracy substantially, particularly when a patient’s body
shape, chest wall, or concomitant pulmonary disease restricts
the transthoracic windows for aortic imaging. With TEE,
sensitivity for proximal AoD is 88% to 98% with a specificity
of 90% to 95%.46 A 2006 meta-analysis that evaluated the
diagnostic utility of TEE in suspected thoracic AoD included
630 patients from 10 different studies. TEE was shown to
both accurately identify and rule out acute AoD with sensi-
tivities and specificities of 98% (95% CI 95% to 99%) and
95% (95% CI 92% to 97%), respectively.46
Major advantages of TEE include its portability (allowing
for bedside patient evaluation), rapid imaging time, and lack
of intravenous contrast or ionizing radiation. Additionally,
dissection-related cardiac complications can be evaluated
including aortic regurgitation, proximal coronary artery in-
volvement, and the presence of tamponade physiology. Dis-
advantages of TEE include a potential lack of availability
(particularly at small centers and during off hours) and
sedation requirements that may include endotracheal intuba-
tion.73 The accuracy of TEE can be quite operator dependent.
For the very distal ascending aorta and the proximal aortic
arch, TEE may be limited by a blind spot caused by
interposition of the trachea and left main bronchus between
the esophagus and aorta. Small, circumscribed AoDs or IMHs
in this region are less well visualized by TEE. Another
limitation of TEE is its inability to visualize the abdominal
aorta; if there is concern of a malperfusion syndrome, an
abdominal CT may also be required.
4.7.2.2. Diagnostic Accuracy of Echocardiography for
Acute Intramural Hematoma
IMH of the aorta has a distinctly different appearance on
echocardiography. In contrast to classic AoD, in IMH there is
no mobile intimal flap within the aortic lumen, and in most
cases the aortic lumen has a relatively normal round appear-
ance. Instead, in IMH there is thickening of the aortic wall
that is typically crescentic in shape and extends along a length
of the aorta. In some cases it can be difficult to distinguish the
wall thickening of IMH from diffuse aortic atherosclerosis or
mural thrombus lining an aortic aneurysm. However, ather-
oma and mural thrombus protrude from the aortic intima into
the lumen, thus giving both the aortic wall and the lumen an
irregular shape, whereas in IMH the inner lining of the aortic
lumen remains smooth. Moreover, in the presence of intimal
calcification, intramural thrombus will present as thickening
Figure 14. Arch aneurysm with dissection flap. Top, Arch dis-
section, 2-dimensional view. Bottom, Arch dissection (arrow)
with color-flow Doppler margination.
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external to calcification, whereas mural thrombus will be
internal to calcification.
4.7.2.3. Role of Echocardiography in Following Patients
With Chronic Aortic Disease
Given that TEE is a semi-invasive procedure; it is usually
not preferred for surveillance of patients with thoracic
aortic diseases. Also, although TTE is noninvasive, its
failure to visualize consistently and measure accurately the
tubular portion of the ascending thoracic aorta is problem-
atic. It is not typically used to follow aneurysms in that
aortic segment. However, because TTE does accurately
visualize the aortic root, its primary role as an imaging
method for serial follow-up is in patients with aortic
disease limited to the root, particularly those with Marfan
syndrome. It is also used, often in conjunction with CT or
MR, to observe patients with concomitant structural heart
disease, such as bicuspid aortic valve, mitral valve prolapse,
cardiomegaly, or cardiomyopathy.
5. Genetic Syndromes Associated With
Thoracic Aortic Aneurysms and Dissection
5.1. Recommendations for Genetic Syndromes
Class I
1. An echocardiogram is recommended at the time of
diagnosis of Marfan syndrome to determine the
aortic root and ascending aortic diameters and 6
months thereafter to determine the rate of enlarge-
ment of the aorta. (Level of Evidence: C)
2. Annual imaging is recommended for patients with
Marfan syndrome if stability of the aortic diameter
is documented. If the maximal aortic diameter is 4.5
cm or greater, or if the aortic diameter shows
significant growth from baseline, more frequent
imaging should be considered. (Level of Evidence: C)
3. Patients with Loeys-Dietz syndrome or a confirmed
genetic mutation known to predispose to aortic
aneurysms and aortic dissections (TGFBR1,
TGFBR2, FBN1, ACTA2, or MYH11) should un-
dergo complete aortic imaging at initial diagnosis
and 6 months thereafter to establish if enlarge-
ment is occurring.74 –77 (Level of Evidence: C)
4. Patients with Loeys-Dietz syndrome should have
yearly magnetic resonance imaging from the cere-
brovascular circulation to the pelvis.23,78,79 (Level of
Evidence: B)
5. Patients with Turner syndrome should undergo im-
aging of the heart and aorta for evidence of bicuspid
aortic valve, coarctation of the aorta, or dilatation of
the ascending thoracic aorta.80 If initial imaging is
normal and there are no risk factors for aortic
dissection, repeat imaging should be performed ev-
ery 5 to 10 years or if otherwise clinically indicated.
If abnormalities exist, annual imaging or follow-up
imaging should be done. (Level of Evidence: C)
Figure 15. Artifact mimicking dissection. Top left, 2-dimensional view. Top right, Color-flow Doppler without margination. Bottom, Arti-
fact not seen in this view.
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Class IIa
1. It is reasonable to consider surgical repair of the
aorta in all adult patients with Loeys-Dietz syn-
drome or a confirmed TGFBR1 or TGFBR2 muta-
tion and an aortic diameter of 4.2 cm or greater by
transesophageal echocardiogram (internal diameter)
or 4.4 to 4.6 cm or greater by computed tomographic
imaging and/or magnetic resonance imaging (exter-
nal diameter).78 (Level of Evidence: C)
2. For women with Marfan syndrome contemplating
pregnancy, it is reasonable to prophylactically re-
place the aortic root and ascending aorta if the
diameter exceeds 4.0 cm.74 (Level of Evidence: C)
3. If the maximal cross-sectional area in square centi-
meters of the ascending aorta or root divided by the
patient’s height in meters exceeds a ratio of 10,
surgical repair is reasonable because shorter pa-
tients have dissection at a smaller size and 15% of
patients with Marfan syndrome have dissection at a
size less than 5.0 cm.16,76,81 (Level of Evidence: C)
Class IIb
1. In patients with Turner syndrome with additional
risk factors, including bicuspid aortic valve, coarc-
tation of the aorta, and/or hypertension, and in
patients who attempt to become pregnant or who
become pregnant, it may be reasonable to perform
imaging of the heart and aorta to help determine the
risk of aortic dissection. (Level of Evidence: C)
5.1.1. Marfan Syndrome
Marfan syndrome is a heritable disorder of the connective
tissue with a high penetrance but variable expression. Ap-
proximately 25% of patients do not have a family history and
represent new cases due to sporadic mutations for the
condition. Marfan syndrome results from mutations in the
FBN1 gene, with over 600 mutations currently entered into
the FBN1 mutation database causing Marfan syndrome or
related conditions (http://www.umd.be/). The FBN1 gene
encodes fibrillin-1, a large glycoprotein that is secreted from
cells and deposited in the extracellular matrix in structures
called microfibrils. Microfibrils are found at the periphery of
elastic fibers, including the elastic fibers in the medial layer
of the ascending aorta, and in tissues not associated with
elastic fibers.82 Only 12% of FBN1 mutations causing Marfan
syndrome have been observed more than once in unrelated
individuals, a fact that complicates using mutational detection
for diagnosis. A second locus for Marfan syndrome, termed
MFS2, was recently identified to be caused by mutations in the
transforming growth factor-beta type II receptor (TGFBR2).83
The phenotype of this locus may overlap for Loeys-Dietz
syndrome. The criteria for Marfan syndrome is based primarily
on clinical findings in the various organ systems affected in the
Marfan syndrome, along with family history and FBN1 muta-
tions status.84
The cardinal features of Marfan syndrome involve the
cardiovascular, ocular, and skeletal systems. Patients with
Marfan syndrome are highly predisposed to thoracic aortic
aneurysm and/or dissection, with virtually every patient with
the syndrome having evidence of aortic disease at some point
during their lifetime. Other cardiovascular manifestations
include valvular disease, primarily mitral valve prolapse and
regurgitation.85 Aortic regurgitation can result from distortion
of the aortic valve cusps by an enlarged aortic root. The
skeletal manifestations reflect overgrowth of the long bones
and include arachnodactyly, dolichostenomelia, kyphoscoli-
osis, dolichocephaly, and pectus deformities. Abnormalities
in the connective tissues are also manifested as joint laxity,
recurrent or incisional hernias, striae atrophica, and dural
ectasia.84 The ocular manifestation that is both sensitive and
fairly specific for Marfan syndrome is ectopia lentis or lens
dislocation. The presence of ectopia lentis is a particularly
useful clinical finding to differentiate Marfan syndrome from
Loeys-Dietz syndrome.78
Most patients with Marfan syndrome present with dilata-
tion of the aortic root/ascending aorta or Type A dissection.
Internal aortic diameter measured at the sinuses of Valsalva
provides a baseline for future evaluations because this is the
aortic segment that dilates in Marfan syndrome. Of note,
echocardiographic studies measure the internal diameter,
whereas most patients undergo definitive imaging by CT
and/or MR, which measures the external diameter (expected
to be 0.2 to 0.4 cm larger than internal diameter), and external
diameter is the measurement used in most cases to determine
the threshold for surgical repair. There is growing awareness
of the importance of relating this measurement to normal
values based on age and body surface area15 (Table 4). The
severity of the aortic disease is related to the degree and
segment length of aortic dilatation with dilatation limited to
the sinuses of Valsalva having a less malignant prognosis
than dilatation that extends to the aortic arch.86 After diag-
nosis, follow-up imaging studies are recommended at 6
months and then annually if stability is documented based on
the high likelihood of aortic disease progression. In most
cases, TTE can be used to monitor the size of the sinuses of
Valsalva.
A subset of patients present with Type B dissection, and a
rare patient will present with AAA. The poor outcome of
patients with Marfan syndrome with acute Type B dissections
has led some to advocate early surgical repair.87
Studies addressing the efficacy of beta blockade in patients
with Marfan syndrome have shown slower aortic root growth,
fewer cardiovascular end points (defined as aortic regurgita-
tion, dissection, surgery, heart failure, or death), and im-
proved survival.88 Patients continue to enlarge their aorta and
dissect on therapy, so such medication does not preclude the
need for routine imaging and prophylactic aortic repair when
the diameter of the aorta warrants repair. It is also important
to note that significant aortic root dilatation is correlated
negatively with therapeutic response.88 Recent studies in a
mouse model of Marfan syndrome with aortic disease similar
to that seen in humans showed that treatment with losartan
normalized aortic root growth,6 and a clinical trial using
losartan in Marfan syndrome patients under the age of 25
years is in progress89,90 (see Section 9.2.1.1).
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Surgical repair of the dilated aortic root/ascending aorta for
patients with Marfan syndrome is usually performed at a
threshold of a external diameter of 5.0 cm,91 smaller than that
for other patients because of the greater tendency for AoD at
a smaller diameter (see Section 9.2.2.1). Factors that will
prompt repair at an external diameter of less than 5.0 cm are
rapid growth defined as greater than 0.5 cm/y, family history
of AoD at a diameter less than 5.0 cm, or the presence of
significant aortic regurgitation.
After prophylactic repair of the ascending aorta, the arch
and descending aorta are sites for later-onset aneurysms and
dissections in patients with Marfan syndrome, prompting the
need for routine imaging of the arch and descending aorta.
Survival in patients with Marfan syndrome has been signifi-
cantly improved with medical and surgical management of
the aortic disease.76,92,93 The David valve sparing reimplan-
tation operation for suitable patients undergoing elective
aortic root surgery at centers with a high volume of these
cases has become standard practice,76,92–99 although some
have reported less-optimal long-term results with valve-
sparing procedures.100,101
Pregnant patients with Marfan syndrome are at increased
risk for AoD if the aortic diameter exceeds 4 cm102 (see
Section 10). All women with Marfan syndrome warrant
frequent cardiovascular monitoring throughout pregnancy
and into the puerperium. Limited data on the treatment of
women with Marfan syndrome who experience dissections
during pregnancy suggest a better outcome with cesarean
section with concomitant aortic repair.103
5.1.2. Loeys-Dietz Syndrome
The Loeys-Dietz syndrome is an autosomal dominant aortic
aneurysm syndrome with involvement of many other sys-
tems.78,104 Loeys-Dietz syndrome results from mutations in
either the transforming growth factor receptor Type I or II
(TGFBR1 or TGFBR2) genes and the diagnosis is confirmed
through mutational analysis of these genes.105
The disease is characterized by the triad of arterial tortu-
ousity and aneurysms, hypertelorism and bifid uvula or cleft
palate, or a uvula with a wide base or prominent ridge on it.
The arterial tortuousity is most commonly observed in the
head and neck vessels but can occur in other vessels. These
patients also have a spectrum of other features, which include
the following: velvety and translucent skin, craniosynostosis,
malar hypoplasia, retrognathia, blue sclera, patent ductus
arteriosus, skeletal features similar to Marfan syndrome,
dural ectasia, atrial septal defects, developmental delay,
cervical spine abnormalities, and joint laxity. The vascular
disease in these patients is particularly aggressive with a
mean age of death of 26 years.78 Most patients have aortic
root aneurysms (98%) that lead to AoD. Because there are
multiple reports of AoD occurring in patients with Loeys-
Dietz when the aortic diameter was less than 5.0 cm, repair is
recommended at smaller diameters78 (see Section 5.1). For
young children with severe systemic manifestations of Loeys-
Dietz syndrome, specifically prominent craniofacial features
that are associated with more severe aortic disease, once the
aortic diameter exceeds the 99th percentile for age and the
aortic valve annulus reaches 1.8 to 2.0 cm, prophylactic
surgery allows for the placement of a graft of sufficient size
to accommodate growth. Of note, echocardiographic exami-
nations that measure the internal aortic diameter were used in
these studies to determine the threshold for surgical repair.
Patients with Loeys-Dietz also develop aneurysms of other
vessels (53%), leading to the recommendation that they have
yearly MR imaging from the cerebrovascular circulation to
the pelvis. Current studies indicate that aggressive surgical
management of the aneurysms in these patients can be
achieved with few complications.23,78 Surgical procedures in
patients with Loeys-Dietz syndrome are not complicated by
tissue fragility.23,79
5.1.3. Ehlers-Danlos Syndrome, Vascular Form
or Type IV
The vascular form of Ehlers-Danlos syndrome is a rare
autosomal dominant disorder characterized by easy bruising,
thin skin with visible veins, characteristic facial features, and
rupture of arteries, uterus, or intestines. Rupture of the
gastrointestinal tract is more likely to occur prior to arterial
rupture, and the majority of patients survive the gastrointes-
tinal rupture.106 Most of the fatal complications are caused by
arterial rupture, with most deaths attributable to arterial
dissections or ruptures involving primarily the thoracic or
abdominal arteries, including AoDs and ruptures. These
arterial ruptures lead to reduced life expectancy, with the
median survival of only 48 years, and often no aneurysms are
documented. If the rupture of an artery is life threatening, it
can be surgically repaired, but tissue fragility, tendency to
hemorrhage extensively, and poor wound healing may com-
plicate the surgical repair.107 Whether there is a role for the
repair of unruptured aneurysms in patients with this syn-
drome is not clear, which is in contrast to Loeys-Dietz
syndrome, where a role for prophylactic surgical repair of
aneurysms is already well established. Nevertheless, when
these patients present with AoD or aortic root aneurysms,
successful aortic surgery can be achieved with careful han-
dling of tissues and resewing of anastomoses with pledgeted
sutures.76 Noninvasive vascular imaging is preferred as fatal
complications have been associated with invasive imaging in
these patients.106 The outcome of pregnancy in women with
Ehlers-Danlos syndrome is poor because of rupture of the
gravid uterus and vessel rupture at delivery or in the postpar-
tum period. The diagnosis of vascular Ehlers-Danlos syn-
drome is based on DNA or protein studies identifying a defect
in type III collagen, encoded by the COL3A1 gene.
5.1.4. Turner Syndrome
Turner syndrome is defined as complete or partial absence of
1 sex chromosome in a phenotypic female, most commonly
45, X. Short stature and ovarian failure are the most prevalent
finding, but women with Turner syndrome have an increased
cardiovascular mortality rate from both structural and ische-
mic heart disease, especially AoD.108,109 Between 10% and
25% of patients with Turner syndrome have a bicuspid aortic
valve. Aortic coarctation is present in approximately 8% of
patients. Determining aortic dilatation in patients with Turner
syndrome is difficult because aortic dilatation is based on
body surface area so the aortas of patients with Turner
syndrome are expected to be smaller than those of the general
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population because of the patient’s short stature. If one
defines aortic dilatation as an ascending-to-descending aortic
diameter ratio of greater than 1.5, then 33% of women with
Turner syndrome had aortic dilatation.110
The average age of AoD in Turner syndrome was 31 years,
and less than half of the patients survived the event.111 Data
indicate a population-based AoD incidence of 36:100 000
Turner syndrome years (1.4% among individuals with Turner
syndrome) compared with 6:100 000 in the general Danish
population.112 Therefore, the risk of AoD is much lower in
patients with Turner syndrome compared with patients with
Marfan syndrome or Loeys-Dietz syndrome. The majority of
dissections in women with Turner syndrome occur in patients
with known risk factors for dissection, such as cardiovascular
malformations (bicuspid aortic valve or coarctation of the
aorta), systemic hypertension, or both. Therefore, the evi-
dence base regarding the value of screening for aortic disease
in women with Turner syndrome is not available. However,
there appears to be an increased risk for dissection in these
women, suggesting that imaging of the heart, aorta, and
pulmonary veins at the time of diagnosis might be valu-
able.80,113 For patients with no risk factors for AoD (bicuspid
aortic valve, coarctation, dilated aorta), re-evaluation of the
aorta has been suggested every 5 to 10 years or if clinically
indicated (eg, attempting pregnancy114 or transition to an
adult clinic). Patients with risk factors for AoD should
undergo more frequent imaging. Recently, studies have not
shown an effect of growth hormone treatment in women with
Turner syndrome on either ascending or descending aortic
diameter.113 In addition, studies have not found any evidence
of left ventricular hypertrophy in patients with Turner syn-
drome who were treated with growth hormone.115,116
5.1.5. Other Genetic Syndromes With Increased Risk for
Thoracic Aortic Aneurysms and Dissections
A substantial proportion of patients with Ehlers-Danlos syn-
drome who do not have the vascular form also have aortic
root dilatation, but the progression of this dilatation to AoD is
rare.76,117 Similarly, patients with congenital contractural
arachnodactyly or Beals syndrome due to mutations in FBN2
have had aortic root enlargement without documented pro-
gression to dissection.118,119
There are other genetic syndromes that have multiple
reports or documentation of thoracic aortic aneurysms lead-
ing to Type A dissections. There are multiple case reports of
AoD in patients with autosomal dominant polycystic kidney
disease.120,121 Although AoD is a complication of autosomal
dominant polycystic kidney disease, it is less common than
cerebral aneurysms leading to subarachnoid hemorrhage in
this population. There is insufficient information to gauge the
value of routine or screening imaging for these patients.
Similar to autosomal dominant polycystic kidney disease,
there are multiple reports in the literature of patients with
Noonan syndrome who are experiencing AoDs.122–124 The value
of imaging or routine monitoring of these patients is unknown.
A review of 200 patients with Alagille syndrome also identified
thoracic aortic disease in a small subset of these patients.125
5.1.6. Recommendations for Familial Thoracic Aortic
Aneurysms and Dissections
Class I
1. Aortic imaging is recommended for first-degree
relatives of patients with thoracic aortic aneurysm
and/or dissection to identify those with asymptom-
atic disease.126,127 (Level of Evidence: B)
2. If the mutant gene (FBN1, TGFBR1, TGFBR2,
COL3A1, ACTA2, MYH11) associated with aortic an-
eurysm and/or dissection is identified in a patient,
first-degree relatives should undergo counseling and
testing. Then, only the relatives with the genetic mutation
should undergo aortic imaging. (Level of Evidence: C)
Class IIa
1. If one or more first-degree relatives of a patient with
known thoracic aortic aneurysm and/or dissection
are found to have thoracic aortic dilatation, aneu-
rysm, or dissection, then imaging of second-degree
relatives is reasonable.126 (Level of Evidence: B)
2. Sequencing of the ACTA2 gene is reasonable in
patients with a family history of thoracic aortic
aneurysms and/or dissections to determine if ACTA2
mutations are responsible for the inherited predis-
position.26,27,77,78,128,129 (Level of Evidence: B)
Class IIb
1. Sequencing of other genes known to cause familial
thoracic aortic aneurysms and/or dissection
(TGFBR1, TGFBR2, MYH11) may be considered
in patients with a family history and clinical
features associated with mutations in these
genes.26,27,77,78,128,129 (Level of Evidence: B)
2. If one or more first-degree relatives of a patient with
known thoracic aortic aneurysm and/or dissection
are found to have thoracic aortic dilatation, aneu-
rysm, or dissection, then referral to a geneticist may
be considered. (Level of Evidence: C)
A genetic basis of nonsyndromic familial thoracic aortic
aneurysms and dissection has only recently been defined.
Familial aggregation studies of patients referred for repair of
thoracic aortic aneurysm and dissection that did not have a
genetic defect have indicated that between 11% and 19% of
these patients have a first-degree relative with thoracic aortic
aneurysms and dissection.127,130 Patients with a family history
of thoracic aortic aneurysm and dissection present at a
younger mean age than do sporadic patients but at a signifi-
cantly older age than patients with Marfan or Loeys-Dietz
syndrome. The disease is primarily inherited in an autosomal
dominant manner with decreased penetrance primarily in
women and variable expression.131 These mapping studies
have firmly established that there is significant genetic
heterogeneity for familial thoracic aortic aneurysm and dis-
section (ie, many different genes can be mutated and cause
the same clinical condition).27,77,129,132–134 The causative gene
has been identified for the following loci: TAAD2 is due to
TGFBR2 mutations, the mutant gene at 16p is the MYH11
gene, and the TAAD4 defective gene is ACTA2.
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The defective gene at the TAAD2 locus for familial thoracic
aortic aneurysms and dissection was identified as TGFBR2,
which is the same gene that is mutated in approximately two
thirds of patients with Loeys-Dietz syndrome. Genetic testing of
unrelated families with familial thoracic aortic aneurysm and
dissections demonstrated that TGFBR2 mutations were only
present in 1% to 5% of families.26 All 4 families had mutations
that affected TGFBR2 arginine 460 of the receptor, suggesting
that missense mutation was associated with familial thoracic
aortic aneurysm and dissection (ie, genotype-phenotype correla-
tion). Although the majority of vascular disease in these families
involved the ascending aorta, affected family members also had
descending aortic disease and aneurysms of other arteries,
including cerebral, carotid, and popliteal aneurysms. It is notable
that similar to Loeys-Dietz syndrome, AoDs occur in patients
with TGFBR2 mutation at diameters less than 5.0 cm, leading to
the recommendation that aortic repair be considered at a internal
diameter by echocardiography of 4.2 cm or greater78 (see
Section 5.1).
A large French family with thoracic aortic aneurysm and
dissection associated with patent ductus arteriosus was used to
map the defective gene causing this phenotype to 16p.135 The
defective gene at this locus was identified as the smooth muscle
cell–specific myosin heavy chain 11 (MYH11), a major protein
in the contractile unit in smooth muscle cells.77 Subsequent
analysis of DNA from 93 unrelated families with thoracic aortic
aneurysm and dissection failed to identify any MYH11 muta-
tions. Sequencing DNA from 3 unrelated families with thoracic
aortic aneurysm and dissection associated with patent ductus
arteriosus identified MYH11 mutations in 2 of these families26;
the remaining family had a TGFBR2 mutation as the cause of the
thoracic aortic aneurysm and dissection and patent ductus
arteriosus. Therefore, MYH11 mutations are responsible for
familial thoracic aortic aneurysm and dissection associated with
patent ductus arteriosus and a rare cause of familial thoracic
aortic aneurysm and dissection.
A defective gene at the locus 10q23–24 was identified in a
large family with multiple members with thoracic aortic aneu-
rysm and dissection as ACTA2, which encodes the the smooth
muscle-specific alpha-actin, a component of the contractile
complex and the most abundant protein in vascular smooth
muscle cells.27,136 Approximately 15% of families with thoracic
aortic aneurysm and dissection have ACTA2 mutations.27 Fea-
tures identified in some families with ACTA2 mutation included
livedo reticularis and iris flocculi, although the prevalence of
these features has not been determined. The majority of affected
individuals presented with acute Type A or B dissections or
Type B dissections, with 16 of 24 deaths occurring due to Type
A dissections. Two of 13 individuals experienced Type A
dissections with a documented ascending aortic diameter less
than 5.0 cm. AoDs occurred in 3 individuals under 20 years of
age, and 2 women died of dissections postpartum. Finally, 3
young men had Type B dissection complicated by rupture or
aneurysm formation at the ages of 13, 16, and 21 years.
Identification of the underlying genetic mutation leading to
familial thoracic aortic aneurysms and dissections provides
critical clinical information for the family. First, only family
members who harbor mutations need to be routinely imaged for
aortic disease. Second, identification of the underlying mutation
may lead to different management of the aortic disease, as is the
case for TGFBR2 mutations. In addition to providing informa-
tion to families, identification of genes leading to familial
thoracic aortic aneurysms and dissections has emphasized the
roles of smooth muscle contractile function in preventing aortic
diseases.11 Individuals who undergo genetic testing for thoracic
aortic disease should receive genetic counseling prior to the
testing to explain the implications for the testing for their
medical follow-up and implications for family members.
5.2. Summary
The genes leading to nonsyndromic forms of aortic aneurysms
and dissections are in the early stages of identification. Tables 6
and 7 summarize the current clinical features associated with
mutations in these genes and recommendations for when to
sequence these genes in families with multiple members with
familial thoracic aortic aneurysm and dissection.
Given the familial risk of thoracic aortic aneurysms,
screening the proband’s first-degree relatives with appropri-
ate imaging studies is indicated in the absence of identifica-
tion of the defective gene leading to the disease.
Because thoracic aortic disease is typically asymptomatic
until a life-threatening event (eg, AoD) occurs, evaluating
Table 6. Gene Defects Associated With Familial Thoracic Aortic Aneurysm and Dissection
Defective Gene Leading to
Familial Thoracic Aortic
Aneurysms and Dissection
Contribution to Familial Thoracic
Aortic Aneurysms and
Dissection Associated Clinical Features Comments on Aortic Disease
TGFBR2 mutations 4% Thin, translucent skin Multiple aortic dissections
documented at aortic
diameters 5.0 cm
Arterial or aortic tortuosity
Aneurysm of arteries
MYH11 mutations 1% Patent ductus arteriosus Patient with documented
dissection at 4.5 cm
ACTA2 mutations 14% Livedo reticularis Two of 13 patients with
documented dissections
5.0 cm
Iris flocculi
Patent ductus arteriosus
Bicuspid aortic valve
ACTA2 indicates actin, alpha 2, smooth muscle aorta; MYH11, smooth muscle specific beta-myosin heavy chain; and TGFBR2, transforming
growth factor-beta receptor type II.
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other family members can potentially prevent premature
deaths. Most syndromes and familial forms of thoracic aortic
disease are inherited in an autosomal dominant manner.
Therefore, an individual with an inherited predisposition to
thoracic aortic aneurysm and dissections has up to a 50% risk
of passing on this predisposition to their children, which is the
basis for genetic evaluation of the offspring. In addition,
siblings and parents of the patient need to be evaluated for
possible predisposition to thoracic aortic aneurysm and dis-
sections. Because of the variable age of onset of aortic disease
in familial thoracic aortic aneurysms and dissections, the
writing committee believes that imaging of family members
at risk of the disease every 2 years is warranted.
6. Other Cardiovascular Conditions
Associated With Thoracic Aortic Aneurysm
and Dissection
6.1. Recommendations for Bicuspid Aortic Valve
and Associated Congenital Variants in Adults
Class I
1. First-degree relatives of patients with a bicuspid
aortic valve, premature onset of thoracic aortic
disease with minimal risk factors, and/or a familial
form of thoracic aortic aneurysm and dissection
should be evaluated for the presence of a bicuspid
aortic valve and asymptomatic thoracic aortic dis-
ease. (Level of Evidence: C)
2. All patients with a bicuspid aortic valve should have
both the aortic root and ascending thoracic aorta
evaluated for evidence of aortic dilatation.137–140
(Level of Evidence: B)
Bicuspid aortic valves is the most common congenital abnor-
mality affecting the aortic valve and the aorta and is found in
1% to 2% of the population.137 Nine percent of patients have
family members who also have bicuspid aortic valves.141 The
ACC/AHA Valvular Heart Disease Guidelines specifically
address this condition.5 Of importance to this guideline,
bicuspid aortic valves can be inherited in families as an
autosomal dominant condition and may be associated with
thoracic aortic aneurysm formation. It is important to note
that in these families, members can have thoracic aortic
aneurysms in the absence of bicuspid aortic valves.142 The
valves are prone to either aortic valve regurgitation, most
commonly seen in younger patients, or aortic valve stenosis,
more common in older patients. Bicuspid aortic valve repair
for regurgitation has excellent long-term results, an important
consideration in the absence of prosthetic aortic valve alter-
natives in this young population.99,139,140,143 The most com-
mon site of fusion of the leaflets is at the left and right leaflet
commissure, and less so at the right noncoronary leaflet
commissure. The latter is typically more often associated with
aortic valve stenosis. In a study of 2000 patients at the Cleveland
Clinic who underwent bicuspid aortic valve surgery, 20% had
concurrent ascending aortic aneurysms that required repair.139,140
Table 7. Genetic Syndromes Associated With Thoracic Aortic Aneurysm and Dissection
Genetic Syndrome Common Clinical Features Genetic Defect Diagnostic Test Comments on Aortic Disease
Marfan syndrome Skeletal features (see text)
Ectopia lentis
Dural ectasia
FBN1 mutations* Ghent diagnostic criteria
DNA for sequencing
Surgical repair when the aorta reaches
5.0 cm unless there is a family history
of AoD at 5.0 cm, a rapidly
expanding aneurysm or presence or
significant aortic valve regurgitation
Loeys-Dietz syndrome Bifid uvula or cleft palate TGFBR2 or TGFBR1
mutations
DNA for sequencing Surgical repair recommended at an
aortic diameter of 4.2 cm by TEE
(internal diameter) or 4.4 to 4.6 cm
by CT and/or MR (external diameter)
Arterial tortuosity
Hypertelorism
Skeletal features similar to MFS
Craniosynostosis
Aneurysms and dissections of other
arteries
Ehlers-Danlos syndrome,
vascular form
Thin, translucent skin COL3A1 mutations DNA for sequencing
Dermal fibroblasts for
analysis of type III
collagen
Surgical repair is complicated by
friable tissues
Noninvasive imaging recommended
Gastrointestinal rupture
Rupture of the gravid uterus
Rupture of medium-sized to large
arteries
Turner syndrome Short stature 45,X karyotype Blood (cells) for
karyotype analysis
AoD risk is increased in patients with
bicuspid aortic valve, aortic
coarctation, hypertension, or
pregnancy
Primary amenorrhea
Bicuspid aortic valve
Aortic coarctation
Webbed neck, low-set ears, low hairline,
broad chest
AoD indicates aortic dissection; COL3A1, type III collagen; CT, computed tomographic imaging; FBN1, fibrillin 1; MFS, Marfan syndrome; MR, magnetic resonance
imaging; TEE, transesophageal echocardiogram; TGFBR1, transforming growth factor-beta receptor type I; TGFBR2, transforming growth factor-beta receptor type II.
*The defective gene at a second locus for MFS is TGFBR2 but the clinical phenotype as MFS is debated.
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AoD is also common, and as many as 15% of patients with acute
AoD have bicuspid aortic valves,144 a frequency more common
than Marfan syndrome. AoD was present in 12.5% of patients
with bicuspid valves with an aortic diameter less than 5 cm,
reminiscent of patients with Marfan syndrome in whom 15%
had AoD at a size less than 5 cm.16,143
The writing committee discussed the potential need to screen
relatives of patients who have undergone aortic valve replace-
ment before age 70, as these younger patients were more likely
to have had bicuspid aortic valve as their primary pathology.
However, 40% of women and around one third of men over age
70 undergoing aortic valve replacement have bicuspid aortic
valve disease.145 The yield from screening relatives of younger
patients with bicuspid aortic valve disease compared with
relatives of older patients is not known.
6.2. Aberrant Right Subclavian Artery
Aberrant right subclavian artery, which arises as the fourth
branch from the aorta, courses behind the esophagus in
approximately 80% of patients and causes dysphagia in many
patients.146–149 The dysphagia usually occurs in adults as the
artery enlarges (Kommerell diverticulum).150,151 In most adult
patients, the aorta is also abnormal and is prone to aneurysm
formation, dissection, and rupture. Surgical treatment in
adults involves resection of the aneurysmal segment of the
subclavian artery (the diverticulum) and the adjacent aorta
and replacement of the aorta with a graft.152 An alternative
treatment is exclusion of the right subclavian artery origin
and adjacent aorta using an aortic endograft, although long-
term follow-up of this endovascular approach is not available
and the compression and aneurysm growth may continue.153
The distal normal segment of the subclavian artery is usually
not reimplanted into the descending aorta directly but rather
revascularized using an interposition graft or carotid-
subclavian bypass. Alternatively, the subclavian artery can be
ligated or coiled distal to the aneurysm, implanting the distal
segment into the adjacent carotid artery in the neck and thus
restoring flow to the upper extremity and the ipsilateral
vertebral artery.148,149,152
6.3. Coarctation of the Aorta
Coarctation of the aorta is a relatively common abnormality
that occurs in about 40 to 50 of every 100 000 live births, with
a 2:1 ratio in males versus females. Most lesions are treated
soon after birth or in childhood, and adults presenting with
untreated coarctation of the aorta are rare. More often,
patients have had previous procedures and present with later
problems such as heart failure, intracranial hemorrhage,
hypertension particularly with exercise, aneurysm formation,
AoD, rupture of old repairs, undersized grafts of previous
repairs, and infections. It is of particular importance in
previously treated patients with some aortic narrowing to
check for a gradient across the stenosis and for hypertension
during exercise testing.154
Untreated coarctation of the aorta has a dismal prognosis,
with 80% of patients dying from complications associated
with the coarctation. Approximately one quarter will die from
AoD or rupture, one quarter will die from heart failure, one
quarter will die from intracranial hemorrhage, and the re-
mainder will die from other complications.
Surgical options, depending on the lesion, include subcla-
vian artery patch aortoplasty, patch aortoplasty, bypass of the
coarctation, tube graft replacement, aneurysm replacement,
2-stage combined bicuspid valve surgery, and arch and
descending aorta replacement or ascending aorta–to–de-
scending aorta bypass.3 Endovascular balloon dilatation and
stent placement has been used successfully and is becoming
a less invasive alternative to conventional open surgical
procedures.155 Occasionally, the adult aorta may be redundant
and kinked opposite the ligamentum arteriosum without any
pressure gradient, the so-called pseudocoarctation. Aneu-
rysms that require surgical treatment may develop proximal
and distal to the kinked area.156
6.4. Right Aortic Arch
A right-sided aortic arch is present in approximately 0.5% of
the population and rarely requires surgical repair. However,
some patients present with dysphagia or asthma-like symp-
toms with expiratory wheezing. CT or MR readily diagnoses
the problem of either tracheal compression or esophageal
compression with the esophagus enlarged and filled with gas
above the level of the arch. Felson and Palayew described 2
types.157
In Type I, the great vessels come off the right-sided arch in
a manner that is a mirror image to normal anatomy; however,
compression of the esophagus or trachea is caused by an
enlarged aorta where it crosses the vertebral bodies or by the
vascular ring formed by the atretic ductus arteriosus. In Type
II, the aberrant left subclavian artery comes off the descend-
ing aorta and typically runs posterior to the trachea and
compresses the trachea. As with an aberrant right subclavian
artery, the proximal segment of the subclavian artery may
enlarge and form a Kommerell diverticulum. Other variations
are also seen but are exceedingly rare. A separate trunk may
arise from the arch, and from this trunk, the innominate,
carotid, and subclavian arteries arise. Another rare finding is
a right-sided arch with a stump of left-sided aorta joining the
right-sided arch after it crosses into the left chest. The stump
of the left-sided aorta gives off a branch to the left subclavian
artery. The aorta with right-sided arches is also abnormal and
typically very fragile and prone to AoD, rupture, or aneurysm
formation. Surgical repair involves resection of the aorta and,
if needed, reimplantation or bypass of the aberrant left
subclavian artery.
7. Inflammatory Diseases Associated With
Thoracic Aortic Disease
7.1. Recommendations for Takayasu Arteritis and
Giant Cell Arteritis
See Table 8.
Class I
1. Initial therapy for active Takayasu arteritis and
active giant cell arteritis should be corticosteroids at
a high dose (prednisone 40 to 60 mg daily at initia-
tion or its equivalent) to reduce the active inflam-
matory state.158,159 (Level of Evidence: B)
e292 Circulation April 6, 2010
D
ow
nloaded from
 http://ahajournals.org by on August 16, 2018
2. The success of treatment of patients with Takayasu
arteritis and giant cell arteritis should be periodi-
cally evaluated to determine disease activity by
repeated physical examination and either an eryth-
rocyte sedimentation rate or C-reactive protein lev-
el.160,161 (Level of Evidence: B)
3. Elective revascularization of patients with Takayasu
arteritis and giant cell arteritis should be delayed
until the acute inflammatory state is treated and
quiescent.162 (Level of Evidence: B)
4. The initial evaluation of Takayasu arteritis or giant
cell arteritis should include thoracic aorta and
branch vessel computed tomographic imaging or
magnetic resonance imaging to investigate the pos-
sibility of aneurysm or occlusive disease in these vessels.
(Level of Evidence: C)
Class IIa
1. It is reasonable to treat patients with Takayasu
arteritis receiving corticosteroids with an additional
anti-inflammatory agent if there is evidence of pro-
gression of vascular disease, recurrence of constitu-
tional symptoms, or re-elevation of inflammatory
marker.158 (Level of Evidence: C)
7.2. Takayasu Arteritis
Takayasu arteritis, also known as pulseless disease, is an
idiopathic vasculitis of the elastic arteries, involving the aorta
and its branches. Initially described in Japan, the disease is
found worldwide. In the United States, a review of cases in
Olmsted County, Minn, reported a rate of 2.6 cases per
million persons.158 In the United States, the disease affects all
ethnic and racial groups in proportion to the census with a
moderate Asian overrepresentation. The disease affects
women approximately 10 times more often than men. Most
commonly diagnosed in the third decade (ie, the 20s) of life,
the disease has been found in children and adults in the fifth
decade (ie, the 40s). Two specific disease distributions have
been reported: Japanese and Indian.167,168
In the Japanese distribution, the thoracic aorta and great
vessels are most commonly affected. In contrast, in the Indian
type, the disease most commonly affects the abdominal aorta
and the renal arteries.28 The pathogenesis of Takayasu arteri-
tis remains poorly defined. A T-cell–mediated panarteritis,
the disease proceeds from adventitial vasa vasorum involve-
ment inward. The antigen for the localized inflammatory
process is undefined but likely specific as the T cells undergo
clonal expansion. The outcome process of destruction and
fibrotic repair depends on the dominant pathophysiologic
process: destruction yields aneurysms while fibrosis causes
stenosis.
The diagnosis of Takayasu arteritis may be made using the
1990 American College of Rheumatology criteria: 1) age of
onset younger than 40 years, 2) intermittent claudication, 3)
diminished brachial artery pulse, 4) subclavian artery or
aortic bruit, 5) systolic blood pressure variation of greater
than 10 mm Hg between arms, and 6) angiographic (CT, MR)
evidence of aorta or aortic branch vessel stenosis163 (Figure
16). When 3 of the criteria are manifest, the sensitivity and
specificity for diagnosis are 90.5% and 97.8%, respectively.
Laboratory testing may aid in diagnosis. Markers of inflam-
mation, such as C-reactive protein and erythrocyte sedimen-
tation rate, are elevated in approximately 70% of patients in
the acute phase and 50% in the chronic phase of disease.158
The clinical manifestations of the disease typically develop
in 2 phases: acute and chronic. Acutely, the inflammation
associated with Takayasu arteritis causes a host of constitu-
tional, or “B,” symptoms, such as weight loss, fatigue, night
sweats, anorexia, and malaise.158 More chronically, once the
vascular process has endured, patients report symptoms
referable to the organs involved. In the largest US experience,
more than half of all patients experienced upper extremity
claudication, half had symptoms associated with cerebrovas-
cular insufficiency (vision loss, lightheadedness, stroke), and
a third reported carotid artery pain.158 In an Indian series,
hypertension as a result of renal artery involvement was the
most common presenting sign.169
The aorta itself may develop either aneurysm or stenosis.
In a Japanese series of 116 patients with Takayasu arteritis,
Table 8. Inflammatory Diseases Associated With Thoracic
Aortic Aneurysm and Dissection
Names
Criteria Used in
Diagnosis/Source
When Is Diagnosis
Established?
Takayasu
arteritis163
Age of onset 40 y 3 criteria are
present (sensitivity
90.5%; specificity
97.8%)
Intermittent claudication
Diminished brachial artery
pulse
Subclavian artery or aortic bruit
Systolic BP variation of
10 mm Hg between arms
Aortographic evidence of aorta
or aortic branch stenosis
Giant cell
arteritis164
Age 50 y 3 criteria are
present (sensitivity
greater than 90%;
specificity 90%)
Recent-onset localized
headache
Temporary artery tenderness or
pulse attenuation
Elevated erythrocyte
sedimentation 50 mm/h
Arterial biopsy shows
necrotizing vasculitis
Behçet
disease165
Oral ulceration Oral ulceration plus 2
of the other 3 criteriaRecurrent genital ulceration
Uveitis or retinal vasculits
Skin lesions—erythema
nodosum, pseudo-folliculitis, or
pathergy
Ankylosing
spondylitis166
Onset of pain 40 y 4 of the diagnostic
criteria are presentBack pain for 3 mo
Morning stiffness
Subtle symptom onset
Improvement with exercise
BP indicates blood pressure.
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Figure 16. Takayasu arteritis with involvement of the thoracoabdominal aorta and great vessels as shown on contrast-enhanced CT
and MR examinations. Note narrowing of the arterial lumen and circumferential soft tissue thickening of the walls of the great vessels
and thoracic and abdominal aorta. Panel A, Image through the great vessels with narrowing of the left common carotid and left subcla-
vian arteries. Panel B, Mid descending thoracic aorta (arrowheads). Panel C, Aorta just above the diaphragm (arrowheads). Panel D,
Infrarenal aorta. Panel E, Volume-rendered image from CT demonstrates the extent of involvement. Panel F, Oblique sagittal MR of the
thoracic aorta. Panel G, Coronal MR of the abdominal aorta. CT indicates computed tomographic imaging; and MR, magnetic reso-
nance imaging.
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nearly 32% of the patients had aortic aneurysm formation.170
Most commonly, aneurysm formation developed in the de-
scending aorta, followed by the abdominal, then ascending
aortic segments. In the National Institutes of Health series of
60 patients with Takayasu arteritis, 23% had aortic aneurysm
formation.158 Aneurysms most commonly formed in the
aortic arch or root, abdomen, and then other thoracic seg-
ments. Stenosis of the aorta is more common than is aneu-
rysm formation, occurring in 53% of patients in the National
Institutes of Health series. Any segment of the aorta may be
involved, but the abdominal aortic segment is affected more
than 70% of the time if stenosis is found.
Treatment of Takayasu arteritis begins with inflammation
reduction with corticosteroids. Steroids are typically started at
high dose, 40 to 60 mg daily at initiation to lower the
erythrocyte sedimentation rate or C-reactive protein to nor-
mal, and are required for 1 to 2 years to ensure proper disease
treatment.169 Despite the prolonged regimen, nearly half of
the patients will relapse during tapering, requiring additional
immunosuppression. Second-line agents that have been used
include methotrexate, azathioprine, and antitumor necrosis
factor-alpha agents.158,169 Unfortunately, markers of inflam-
mation are imperfect barometers of disease activity. Disease
progression has been shown to occur in the setting of normal
marker levels.158
Revascularization for aortic stenosis or aneurysm occurs
for the same indications as in noninflammatory disorders:
secondary organ vascular insufficiency or risk of rupture.
There are no randomized trials of percutaneous or surgical
intervention in this disease.158,171–173 Nonrandomized reports
have shown that revascularization of either variety may be
appropriate, with one caveat. The risk of graft failure is higher
in patients with active local inflammation.162 Moreover, the
presence of aneurysmal disease itself may be problematic.
One report documented a 12% incidence of anastomotic
aneurysms over 2 decades of follow-up related to the pres-
ence of aneurysms at surgery.174
7.3. Giant Cell Arteritis
GCA, also known as temporal arteritis, is an elastic vessel
vasculitis involving the aorta and its secondary and tertiary
branches. Distinguishing it from Takayasu arteritis, GCA
affects patients above the age of 50 years, with an incidence
peaking in the eighth decade of life.175 The disease affects
women in a 3:2 ratio to men and has a predilection for those
of northern European ancestry.29 In the United States, epide-
miologic investigation reports a prevalence of 20 cases per
100 000 persons. The incidence is higher in Scandinavian
nations but lower in southern Europe, suggesting a genetic
predisposition in certain populations.176
The clinical presentation of GCA is varied, requiring a
heightened suspicion by clinicians for early diagnosis. Half of
the patients report constitutional symptoms, such as weight
loss, night sweats, malaise, and fever.177 Because of the
predilection for secondary and tertiary thoracic branches of
the aorta, cranial symptoms are common. Scalp tenderness
and headache are present in two thirds of patients and in up
to 90% of patients with biopsy-proved disease.177 Jaw clau-
dication is common and affects half of the patients, 20%
develop visual changes, and other neurologic symptoms such
as stroke or neuropathy occur in nearly one third.29 Visual
changes are particularly important to notice, because early
treatment may prevent permanent blindness. Patients may
report diplopia, amaurosis fugax, or blurriness prior to blind-
ness. Polymyalgia rheumatica characterized by a generalized
inflammatory state with proximal muscle involvement is
found in nearly half of patients with GCA.29 Patients with
polymyalgia rheumatica report muscular pain and stiffness,
particularly on initiation of movement.
Extracranial vascular involvement is less common in GCA
than in Takayasu arteritis, occurring in 25% of patients. In a
50-year study of Olmsted County, Minn, that included 168
patients with GCA, aortic aneurysm/dissection was found in
18% of the subjects, whereas large-artery stenosis was noted
in 13% of patients.178 No patient had stenosis of the aorta.
Aortic aneurysm formation represents an important marker.
Although aneurysm formation per se does not reduce survival
compared with the GCA cohort as a whole, AoD in the setting
of an aneurysm reduces survival to an average of 1.1 years.178
Similarly, aortic aneurysm rupture or dissection caused two
thirds of deaths in a series of patients with GCA in California.179
The American College of Rheumatology diagnostic criteria
for GCA include 1) age older than 50 years, 2) recent-onset
localized headache, 3) temporal artery pulse attenuation or
tenderness, 4) erythrocyte sedimentation rate greater than
50 mm/h, and 5) an arterial biopsy demonstrating necrotizing
vasculitis.164 Three or more criteria confer a sensitivity and
specificity above 90% for the disease. With intracranial
disease, temporal artery biopsies are diagnostic in up to 80%
of cases.180 The rate of positivity declines with initiation of
glucocorticoid therapy, but this should not delay treatment to
avoid GCA complications. Biopsies performed within 7 days
of steroid initiation retain a high diagnostic yield.181
The pathophysiology of GCA shares important features
with Takayasu arteritis.28 GCA is marked by a T-cell clonal
expansion suggesting a specific antigenic response, which
currently remains unelucidated. The inflammatory response,
which begins in the adventitial layer, is marked by augmented
cytokine and MMP production causing granuloma formation.
Granuloma formation both shields the vessel from the incit-
ing antigen and causes vessel destruction. The inflammatory
environment within the vessel wall with the possible forma-
tion of aneurysms or vessel stenosis is histologically identical
to that of Takayasu arteritis. Because of the multiyear cyclical
nature of disease incidence, some have posited an infectious
etiology.29
Corticosteroids represent the standard in therapy for pa-
tients with GCA.182 The typical treatment regimen includes
starting prednisone dose of 40 to 60 mg daily, although recent
evidence suggests a similar efficacy with 30 to 40 mg
daily.183 Therapy is typically required for 1 to 2 years to avoid
recurrence, although the dose may be tapered beginning 2 to
3 months after initiation. Patients commonly report feeling
much better rapidly but, as with Takayasu arteritis, new
vascular involvement may occur in up to half of patients
treated with steroids.184 In contrast to Takayasu arteritis,
additional immunomodulatory agents do not seem to modu-
late the disease’s progress. Methotrexate studied in a double-
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blind, placebo-controlled study as an adjunct to prednisone did
not reduce morbidity, erythrocyte sedimentation rate level, or
cumulative prednisone dose.184a Revascularization recommen-
dations follow the same pattern as in Takayasu arteritis.
7.4. Behc¸et Disease
In 1937, Hulusi Behc¸et described his eponymous syndrome
based on a set of 3 symptoms: uveitis, aphthous stomatitis,
and genital ulcers. Most common in Turkey, with a preva-
lence of 80 to 370 cases per 100 000 persons,185,186 the
disease is much less common in the United States, with an
estimated prevalence of 1 to 3 cases per million persons.187
The diagnostic criteria were established by the International
Group for Behc¸et’s disease and require oral ulceration and 2
of these 3 lesions: recurrent genital ulceration, uveitis or
retinal vasculitis, or skin lesions, such as erythema nodosum,
pseudofolliculitis, or pathergy.188 In addition to these cardinal
manifestations, vascular involvement may occur in one third
of patients. A small vessel vasculitis commonly associated
with the human leukocyte antigen (HLA) B51 allele,187
Behc¸et disease is 1 of 2 vasculitides that may also involve
veins. Venous involvement is most commonly superficial
thrombophlebitis, but deep vein thrombosis in the vena cava,
varices, and cerebral sinuses has been reported.189 The small
vessel involvement of Behc¸et disease may result in nonvas-
cular complaints, such as erythema nodosum, arthritis, and
gastrointestinal involvement with diarrhea, gastrointestinal
bleeding, or perforation.187 Treatment of Behc¸et disease
varies based on the manifestation of disease. Systemic corti-
costeroids are the typical therapy for those with vascular
involvement.
Specifically with regard to vascular manifestations of
Behc¸et disease, any artery or vein, large or small, systemic or
pulmonary, may be involved by the vasculitic process. Aortic
histopathology shows lymphocytic infiltration mixed with
histiocytes and eosinophils with giant cells around vasa
vasorum of media and adventitia. Destruction of media leads
to aneurysm formation and may proceed to pseudoaneurysm
formation and rupture. Aneurysm formation may occur in
multiple sites and in different sites over a period of follow-up.
Aneurysm, stenotic lesions, and occlusion of brachiocephalic
arteries may occur with or without aortic involvement.
Although aortic involvement is unusual for patients with
Behc¸et vasculitis, aneurysm rupture can be unpredictable and
fatal.190,191 With regard to surgical repair, anastomotic
pseudoaneurysms often occur (12.9% within 18 months in 1
series) and may be related to ongoing inflammatory changes
in the area of anastomotic suture lines.192 Endovascular repair
with stent grafts has also been described.193
7.5. Ankylosing Spondylitis (Spondyloarthropathies)
The group of diseases labeled spondyloarthropathies are
linked by the strong association of major histocompatibility
complex HLA B-27 and the absence of rheumatoid fac-
tor.194,195 Several features are common to the spondyloar-
thropathies, including sacroilitis, inflammatory arthritis or
enthesitis (inflammation of tendon insertions), associations
with inflammatory bowel disease or psoriasis, and aortitis and
heart block.195
Ankylosing spondylits is the most common variant and
often begins with back pain and stiffness in the second or
third decade of life. It affects men 2 to 3 times as often as
women, worsens with inactivity, and commonly takes years
for the diagnosis to be made.196 The diagnosis requires 4 of
the 5 criteria: onset of pain at younger than 40 years, back
pain for longer than 3 months, morning stiffness, subtle
symptom onset, and improvement with exercise.197 Patients
may also report constitutional symptoms, such as malaise or
fever. Acute anterior uveitis is reported in up to 40% of
patients. Aortic root and aortic valve involvement are re-
ported in up to 80% of patients.198 When involved, the aortic
valve may have a nodular appearance, and aortic valvular
regurgitation is present in nearly half of the patients.198
Treatment of aortic root expansion and aortic valvular abnor-
malities is the same as for other conditions.
7.6. Infective Thoracic Aortic Aneurysms
Infection (due to bacterial, fungal, viral, spirochetal, or
tubercular organisms) is a rare cause of thoracic aortic
aneurysms. Originally named mycotic endarteritis by Os-
ler,199 the terms infected aneurysm or infectious aortitis are
now used more commonly, because the majority of etiologic
agents are nonfungal. Saccular aneurysms are most common,
but infected aneurysms can be fusiform and often even
pseudoaneurysms. The ascending thoracic aorta, aortic arch,
and descending thoracic aorta can all be affected, as can
prosthetic aortic grafts and aortic homografts. Typically, the
sites of infected aneurysms are opposite the great vessels in
the aortic arch or opposite the visceral ateries in the abdomen.
There are several mechanisms by which the aortic infection
may arise. First, there may be contiguous spread from
adjacent thoracic structures, such a mediastinitis, abscess,
infected lymph nodes, infectious pericarditis, empyema, or
paravertebral abscess. Second, there may be septic emboli
from underlying bacterial endocarditis. Third, there may be
hematogenous dissemination of bacteria in the setting of
sepsis or intravenous drug abuse. Infection most often arises
in a diseased aorta, either in a preexisting aneurysm, at the
site of an atherosclerotic plaque, or at the site of some
accidental or iatrogenic aortic trauma. Indeed, infected tho-
racic aortic aneurysms may arise as a late complication of
cardiac surgery, often associated with postoperative medias-
tinitis, typically at the sites of aortic cannulation or anasto-
motic suture lines.200,201
Various organisms can infect the aorta, with most infec-
tions being bacterial. Staphylococcus aureus and Salmonella
are the organisms most commonly identified.202–204 Pneumo-
coccus and Escherichia coli are relatively common gram-
positive and gram-negative pathogens, respectively.
Treponema pallidum, the gram-negative spirochete bacte-
rium that causes syphilis, as well as other Treponema species,
can cause infected aortitis, with the ascending thoracic aorta
most often involved. However, in syphilitic aortitis, thoracic
aortic aneurysm does not appear for 10 to 25 years after the
initial spirochetal infection. Fungal infections of the aorta,
with either Candida or Aspergillus, occur less often205 and
typically occur in the setting of impaired immunity, such as
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patients with systemic illness, human immunodeficiency
virus, or prior organ or bone marrow transplant.
Indeed, patients with impaired immunity are also at in-
creased risk of tuberculous aortitis attributable to mycobac-
terium tuberculosis. Tuberculous aortitis has until now been
exceedingly rare, but the incidence may rise as the prevalence
of tuberculosis rises worldwide. Tuberculous aortitis typically
affects the distal aortic arch and descending thoracic aorta,
likely because the aorta is thought to become infected via
direct extension from continuous infected lymph nodes,
empyema, or pericarditis.206
Finally, there appears to be an independent association
between human immunodeficiency virus and ascending tho-
racic aortic dilatation, although its mechanisms are poorly
understood.207,208 Moreover, the incidence of frank aneu-
rysms remains extremely low.
8. Acute Aortic Syndromes
Acute aortic syndromes consist of 3 interrelated conditions
with similar clinical characteristics and include AoD, IMH,
and PAU.209
8.1. Aortic Dissection
8.1.1. Aortic Dissection Definition
AoD is defined as disruption of the media layer of the aorta
with bleeding within and along the wall of the aorta resulting
in separation of the layers of the aorta. In the majority of
patients (90%), an intimal disruption is present that results in
tracking of the blood in a dissection plane within the media.
This may rupture through the adventitia or back through the
intima into the aortic lumen (Figure 17). This classic dissec-
tion results in a septum, or “flap,” between the 2 lumens
(Figure 18). The false lumen may thrombose over time
(Figure 19). While on noninvasive imaging, 15% of patients
with aortic dissection syndromes have an apparent IMH
without evidence of an intimal tear, autopsy studies show
only 4% have no visible intimal tear; indeed, at the time of
surgery a tear is found in most patients.210,211 Occasionally,
AoD originates from a small atheromatous ulcer that is
difficult to identify. On the other hand, extensive atheroma-
tous disease of the aorta may lead to PAU or a localized IMH.
The true incidence of acute AoD is difficult to define for 2
principal reasons: 1) acute AoD can be rapidly fatal, and
when patients die prior to hospitalization, death may be
erroneously attributed to another cause and 2) acute AoD is
frequently missed on initial presentation, and early mortality
among this group may be misclassified as non–dissection
related. Population-based studies suggest that the incidence of
acute AoD ranges from 2 to 3.5 cases per 100 000 person-
years, which correlates with 6000 to 10 000 cases annually in
the United States.75,212,215–217 A review of 464 patients from
IRAD reported a mean age at presentation of 63 years, with
significant male predominance (65%).47 The prevalence of
AoD appears to be increasing, independent of the aging
population, as noted by Olsson and colleagues,218 who found
the incidence of AoD among Swedish men has increased to
16 per 100 000 men yearly. It may be that 2 to 3 times as
many patients die from AoD than from ruptured AAA;
approximately 75% of patients with AAA will reach an emer-
gency department alive, whereas for AoD, the prognosis appears
to be worse, with 40% dying immediately, 1% per hour dying
thereafter, and between 5% and 20% dying during or shortly
after surgery.219–221 Furthermore, only 50% to 70% will be alive
5 years after surgery depending on age and underlying etiolo-
gy.222 Because AoD tends to occur in areas of aneurysmal
dilatation, treatment of aneurysms before dissection occurs is
important to long-term survival3 (see Section 8.1).
Regarding time from onset of initial symptoms to time of
presentation, acute dissection is defined as occurring within 2
weeks of onset of pain; subacute, between 2 and 6 weeks
from onset of pain; and chronic, more than 6 weeks from
onset of pain.
8.1.2. Anatomic Classification of Aortic Dissection
Anatomically, acute thoracic AoD can be classified according to
either the origin of the intimal tear or whether the dissection
involves the ascending aorta (regardless of the site of origin).
Accurate classification is important as it drives decisions
regarding surgical versus nonsurgical management. The 2 most
Figure 17. Classes of intimal tears. I. Classic dissection with
intimal tear and double lumen separated by septum. Communi-
cation between lumens is typically in descending aorta at
sheared-off intercostal arteries or distal reentry site. II. IMH. No
intimal tear or septum is imaged but is usually found at surgery
or autopsy. DeBakey Types II and IIIa are common extent of this
lesion. III. Intimal tear without medial hematoma (limited dissec-
tion) and eccentric aortic wall bulge. Rare and difficult to detect
by TEE or CT. Patients with Marfan syndrome prone to this
type. May result in aortic rupture or extravasation. IV. PAU usu-
ally to the adventitia with localized hematoma or saccular aneu-
rysm. May propagate to Class I dissection, particularly when
involving ascending aorta or aortic arch. V. Iatrogenic (catheter
angiography or intervention)/traumatic (deceleration) dissection.
CT indicates computed tomographic imaging; IMH, intramural
hematoma; PAU, penetrating atherosclerotic ulcer; and TEE,
transesophageal echocardiography. Figure reprinted with per-
mission from the Cleveland Clinic Foundation. Legend adapted
from Svensson et al,212 Chirillo et al,213 and Murray et al.214
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commonly used classification schemes are the DeBakey and the
Stanford systems (Figure 20). For purposes of classification, the
ascending aorta refers to the aorta proximal to the brachioce-
phalic artery, and the descending aorta refers to the aorta distal
to the left subclavian artery.
The DeBakey classification system categorizes dissections
based on the origin of the intimal tear and the extent of the
dissection:
● Type I: Dissection originates in the ascending aorta and propa-
gates distally to include at least the aortic arch and typically the
descending aorta (surgery usually recommended).
● Type II: Dissection originates in and is confined to the
ascending aorta (surgery usually recommended).
● Type III: Dissection originates in the descending aorta and
propagates most often distally (nonsurgical treatment usually
recommended).
– Type IIIa: Limited to the descending thoracic aorta.
– Type IIIb: Extending below the diaphragm.
The Stanford classification system divides dissections into
2 categories, those that involve the ascending aorta and those
that do not.
Figure 18. Type A aortic dissection and extent of involvement depicted on axial CT images from the cranial to caudal direction.
Although the flap appears to disappear in the infrarenal, it is actually compressed against the anterior wall of the aorta in Panel G
(arrowheads) and it is clearly present caudally in the common iliac arteries in Panel H. Hemopericardium (asterisk) is visible in Panel D.
Bowel wall thickening (arrowheads) indicates ischemia in Panel I. Panel A, Aortic arch. Panel B, Mid thorax. Panel C, Aortic root. Panel
D, Just above the diaphgram. Panel E, At the level of the celiac axis. Panel F, Mid kidneys. Panel G, Infrarenal aorta. Panel H, Proximal
common iliac arteries. Panel I, Image through the mid abdomen at narrow window/level settings demonstrates small bowel wall thick-
ening due to bowel ischemia caused by apposition of the flap against the origins of the celiac axis and superior and inferior mesenteric
arteries. CT indicates computed tomographic imaging; F, false lumen; and T, true lumen.
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● Type A: All dissections involving the ascending aorta
regardless of the site of origin (surgery usually recom-
mended) (Figures 18 and 20).
● Type B: All dissections that do not involve the ascending
aorta (nonsurgical treatment usually recommended). Note
involvement of the aortic arch without involvement of the
ascending aorta in the Stanford classification is labeled as
Type B (Figure 21).
At this time, there is no unanimity regarding which
classification system is the ideal one to use. Some of the
writing committee members believe that a more pragmatic
approach is to refer to the dissection involving the aorta as
either proximal or distal to the left subclavian artery. Others
of the writing committee do not use this approach. Thus, if a
patient has an arch dissection even without ascending aortic
involvement, then immediate surgery would be recommended
by some, if feasible and the patient is viable. Others on the
writing committee would select medical management if the
patient has only an arch dissection without proximal exten-
sion, malperfusion, or bleeding, as long as repeat imaging
demonstrates stability. If there is evidence of malperfusion or
bleeding in such a patient, then the writing committee would
usually select a surgical approach.
The intimal tear and AoD can also be categorized into classes
that may have a bearing on treatment212,213 (Figure 17).
8.1.3. Risk Factors for Aortic Dissection
Risk factors for AoD include conditions that result in aortic
medial degeneration or place extreme stress on the aortic wall
(Table 9). Two thirds to three quarters of patients have
hypertension, which is often uncontrolled. Genetic predispo-
sition (see Section 5) to AoD can occur in the context of a
syndrome, such as Marfan syndrome or Loeys-Dietz syn-
drome, or can be inherited in families in the absence of
syndromic features.3 IRAD data showed that of patients under
40 years of age with AoD, 50% had a history of Marfan
syndrome.223 Other congenital or genetically based diseases
as well as inflammatory conditions associated with a higher
risk of AoD are noted in Sections 6.3, 6.4, and 7.
First and foremost, a family history of thoracic aortic
aneurysm is an important risk factor. In 2 separate clinical
studies, 13% to 19% of patients without an identified genetic
syndrome with thoracic aortic aneurysms had first-degree
relatives with thoracic aortic aneurysms or AoD.127,130 The
term “familial thoracic aortic aneurysm and dissection syn-
drome” is often applied (see Section 5). In taking a history for
thoracic aortic disease, one should be careful to distinguish a
history of an abdominal aortic aneurysm from a thoracic
aortic aneurysm. Many people, even healthcare providers,
mistakenly use the terms AAA or triple A for any aortic
aneurysm, regardless of location. Clarifying that the aneu-
rysm was thoracic rather than abdominal affects one’s con-
sideration of risk. Also, one must consider the potential
underlying diagnosis when a patient reports a family history
of “sudden death” or “heart attack” when there was no
confirmatory autopsy. If the patient’s father, at the age of 45,
had sudden onset of chest pain and then died moments later,
Figure 19. Type A Aortic dissection with
thrombosed false lumen and left renal artery
involvement depicted on axial CT images.
Demonstrates marked narrowing of the true
lumen, patent right renal artery arising from the
true lumen (bottom left, arrow), and narrow left
renal artery compressed by thrombus in the
false lumen, with secondary decreased
enhancement of the left kidney compared with
the right kidney. Top left, At the level of the left
main coronary artery. Top right, At the celiac
axis. Bottom left, At the right renal artery
(arrow). Bottom right, At the left renal artery
(arrow). *Thrombus in false lumen. CT indicates
computed tomographic imaging; L, left kidney;
and R, right kidney.
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there is a chance that the death may have been from an acute
AoD rather than an acute MI.
The history may reveal syndromic causes of thoracic aortic
aneurysm and dissections, especially Marfan, Loeys-Dietz,
and vascular Ehlers-Danlos syndromes. In some cases, pa-
tients have only some of the features of Marfan or Loeys-
Dietz syndrome, rather than the full-blown clinical syndrome,
so a history of any phenotypic features, such as mitral valve
prolapse or pectus excavatum, should prompt consideration
of thoracic aortic aneurysms or dissections.224,225 Bicuspid
aortic valve is a strong risk factor for ascending thoracic
aortic aneurysms, as well as coarctation of the aorta. In
addition, a history of extreme exertion or emotional distress
may preceed the onset of pain.226
8.1.4. Clinical Presentation of Acute Thoracic
Aortic Dissection
The clinical presentation of acute AoD spans a spectrum from
the overt with classic pain and physical examination findings
to the enigmatic as a painless process with few physical
manifestations of the disease (Table 10). Given its exceed-
ingly high mortality, clinicians must maintain a high index of
suspicion for acute AoD, as noted in Section 8.6 (Figure 22).
8.1.4.1. Symptoms of Acute Thoracic Aortic Dissection
Patients with acute aortic syndromes often present in a similar
fashion, regardless of whether the underlying condition is
AoD, IMH, PAU, or contained aortic rupture. Pain is the most
commonly reported presenting symptom of acute AoD re-
gardless of patient age, sex, or other associated clinical
complaint.228–235 Pooled data from over 1000 patients in 8
studies found that the pain of acute dissection is perceived as
abrupt in onset in 84% of cases (95% CI 80% to 89%) and of
severe intensity in 90% of cases (95% CI 88% to 92%).236
Although classically described as having a tearing or ripping
quality, registry data suggest patients are more likely to
describe the pain of acute dissection as sharp or stabbing
(51% to 64%, respectively) and that report of a migrating
quality to pain is highly variable (12% to 55%).228,236 Pain
may subsequently ease or abate, leading to a false reassurance
on the part of the patients and physicians.
Figure 20. Aortic dissection classification:
DeBakey and Stanford Classifications.
Reprinted with permission from the
Cleveland Clinic Foundation.
Figure 21. Type B aortic dissection with medi-
astinal hematoma and pleural blood. Ruptured
Type B aortic dissection with mediastinal
hematoma (*) and pleural blood. Left, Flap
arises in the proximal descending thoracic
aorta, with faint contrast-enhanced blood adja-
cent to the site of rupture outside the confines
of the aortic wall (arrow). Right, At the level of
the aortopulmonary window. FL indicates false
lumen; PL, pleural blood; and TL, true lumen.
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Pain location and other associated symptoms reflect the
site of initial intimal disruption and may change as the
dissection extends along the aorta or involves other arteries or
organ systems.236 Data from 464 patients enrolled in IRAD
found that patients with Type A dissections most frequently
present with chest pain (80%), more commonly described as
anterior (71%) than as posterior (32%).228 Although less
common, patients with Type A dissection report back pain
(47%) and abdominal pain (21%), presumably as a result of
antegrade dissection into the descending aorta.228 In contrast,
patients with Type B dissections are most likely to present
with back pain (64%) followed by chest and abdominal pain
(63% and 43%, respectively).228 Some patients present with
abdominal pain in the absence of chest pain or with only
painful or numb lower extremities related to end-organ
ischemia. In 1 retrospective study of 44 patients ultimately
diagnosed with acute thoracic AoD, the location of the
patient’s pain was highly predictive of the clinician’s
suspicion for acute AoD; dissection was suspected in 86%
of patients who presented with chest and back pain, 45% of
those who presented with chest pain alone, and only 8% of
those primarily abdominal pain.237
Although uncommon, acute AoD may present without
pain.238–240 In a separate analysis of 977 IRAD patients, 63
patients (6.4%) presented without pain.241,242 This group of
patients was noted to be older and more likely to present with
syncope, stroke, or congestive heart failure than were patients
with painful dissection.241 Patients on steroids and patients
with Marfan syndrome may be more prone to present without
pain.243
8.1.4.2. Perfusion Deficits and End-Organ Ischemia
Perfusion deficits as a result of dissection-related obstruction
of aortic branch vessels have long been recognized as a
common clinical manifestation, resulting in organ complica-
tions at initial presentation (Table 11). End-organ involve-
ment in acute thoracic AoD can occur via several mecha-
nisms. Most occlusions are caused by obstruction by the
dissection flap, which can either prolapse across a vessel
origin without entering it (dynamic obstruction) or directly
extend into a vessel (static obstruction)244 (Figure 18). Other
causes include postobstructive arterial thrombosis, embolism
to branches of either the true or false lumen, direct compres-
sion of an aortic branch artery or adjacent structures by an
expanding false lumen,245 rupture or leakage of the false
lumen into contiguous structures, and occlusion or dissection
of coronary arteries and/or aortic valve distortion leading to
heart failure.
Physical examination is insensitive to renal and mesen-
teric ischemia early in the course of acute AoD. Elevated
serum creatinine or refractory hypertension may be due to
renal ischemia but may represent the clinical baseline in a
patient with poorly documented or inadequately treated
prior medical conditions. Serologic markers of mesenteric
ischemia may not be present until hours after onset.
Combined data from over 1500 patients in 16 studies found
that pulse deficits were present in 31% of cases (95% CI 24%
Table 9. Risk Factors for Development of Thoracic
Aortic Dissection
Conditions associated with increased aortic wall stress
Hypertension, particularly if uncontrolled
Pheochromocytoma
Cocaine or other stimulant use
Weight lifting or other Valsalva maneuver
Trauma
Deceleration or torsional injury (eg, motor vehicle crash, fall)
Coarctation of the aorta
Conditions associated with aortic media abnormalities
Genetic
Marfan syndrome
Ehlers-Danlos syndrome, vascular form
Bicuspid aortic valve (including prior aortic valve replacement)
Turner syndrome
Loeys-Dietz syndrome
Familial thoracic aortic aneurysm and dissection syndrome
Inflammatory vasculitides
Takayasu arteritis
Giant cell arteritis
Behçet arteritis
Other
Pregnancy
Polycystic kidney disease
Chronic corticosteroid or immunosuppression agent administration
Infections involving the aortic wall either from bacteremia or extension
of adjacent infection
Table 10. International Registry of Acute Aortic Dissection
(IRAD) Physical Findings of 591 Patients With Type A
Aortic Dissection
Presenting Hemodynamics and Clinical Findings Frequency/Finding
Hypertensive 32%
Normotensive 45%
Hypotensive 14%
Shock 13%
Cardiac tamponade 5%
Murmur of aortic insufficiency 45%
Pulse deficits 26%
Pericardial friction rub 2%
Cerebrovascular accident 8%
Ischemic peripheral neuropathy 3%
Ischemic spinal cord damage 2%
Ischemic lower extremity 10%
Coma/altered consciousness 12%
Congestive heart failure 5%
First blood pressure systolic, mean 130 mm Hg
First blood pressure diastolic, mean 75 mm Hg
Adapted from Pape et al.227
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to 39%) and, when present, were strongly suggestive of AoD
(positive likelihood ratio 5.7; 95% CI 1.4 to 23)37 and predict
increased risk. Of 513 cases of Type A dissection, patients
with perfusion deficits were more likely to present with
hypotension, shock, neurologic deficits, and tamponade and
were more likely to have higher rates of hospital complica-
tions and mortality (41% versus 25%, P0.0002).246 Further-
more, overall mortality rates correlated with the number of
pulse deficits present, likely as a reflection of the extent of
vascular compromise and associated end-organ ischemia.246
Similarly, of 118 patients with Type A acute dissection, limb
ischemia (defined as loss of pulse with associated pain and
neurologic symptoms) was present in 38 cases (32%).247 The
presence of limb ischemia was associated with an increased
likelihood of other end-organ ischemia (ie, cerebral, visceral,
or coronary) and a significant increase in overall mortality.247
Figure 22. Acute surgical management pathway for AoD. *Addition of ‘if appropriate’ based on Patel et al.226a AoD indicates aortic dis-
section; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; TAD, thoracic aortic disease; and TEE, transesoph-
ageal echocardiogram.
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Among the 38 patients with limb ischemia, in-hospital
mortality was 45% compared with 15% among the 61
patients without organ malperfusion.247
These studies underscore the clinical importance of an
adequate vascular examination to help both identify the
disease and stratify risk once the diagnosis is established.
Every patient being evaluated for possible acute AoD should
have pulses checked in all extremities to identify the presence
of perfusion deficits. In patients with acute limb ischemia
versus those without, renal and mesenteric malperfusion were
nearly 2-fold more frequent and mortality was twice as high,
further highlighting the importance of this finding.248
8.1.5. Cardiac Complications
The heart is the most frequently involved end organ in acute
AoD involving the ascending aorta. In distinction to other
end-organ pathology, most cardiac complications are a direct
result of dissection-related disruption of normal anatomic
relationships.215,245
8.1.5.1. Acute Aortic Regurgitation
Acute aortic regurgitation is the most commonly recognized
cardiac complication of Type A dissection,228–234 occurring in
41% to 76% of cases.228–232 Three distinct dissection-related
mechanisms for acute aortic valve incompetence have been
identified, and they can occur in combination: 1) acute
dilatation of the aortic root by an expanding false lumen,
resulting in incomplete aortic valve closure; 2) a dissection
extending into the aortic root and disrupting aortic valve
commissural attachments, resulting in valve leaflet prolapse;
and 3) a portion of dissection flap prolaping through the
aortic valve in diastole, preventing adequate leaflet closure.235
Clinical manifestations of dissection-related aortic regurgita-
tion span the spectrum from only a hemodynamically insig-
nificant diastolic murmur to congestive heart failure and
cardiogenic shock.236,249
8.1.5.2. Myocardial Ischemia or Infarction
Myocardial ischemia or infarction is an infrequent but serious
complication of acute AoD. Registry and review data suggest
that ECG evidence of myocardial ischemia was present in up
to 19% of patients with acute AoD, whereas pooled data from
988 patients in 9 different studies found that acute MI was
present in 7% of cases (95% CI 4% to 14%).37,47,250 Coronary
artery flow can be compromised by an expanding false lumen
compressing the proximal coronary or by extension of the
dissection flap into the coronary artery ostium.251
Clinically, a dissection-related cardiac malperfusion syn-
drome may present with ECG changes that are indistinguish-
able from those of primary myocardial ischemia or infarction,
increasing the likelihood of misdiagnosis and inappropriate
therapeutic intervention.252
8.1.5.3. Heart Failure and Shock
Heart failure is a relatively uncommon complication of AoD,
found to occur in approximately 6% of cases.236 In this
setting, heart failure may result from acute aortic insuffi-
ciency, acute myocardial ischemia or infarction, or cardiac
tamponade. Registry data suggest that patients with acute
AoD complicated by heart failure are often atypical in their
presentation, frequently leading to a delay in diagnosis.236
The largest study to evaluate heart failure in acute AoD
included 1069 patients from the IRAD database and found
that patients with AoD and concomitant heart failure were
more likely to present in shock but were less likely to
complain of chest pain and that, when chest pain was present,
the pain was more often mild and less often abrupt in onset.236
8.1.5.4. Pericardial Effusion and Tamponade
Pericardial pathology is a frequent complication of acute Type A
AoD and can occur via 2 distinct mechanisms.37,253–256 Most
commonly, transudation of fluid across the thin wall of an
adjacent false lumen into the pericardial space leads to a
hemodynamically insignificant pericardial effusion,256 which
is present in about one third of patients.257 Less often, the
dissected aorta ruptures directly into the pericardium, leading
rapidly to tamponade physiology and hemodynamic compro-
mise.245,258,259 Cardiac tamponade is diagnosed in 8% to 10%
of patients presenting with acute Type A AoD and is an
ominous clinical predictor of poor outcomes,260 as well as the
leading cause of mortality in this group.47,215,231 Conse-
quently, the presence of cardiac tamponade should prompt
truly urgent aortic repair.260
8.1.6. Syncope
Syncope is a well-recognized dissection-related complaint
occurring in approximately 13% of cases242,261 with multiple
potential etiologies, including: 1) cardiac (eg, severe aortic
regurgitation, ventricular outflow obstruction, cardiac tam-
ponade), 2) vascular (eg, impaired cerebral blood flow and
aortic baroreceptor activation); 3) neurologic (eg, vasovagal
in response to pain), and 4) volume-related (eg, false lumen
rupture into the pleural space) causes.240,261–267 Regardless of
its etiology, syncope in the setting of AoD increases the risk
of near-term adverse events. In a review of 728 cases of acute
AoD, patients with a history of syncope were significantly
more likely to die than were those without syncope (34%
Table 11. End-Organ Complications of Acute Aortic Dissection
Type End-Organ Complication
Cardiovascular Aortic insufficiency
Syncope
Pericardial tamponade
Myocardial ischemia or infarction
Congestive heart failure
Neurologic Ischemic stroke or transient ischemic attack
Peripheral neuropathy
Paraplegia/paraparesis
Spinal ischemia
Pulmonary Pleural effusion
Aortopulmonary fistula with hemorrhage
Gastrointestinal Mesenteric ischemia or infarction
Aortoenteric fistula with hemorrhage
Renal Renal failure
Renal ischemia or infarction
Extremities Limb ischemia
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versus 23%, respectively; P0.01).242 Additionally, patients
who presented with syncope more frequently had associated
cardiac tamponade, stroke, decreased consciousness, and
evidence of spinal cord ischemia.242
8.1.7. Neurologic Complications
Acute AoD frequently presents with dissection-related neu-
rologic complications. Pooled data from more than 1300
patients in 13 studies that included both Type A and B
dissections found that neurologic symptoms were reported in
17%.37 Neurologic complications may result from hypoten-
sion, malperfusion, distal thromboembolism, or nerve com-
pression.251,253,254 In a recent study of 102 patients with Type
A AoD, 29% had neurologic symptoms on initial presenta-
tion253; of those with neurologic symptoms, 53% had ische-
mic stroke (predominantly right hemispheric) and 37% had
ischemic neuropathy (described as limb pain with sensory or
motor deficit).253
Last, although uncommon, acute paraplegia as a result of
spinal cord malperfusion has been described as a primary
manifestation of thoracic AoD, occurring in 1% to 3% of
patients.215,251,253,254,268,269
Of clinical note, up to 50% of dissection-related neurologic
symptoms may be transient and as many as one-third of
patients with neurologic symptoms present without com-
plaints of chest pain, complicating appropriate diagnosis and
treatment.253,255,256,262,269–271
8.1.8. Pulmonary Complications
Pleural effusion, the most common pulmonary complication
of acute AoD, is noted in 16% of cases at presentation37;
whereas large effusions may result from leaking of blood
from the aorta into the pleural space, small effusions are
typically a nonhemorrhagic exudate believed to be inflamma-
tory in origin.37,272–275
Other pulmonary complications of acute AoD include
dissection-related compression of the pulmonary artery and
development of an aortopulmonary fistula, either of which
may present with dyspnea as a prominent symptom.276–278
Hemoptysis, noted in 1 study in 3% of patients presenting
with thoracic AoD, may result from compression of lung
parenchyma by an expanding false lumen or via direct
aneurysmal rupture into the lung, leading to massive hemop-
tysis and death.215,279,280
8.1.9. Gastrointestinal Complications
Mesenteric ischemia is the most common gastrointestinal
complication of acute AoD228 and can result from malperfu-
sion or systemic hypotension. It is the most common cause of
death among those with Type B AoD. Mesenteric ischemia is
associated with abdominal pain, but pain may be nonspecific
and out of proportion to the physical examination of the
abdomen, so the cause of pain often goes unrecognized early
on. Unfortunately, by the time serum markers of bowel
ischemia or infarction turn positive, it is often too late to
salvage the bowel or the patient. Therefore, it is essential to
be viligant for mesenteric ischemia in every patient with
acute AoD and associated abdominal pain.
Gastrointestinal hemorrhage is a rare but potentially cata-
strophic complication of acute AoD.281–283 Dissection-related
gastrointestinal bleeding may present with limited bleeding as
a result of mesenteric infarction or as massive hemorrhage
secondary to an aortoesophageal fistula or false lumen rup-
ture into proximal small bowel.281–283 Although rare,
dissection-related gastrointestinal hemorrhage should be in
the differential of all patients presenting with bleeding and
complaints of thoracic or abdominal pain.
8.1.10. Blood Pressure and Heart Rate Considerations
Blood pressure abnormalities are common in patients pres-
enting with acute thoracic AoD. About half of patients are
hypertensive at presentation, with 71% of Type B patients
having a systolic blood pressure greater than 150 mm Hg
versus only 36% of Type A patients.284–287 Conversely,
nearly 20% present with either hypotension or shock.37
Hypotension and shock can result from cardiac tamponade,
aortic hemorrhage, severe aortic insufficiency, myocardial
ischemia or infarction, true lumen compression by distended
false lumen, or an intra-abdominal catastrophe. Of more than
1000 patients with acute AoD, those with hypotension on
admission were found more likely to have neurologic com-
plications; myocardial, mesenteric, or limb ischemia; and
death.249
Accurate systemic blood pressure measurement may be
complicated by dissection-related occlusion of aortic branch
arteries, resulting in erroneously low blood pressure readings
in the affected limb. Accordingly, blood pressures may need
to be measured in both arms and, at times, both legs to
determine the highest central blood pressure.
8.1.11. Age and Sex Considerations
Acute AoD presentation varies with patient age and sex. In
951 IRAD patients, 7% were younger than 40 years. Com-
pared with patients 40 years of age and older, this group was
less likely to have a history of hypertension and significantly
more likely to have Marfan syndrome, bicuspid aortic valve,
or a history of prior aortic surgery.223 Clinically, young
patients in this study were more likely to describe pain as
abrupt in onset but less likely to be hypertensive at presen-
tation (25% versus 45%).223 In contrast, a separate study of
IRAD data evaluating 550 patients with Type A dissection
found that among patients more than 70 years of age (32% of
total), typical symptoms (abrupt onset of pain) and signs
(murmur of aortic regurgitation or pulse deficits) were sig-
nificantly less common, suggesting that extra vigilance may
be required to identify acute AoD in young and elderly
patients.288
Sex appears to affect the presentation of acute AoD as well.
In a study of 1078 patients enrolled in IRAD, 32% were
women. Women were older; were less likely to present within
6 hours of symptom onset, to complain of abrupt onset of
pain, and to have a pulse deficit; and were more likely to
present with either altered mental status or congestive heart
failure. Consequently, women were less likely to be diag-
nosed within 24 hours of symptom onset and had signifi-
cantly higher in-hospital mortality (30% versus 21%,
P0.001) than men.289
8.2. Intramural Hematoma
Among acute aortic syndromes, acute dissection is the most
common, but approximately 10% to 20% of patients290–292
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with a clinical picture of dissection exhibit an IMH via
imaging without identification of blood flow in a false lumen
or an intimal lesion. Some believe IMH arises from hemor-
rhage of the vasa vasorum located within the medial layer of
the aorta,293,294 whereas others argue that the hematoma arises
from microscopic tears in the aortic intima. The resulting
hematoma may then propagate in an antegrade or a retrograde
manner, producing symptoms that may be impossible to
differentiate clinically from those of a classic AoD.61 IMH
has a variable radiologic appearance (Figure 23) according to
the area of the aorta involved. In some cases, IMH may be
associated with a PAU (see Section 8.2 or 8.3).
Clinically, IMH most commonly occurs in the descending
aorta and in older patients. Pain is characteristic of IMH,
whereas malperfusion and pulse deficit are much less likely
than with classic AoD.295,296
Imaging criteria of IMH are based on the appearance of
fresh thrombus in the aortic wall. These include crescentic or
circular thickening of the aortic wall with maximal thickness
greater than or equal to 7 mm on TEE without intimal flap or
tear or longitudinal flow in the false lumen. The thickened
wall has a higher tissue density than unenhanced blood on CT
and is without enhancement after contrast on the CT/
MR.290,296–298 When the term IMH is used strictly, no intimal
defect such as a tear or an ulcer is present. But in practice, the
term is used loosely to mean a thrombosed false lumen
regardless of a small intimal defect. The distinction is further
blurred by the facts that the intimal defect may be subtle and
difficult to exclude and that some patients with IMH begin
with a CT scan that shows a thrombosed false lumen with no
apparent intimal defect and then over the course of 1 or 2
months develop 1 or more distinct ulcerlike communica-
tions.299,300 Because of this overlap in imaging findings, it is
difficult and perhaps somewhat arbitrary to base treatment on
the appearance of the CT snapshot of the aorta in its disease
progression.
The natural history of IMH is variable. The hematoma may
entirely resolve (10%),301 it may convert to a classic dissec-
tion, or the aorta may enlarge and potentially rupture. The
clinical behavior of IMH varies according to the location and
mimics that of classic AoD. IMH involving the ascending
aorta has a high, early risk of complication and death with
medical treatment alone, and surgery is usually indicated.
IMH involving the descending aorta may be treated with
blood pressure control, and the use of beta blockers has been
shown to improve the long-term survival rate.296 Conversion
of the IMH to a more classic picture of dissection occurs in
3% to 14% of cases involving the descending aor-
ta297,298,302,303 and in 11% to 88% of cases involving the
ascending aorta,302–305 with that figure increasing with in-
creased length of follow-up. Progressive increase in aortic
diameter has been demonstrated by serial imaging stud-
ies.298,306 In 1 study, the mortality after 2 years of patients
with acute proximal Type A IMH versus that of patients with
classic dissection was not significantly different.307 Another
group found improved actuarial survival rates at 1, 2, and 5
years in patients with IMH versus classic dissection: 90%,
90%, and 90% versus 67%, 66%, and 62%, respectively, for
Type A,304 and 100%, 97%, and 97% versus 83%, 79%, and
79%, respectively, for Type B.297 Song et al also described
increased risk for complications or mortality for patients with
IMH involving the ascending aorta when ascending aortic
Figure 23. Intramural hematoma demonstrated as a low-attenuation band of hematoma (arrows) in the aortic wall on CT images. Top
left, Axial image at the level of the aortic arch. Top middle, Through the mid thorax. Top right, At the level of the superior mesenteric
artery with narrowing of the aortic lumen. Bottom left, Oblique sagittal reformatted image through the thorax (note band artifact evident
without the use of ECG gating). Bottom right, Coronal reformatted image through the abdomen demonstrate the length of the hema-
toma, and an incidental infarenal aortic aneurysm. CT indicates computed tomographic imaging; and ECG, electrocardiogram.
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diameter is greater than 4.8 cm or IMH thickness is greater
than 11 mm.308
8.3. Penetrating Atherosclerotic Ulcer
PAU refers to an atherosclerotic lesion with ulceration that
penetrates the internal elastic lamina and allows hematoma
formation within the media of the aortic wall.309 This lesion
sets the stage for development of IMH, AoD, or frank vessel
rupture309 (Figure 24). Anatomically PAUs develop in aortic
segments where atherosclerotic changes are most common
and therefore are localized to the descending thoracic aorta in
over 90% of cases.310 When viewed tangentially, the classic
appearance of the lesion is a mushroom-like outpouching of
the aortic lumen with overhanging edges, resembling a gastric
ulcer, as depicted on a barium study (Figure 24). The typical
patient is elderly (usually over 65 years of age) and has
hypertension and diffuse atherosclerosis, who presented with
chest or back pain but without signs of aortic regurgitation or
malperfusion. Less commonly, patients presented only with
signs of distal embolization.311 Asymptomatic patients may
also be found with aortic lesions that are indistinguishable, by
imaging criteria, from PAUs.310,311
Two entities can mimic PAUs. A branch artery pseudoan-
eurysm represents a small collection of flowing blood within
an otherwise thrombosed aortic false lumen, which is created
by an injury to a small branch artery during the propagation
of the IMH.312 These are usually incidental findings, are
distinguished from ulcers by the apparent absence of a
communication with the aortic lumen by CT, and do not
usually require specific treatment. A dissection entry or
reentry tear may develop in an area of IMH as detected by
several imaging studies over a period of several
months.297,299,300,306
8.4. Pseudoaneurysms of the Thoracic Aorta
Pseudoaneurysms of the thoracic aorta are frequently related
to deceleration or torsional trauma to the aorta from motor
vehicle accidents, falls, and sports injuries.3,313–319 Aortic
pseudoaneurysms are relatively rare, with posttraumatic
pseudoaneurysms having an incidence of 3% to 4% after
blunt trauma.51 Other pseudoaneurysms may occur following
aortic surgery, catheter-based interventions, or penetrating
trauma. Pseudoaneurysms often have a slim “neck” that leads
to the “aneurysm” that corresponds to points of penetration
and containment.320 Aortic infections (mycotic aneurysms)
and penetrating ulcers may also result in pseudoaneurysms
(see Section 9.2.2). Penetrating injuries are usually repaired
immediately whenever recognized and feasible.317,318,321
8.5. Traumatic Rupture of the Thoracic Aorta
A UK survey of all motor vehicle accident fatalities found
that approximately 20% of patients had an autopsy finding of
a ruptured aorta, emphasizing the importance of traumatic
rupture of the aorta (TRA). In the United States, there are
around 40 000 motor vehicle deaths annually, and it is likely
that around 8000 of the victims had TRA. It is estimated that
only 9% to 14% of patients with TRA reach a hospital alive
and only 2% ultimately survive. In this survey, 29% were
involved with frontal impact crashes and 44% were involved
with side impact crashes.318,319
Parmley and colleagues318 noted the correlation of high
risk of early death and the sites of TRA on the basis of
autopsies in 275 deaths from unrelated aortic rupture. In 45%,
the tear was at the aortic isthmus; 23%, in the ascending
aorta; 13%, in the descending aorta; 8%, in the transverse
aorta; 5%, in the abdominal aorta; and 6%, multiple sites.
Examination of the patient usually reveals signs similar to
those of coarctation of the aorta with arm blood pressure
higher than leg blood pressure, delay between radial versus
femoral artery pulsation, and a harsh interscapular murmur.3
Evidence of polytrauma is, however, common.
The best method for detection of a TRA is debated. A chest
x-ray with a nasogastric tube in position has 80% sensitivity
for suggesting TRA by showing displacement of the naso-
gastric tube by the hematoma. However, signs of hemome-
diastinum are more often false positive than true positive.40
Even when present, mediastinal blood is less likely to be due
to arterial/aortic injury than to less-consequential venous
bleeding. A biplane contrast aortogram may fail to detect the
tear until the development of a pseudoaneurysm. TEE may be
used, but if dilatation has not occurred, the diagnosis may still
be in doubt. CT is used but is not absolutely certain to
establish the diagnosis. In questionable cases, intravascular
ultrasound can also be used3,322,323 (Figure 8). Realistically,
the imaging sequence often depends on the stability of the
patient and the need for the diagnosis of concomitant injuries.
Sometimes, this may even fail to detect the tear, and the study
may have to be repeated at a later date to detect the tear.
Figure 24. Penetrating atherosclerotic ulcer of
the proximal descending thoracic aorta. Axial
CT images at the level of the aortopulmonary
window (left) and at the level of the left pulmo-
nary artery (right) demonstrate a small penetrat-
ing ulcer (long arrow, U) that extends beyond
the expected confines of the aortic lumen with
adjacent IMH both at the level of the ulcer itself
and that extends a few centimeters caudally in
the wall of the descending thoracic aorta (short
arrows). CT indicates computed tomographic
imaging; IMH, intramural hematoma; and U,
penetrating ulcer.
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8.6. Evaluation and Management of Acute
Thoracic Aortic Disease
8.6.1. Initial Evaluation and Management
8.6.1.1. Recommendations for Estimation of Pretest Risk of
Thoracic Aortic Dissection
Class I
1. Providers should routinely evaluate any patient pres-
enting with complaints that may represent acute tho-
racic aortic dissection to establish a pretest risk of
disease that can then be used to guide diagnostic
decisions. This process should include specific ques-
tions about medical history, family history, and pain
features as well as a focused examination to identify
findings that are associated with aortic dissection,
including:
a. High-risk conditions and historical features47,127,223,261
(Level of Evidence: B):
● Marfan syndrome, Loeys-Dietz syndrome, vascu-
lar Ehlers-Danlos syndrome, Turner syndrome,
or other connective tissue disease.
● Patients with mutations in genes known to pre-
dispose to thoracic aortic aneurysms and dissec-
tion, such as FBN1, TGFBR1, TGFBR2, ACTA2,
and MYH11.
● Family history of aortic dissection or thoracic
aortic aneurysm.
● Known aortic valve disease.
● Recent aortic manipulation (surgical or
catheter-based).
● Known thoracic aortic aneurysm.
b. High-risk chest, back, or abdominal pain fea-
tures37,47,215,223,261,264,288 (Level of Evidence: B):
● Pain that is abrupt or instantaneous in onset.
● Pain that is severe in intensity.
● Pain that has a ripping, tearing, stabbing, or
sharp quality.
c. High-risk examination features37,47,253,257,261,324
(Level of Evidence: B):
● Pulse deficit.
● Systolic blood pressure limb differential greater
than 20 mm Hg.
● Focal neurologic deficit.
● Murmur of aortic regurgitation (new).
2. Patients presenting with sudden onset of severe
chest, back, and/or abdominal pain, particularly
those less than 40 years of age, should be questioned
about a history and examined for physical features
of Marfan syndrome, Loeys-Dietz syndrome, vascu-
lar Ehlers-Danlos syndrome, Turner syndrome, or
other connective tissue disorder associated with tho-
racic aortic disease.223 (Level of Evidence: B)
3. Patients presenting with sudden onset of severe chest,
back, and/or abdominal pain should be questioned
about a history of aortic pathology in immediate family
members as there is a strong familial component to
acute thoracic aortic disease.223 (Level of Evidence: B)
4. Patients presenting with sudden onset of severe chest,
back, and/or abdominal pain should be questioned about
recent aortic manipulation (surgical or catheter-based) or
a known history of aortic valvular disease, as these
factors predispose to acute aortic dissection. (Level of
Evidence: C)
5. In patients with suspected or confirmed aortic dissec-
tion who have experienced a syncopal episode, a fo-
cused examination should be performed to identify
associated neurologic injury or the presence of peri-
cardial tamponade (see Section 8.1.6). (Level of Evi-
dence: C)
6. All patients presenting with acute neurologic com-
plaints should be questioned about the presence of
chest, back, and/or abdominal pain and checked for
peripheral pulse deficits as patients with dissection-
related neurologic pathology are less likely to report
thoracic pain than the typical aortic dissection pa-
tient253 (see Section 8.1.7). (Level of Evidence: C)
8.6.1.2. Laboratory Testing
Several plasma markers have been investigated for their
utility in the evaluation of acute AoD. Plasma smooth muscle
myosin heavy chain protein, D-dimer, and high-sensitivity
C-reactive protein have shown diagnostic promise, although a
lack of large prospective studies precludes a recommendation
regarding their use.325–328
Elevation of D-dimer levels occurs with intravascular
activation of the coagulation cascade and secondary fibrino-
lysis and in conditions such as venous thromboembolism,
sepsis, disseminated intravascular coagulation, malignancies,
recent trauma or surgery, and acute MI and following
fibrinolytic therapy. The ACEP has published guidelines
regarding the use of certain D-dimer assays to rule out
pulmonary embolism in low-risk patients.329
Regarding the potential role of plasma D-dimer levels to
screen for AoD, significant elevations of D-dimer were seen
in all 24 patients with documented acute AoD involving
either the ascending or descending thoracic aorta regardless
of time from presentation, ranging from 1 to 120 hours.325 A
meta-analysis of 11 studies330 noted that the pooled sensitiv-
ity of D-dimer in 349 patients with documented acute AoD
was 94% (95% CI 91% to 96%) with specificity ranging from
40% to 100%. Two patients had limited ascending aortic IMH
without intimal flap and had negative D-dimer assays.331
Some authors325,332 recommend that D-dimer assays be
performed in all patients where clinical suspicion exists, to
help identify those who do not require definitive imaging
studies. However, the efficacy and safety of this strategy have
not been tested in a large clinical trial, and several caveats
should apply. The negative likelihood ratio provided by the
most sensitive D-dimer assay is not of sufficient magnitude to
provide useful information in high-risk individuals and there-
fore cannot be used to “rule out” the disease in this group.
Clinical scoring systems to identify the true pretest probabil-
ity for AoD in individual patients have not been developed or
validated, thus limiting an accurate determination of the true
“posttest” probability associated with a negative D-dimer
result. Finally, there are reports of negative D-dimer assays
Hiratzka et al 2010 Guidelines on Thoracic Aortic Disease e307
D
ow
nloaded from
 http://ahajournals.org by on August 16, 2018
associated with ascending aortic IMH or a thrombosed false
lumen, such that further studies are needed regarding the
sensitivity of D-dimer levels to detect the presence of IMH or
PAU.331 Given these issues, the writing committee cannot
recommend serum D-dimer screening for all patients being
evaluated for AoD.
Where a high level of suspicion for acute AoD exists,
laboratory testing aimed at presurgical screening (blood
count, serum chemistries, coagulation profiles, and blood
type and screen) may reduce preoperative delays.
8.6.1.3. Recommendations for Screening Tests
Class I
1. An electrocardiogram should be obtained on all pa-
tients who present with symptoms that may represent
acute thoracic aortic dissection.
a. Given the relative infrequency of dissection-related
coronary artery occlusion, the presence of ST-
segment elevation suggestive of myocardial infarc-
tion should be treated as a primary cardiac event
without delay for definitive aortic imaging unless
the patient is at high risk for aortic dissection.37,47,333
(Level of Evidence: B)
2. The role of chest x-ray in the evaluation of possible
thoracic aortic disease should be directed by the pa-
tient’s pretest risk of disease as follows:
a. Intermediate risk: Chest x-ray should be per-
formed on all intermediate-risk patients, as it may
establish a clear alternate diagnosis that will
obviate the need for definitive aortic imaging.
(Level of Evidence: C)
b. Low risk: Chest x-ray should be performed on all
low-risk patients, as it may either establish an
alternative diagnosis or demonstrate findings that
are suggestive of thoracic aortic disease, indicating
the need for urgent definitive aortic imaging. (Level
of Evidence: C)
3. Urgent and definitive imaging of the aorta using
transesophageal echocardiogram, computed tomo-
graphic imaging, or magnetic resonance imaging is
recommended to identify or exclude thoracic aortic
dissection in patients at high risk for the disease by
initial screening.42–46,67,73 (Level of Evidence: B)
Class III
1. A negative chest x-ray should not delay definitive
aortic imaging in patients determined to be high risk
for aortic dissection by initial screening. (Level of
Evidence: C)
8.6.1.4. Recommendations for Diagnostic Imaging Studies
Class I
1. Selection of a specific imaging modality to identify or
exclude aortic dissection should be based on patient
variables and institutional capabilities, including
immediate availability. (Level of Evidence: C)
2. If a high clinical suspicion exists for acute aortic
dissection but initial aortic imaging is negative, a
second imaging study should be obtained.212 (Level
of Evidence: C)
8.6.1.5. Recommendations for Initial Management
Class I
1. Initial management of thoracic aortic dissection should
be directed at decreasing aortic wall stress by control-
ling heart rate and blood pressure as follows:
a. In the absence of contraindications, intravenous
beta blockade should be initiated and titrated to a
target heart rate of 60 beats per minute or less.
(Level of Evidence: C)
b. In patients with clear contraindications to beta
blockade, nondihydropyridine calcium channel-
blocking agents should be used as an alternative for
rate control. (Level of Evidence: C)
c. If systolic blood pressures remain greater than
120 mm Hg after adequate heart rate control has
been obtained, then angiotensin-converting enzyme
inhibitors and/or other vasodilators should be ad-
ministered intravenously to further reduce blood
pressure that maintains adequate end-organ perfu-
sion. (Level of Evidence: C)
d. Beta blockers should be used cautiously in the
setting of acute aortic regurgitation because they
will block the compensatory tachycardia.5 (Level of
Evidence: C)
Class III
1. Vasodilator therapy should not be initiated prior to
rate control so as to avoid associated reflex
tachycardia that may increase aortic wall stress,
leading to propagation or expansion of a thoracic
aortic dissection. (Level of Evidence: C)
8.6.1.6. Recommendations for Definitive Management
Class I
1. Urgent surgical consultation should be obtained for
all patients diagnosed with thoracic aortic dissection
regardless of the anatomic location (ascending ver-
sus descending) as soon as the diagnosis is made or
highly suspected. (Level of Evidence: C)
2. Acute thoracic aortic dissection involving the as-
cending aorta should be urgently evaluated for
emergent surgical repair because of the high risk of
associated life-threatening complications such as
rupture.47 (Level of Evidence: B)
3. Acute thoracic aortic dissection involving the de-
scending aorta should be managed medically unless
life-threatening complications develop (eg, malper-
fusion syndrome, progression of dissection, enlarg-
ing aneurysm, inability to control blood pressure or
symptoms).285,288,334–337 (Level of Evidence: B)
Early identification of acute thoracic dissection is challeng-
ing. During the initial evaluation, the correct diagnosis of
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AoD has been made in only 15% to 43% of patients initially
thought to have the disease.215,237,252 Factors that may impede
accurate diagnosis of AoD include the following:
1. Acute AoD is often believed to be a rare disease (2.9 to 3.5
cases per 100 000 person-years),215,217 whereas the incidence
of acute MI is several orders of magnitude greater (more than
200 cases per 100 000 person-years).338 Data previously cited
in this guideline from UHC suggest that acute AoD is not
“rare.” Some common explanations that clinicians give for
this underlying belief include the following:
a. It is difficult for clinicians to effectively separate
patients with AoD from the multitude of other patients
who present to emergency departments and primary
care physicians with common complaints that are much
more often not due to acute AoD.
b. Front-line medical providers may have little direct expe-
rience with acute AoD and are unlikely to be aware of the
subtleties of its presenting signs and symptoms.
c. Institutional multidisciplinary pathways developed for
other emergencies such as ST-elevation myocardial
infarction (STEMI) or acute stroke have not generally
existed for acute AoD.
2. In contrast to other more common cardiovascular emer-
gencies, acute AoD may occur in younger patients. Accu-
rate identification of acute AoD; however, requires that
clinicians recognize on a routine basis that the disease may
present in younger patients. Case reports exist of children
as young as 3 years of age presenting with acute AoD.105
3. Acute AoD may present with a wide range of unusual
manifestations that do not conform with classic “textbook
findings.”339–341
4. There are no well-studied, rapidly available, and effective
screening tests for acute AoD.
8.6.2. Evaluation and Management Algorithms
The provided algorithms guide the initial evaluation of patients
whose presentations are concerning for AoD and the manage-
ment of patients in whom the diagnosis of acute thoracic AoD is
confirmed. Although clinicians may ultimately choose to deviate
from the pathway for patient-specific reasons, the algorithms
provide a framework with which to quickly diagnose (Figure 25)
and provide early management (Figure 26) of AoD. This
decision model is supported by several large studies that indicate
a targeted history and physical examination are likely to identify
the vast majority of patients who present with acute AoD,
suggesting that adequate screening need not be time intensive or
technology dependent.47,215,264 Using a target history and phys-
ical examination, patients can be placed into 1 of 3 categories: 1)
those with immediately apparent acute AoD requiring emergent
surgical evaluation and expedited aortic imaging, 2) those whose
presentation is concerning for acute AoD and in the absence of
a clear alternative diagnosis require expedited aortic imaging,
and 3) those whose clinical presentation is not initially sugges-
tive of acute AoD but may benefit from aortic imaging in the
absence of a likely alternative diagnosis at the completion of the
initial evaluation.
Several high-risk conditions (Figure 25, T2–1) greatly
increase the likelihood that presenting complaints that could
be a result of acute AoD.
Pain (Figure 25, T2–2) is the most commonly reported pres-
enting symptom of acute AoD regardless of patient age, sex, or
other associated clinical complaint.37,47,215,223,242,264,289 Pain de-
scribed as abrupt or instantaneous in onset, that is severe in
intensity, or that has a ripping or tearing quality establishes a
high pretest probability for AoD.47,261
The combination of 2 or more high-risk features (Figure
25, T3) is strongly suggestive of acute AoD.
The presence of a single high-risk feature (ie, high-risk
condition, pain, or physical examination) may trigger imme-
diate concern for acute AoD; however, other diagnostic
considerations may exist. Pain with high-risk features, al-
though suggestive of acute AoD, may occur as a result of an
alternate disease process (Table 12). For patients who are
determined to have an intermediate probability of acute AoD
on the basis of initial bedside assessment, Figure 25, T4,
provides a pathway for further evaluation.
Figure 25, T5, provides a pathway for further evaluation of
patients without any high risk features. Delay in diagnosis
and increased mortality is common in this group.241,288,289
For patients presenting with new ST-segment elevations on
the initial ECG and without high-risk AoD features, imme-
diate coronary angiography and reperfusion therapy (ie,
thrombolysis or percutaneous coronary intervention) are in-
dicated.333 However, if coronary angiography is performed
and no culprit coronary lesion is identified, then Figure 25,
T6, provides a pathway to dedicated aortic imaging. As
approximately 40% of chest films in acute AoD lack a
widened mediastinum, and as many as 16% are normal, the
absence of radiographic abnormalities does not exclude the
diagnosis of AoD37,47 (Figure 25, T7).
Missed or delayed diagnosis of acute AoD is most com-
monly ascribed to an incorrect working diagnosis of acute
coronary syndrome, a condition that may require a prolonged
time interval to correctly identify (ie, serial cardiac biomar-
kers) and whose management with antiplatlet and antithrom-
bin agents may cause harm to the patient with AoD. For
patients with an intermediate-risk profile for acute AoD and
who do not have diagnostic STEMI but who are being
evaluated for a possible acute coronary syndrome, aortic
imaging may detect AoD prior to the administration of
antiplatelet and antithrombin agents (Figure 25, T8).
Unexplained hypotension is present in approximately 20%
of patients with acute AoD.37,47 Similarly, a widened medi-
astinum on chest x-ray strongly suggests the need for addi-
tional definitive diagnostic aortic imaging, particularly in
patients without a clear alternative explanation for their
presenting complaint342 (Figure 25, T9).
Some patients with acute AoD present without any high-
risk features, making early diagnosis difficult. If a clear
alternative diagnosis is not established after the initial eval-
uation, then obtaining a diagnostic aortic imaging study,
particularly in patients with advanced age (older than 70
years), syncope, focal neurologic deficit, or recent aortic
manipulation (surgery or catheter based), should be consid-
ered47,242,253,288,343 (Figure 25, T10).
Multidetector CT, TEE, and MR all provide acceptable
diagnostic accuracy for the diagnosis of acute AoD. In
patients with hemodynamic instability, requiring close mon-
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itoring, bedside TEE is preferred to avoid moving the patient
out of the acute care environment (Figure 25, T11).
The most recent comparative study with nonhelical CT, 0.5
Tesla MR and TEE showed 100% sensitivity for all modalities,
with better specificity of CT (100%) than for TEE and MR.44 A
recent meta-analysis that evaluated the diagnostic accuracy of
TEE, helical CT, and MR for suspected AoD found that all 3
imaging techniques provided equally reliable diagnostic val-
ues.46 Accordingly, selection of an imaging modality is influ-
enced by individual patient variables and institutional
capabilities.
The diagnosis of acute AoD cannot be excluded defin-
itively based on the results of a single imaging study.
Although TEE, CT, and MR are all highly accurate for the
evaluation of acute AoD; false-negative studies can and do
occur47 (Figures 9 and 15). If a high clinical suspicion
exists for acute AoD but initial aortic imaging is negative,
strongly consider obtaining a second imaging study (Fig-
ure 25, T12).
8.6.3. Initial Management
Once the diagnosis of AoD or one of its anatomic variants
(IMH or PAU) is obtained, initial management is directed at
limiting propagation of the false lumen by controlling aortic
shear stress while simultaneously determining which patients
will benefit from surgical or endovascular repair (Figure 26).
Figure 25. AoD evaluation pathway. ACS indicates acute coronary syndrome; AoD, aortic dissection; BP, blood pressure; CNS, central
nervous system; CT, computed tomographic imaging; CXR, chest x-ray; EKG, electrocardiogram; MR, magnetic resonance imaging;
STEMI, ST-elevation myocardial infarction; TAD; thoracic aortic disease; and TEE, transesophageal echocardiogram.
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8.6.3.1. Blood Pressure and Rate Control Therapy
Aortic wall stress is affected by the velocity of ventricular
contraction (dP/dt), the rate of ventricular contraction, and
blood pressure. Initial medical stabilization using beta block-
ers controls these 3 parameters by reducing heart rate and
blood pressure to the lowest amounts that will still maintain
adequate end-organ perfusion.61 Reasonable initial targets are
a heart rate less than 60 bpm and a systolic blood pressure
between 100 and 120 mm Hg.61
Intravenous propranolol, metoprolol, labetalol, or esmolol
is an excellent choice for initial treatment. In patients who
have a potential contraindication to beta blockade (eg, those
with asthma, congestive heart failure, or chronic obstructive
pulmonary disease), esmolol may be a viable option given its
extremely short half-life. Use of labetalol, which is both an
alpha- and beta-receptor antagonist, offers the advantage of
potent heart rate and blood pressure control from a single
agent, potentially eliminating the need for a secondary
Figure 26. Acute AoD management pathway. AoD indicates aortic dissection; BP, blood pressure; MAP, mean arterial pressure; and
TTE, transthoracic echocardiogram.
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vasodilator. In patients who are unable to tolerate beta
blockade, nondihydropyridine calcium channel antagonists
(verapamil, diltiazem) offer an acceptable, although less-
established, alternative.61 Beta blockers, verapamil, or dilti-
azem for rate control in patients with significant aortic
regurgitation may be problematic because of deleterious
affects on reflex tachycardia.
8.6.3.2. Additional Antihypertensive Therapy
It is frequently difficult to reduce blood pressure to optimum
levels.285–287,344–346 In 1 study, patients required a median of
4 different antihypertensive drugs.347 In addition to beta
blockade, vasodilators may be required to control blood
pressure. Intravenous sodium nitroprusside is the most estab-
lished agent and offers the advantage of being rapidly
titratable.61 Nicardipine,348 nitroglycerin, fenoldopam, and
various other intravenous antihypertensive agents are appro-
priate for this situation. Vasodilator therapy without prior
beta blockade may cause reflex tachycardia and increased
force of ventricular contraction leading to greater aortic wall
stress and potentially causing false lumen propagation.42
Following initial stabilization with intravenous antihyper-
tensives, most patients will require long-term antihyper-
tensive treatment including the use of a beta blocker plus
additional classes of agents. Angiotensin-converting en-
zyme inhibitors or angiotension receptor blockers may
retard aortic dilatation and their use may be indicated as
outlined in Section 9.2.1.1.
8.6.3.3. Pain Control
Adequate pain control is essential in the setting of acute AoD
to decrease sympathetic mediated increases in heart rate and
blood pressure. Appropriate use of intravenous opiate anal-
gesia will help augment the effects of rate control and
vasodilator agents.
8.6.3.4. Hypotension
Medical management options for all forms of dissection-
related hypotension are limited. Volume administration ti-
trated to improvement of blood pressure is a reasonable first
approach. Vasopressors can be added, if needed, to maintain
adequate perfusion but have the potential to cause further
false lumen propagation. Inotropic agents are likely to in-
crease the force and rate of ventricular contraction and
therefore increase sheer stress on the aortic wall.
Pericardiocentesis for dissection-related hemopericardium
has been associated with recurrent pericardial bleeding and
associated mortality.307,349,350 Several articles from the Asian
literature suggest that pericardiocentesis may be safe in the
setting of acute Type A IMH.351,352 Other cardiac complica-
tions that may result in hypotension include severe
dissection-related aortic regurgitation, true lumen obstruction
by a compressing false lumen, and acute MI. All require
definitive operative management. Hypotension or shock in
the setting of AoD may also result from contained rupture of
the false lumen into adjacent structures (ie, pleural space or
mediastinum), a scenario that also mandates immediate op-
erative intervention.
Ultimately, hypotension or shock in the acute AoD patient
suggests the need for immediate operative management. For
patients with hemopericardium and cardiac tamponade who
cannot survive until surgery, pericardiocentesis can be per-
formed by withdrawing just enough fluid to restore perfusion.
8.6.3.5. Determining Definitive Management
In the clinically stable patient, the decision for surgical versus
medical management of patients with acute AoD is based
primarily on the location of the dissection as described by the
Stanford and DeBakey classification systems61,353 (see Sec-
tion 8.1.2). A prompt cardiac surgical consultation provides
the best management resource, regardless of location of the
AoD, as it is impossible to predict which complications may
develop or when they may occur.
8.6.4. Recommendation for Surgical Intervention for
Acute Thoracic Aortic Dissection
Class I
1. For patients with ascending thoracic aortic dissec-
tion, all of the aneurysmal aorta and the proximal
extent of the dissection should be resected. A par-
tially dissected aortic root may be repaired with
aortic valve resuspension. Extensive dissection of the
aortic root should be treated with aortic root re-
placement with a composite graft or with a valve
sparing root replacement. If a DeBakey Type II
dissection is present, the entire dissected aorta
should be replaced. (Level of Evidence: C)
When a Type A AoD involves the aortic root, resuspension
of the valve with preservation of the aortic sinuses and
excision of the sinuses and resuspension of the valve within
a polyester graft are suitable options. If the aortic root is
dilated, or if there is extensive dissection and disruption of the
Table 12. Differential Diagnosis for High-Risk Pain or
Examination Features
Chest pain
● Acute myocardial infarction
● Pulmonary embolism
● Spontaneous pneumothorax
● Esophageal rupture
Abdominal pain
● Renal/biliary colic
● Bowel obstruction/perforation
● Non–dissection-related mesenteric ischemia
Back pain
● Renal colic
● Musculoskeletal pain
● Intervertebral disk herniation
Pulse deficit
● Non–dissection-related embolic phenomena
● Non–dissection-related arterial occlusion
Focal neurologic deficit
● Primary ischemic cerebrovascular accident
● Cauda equina syndrome
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aortic sinuses, replacement with a composite graft is
necessary.
8.6.5. Endovascular Interventions
Endovascular stent grafts are not approved for AoD involving
the ascending aorta or aortic arch. Endovascular stent grafts
used for descending thoracic aortic dissection is discussed in
Section 9.2.2.3.1. Indications for either surgical or endovas-
cular interventions are discussed in Section 9.
8.6.6. Principles of Treatment for Intramural Hematoma
and Penetrating Atherosclerotic Ulcer
The goals of treatment are to prevent aortic rupture or
progression to classic AoD, allow patient stabilization before
urgent surgery, and reduce complexity of unavoidable aortic
surgery. Aggressive medical treatment usually includes, par-
ticularly in symptomatic patients, beta blockers and other
antihypertensive therapy. Indications for open or endograft
treatment are based on the anatomic features of the lesion,
clinical presentation and course, patient comorbidities, and
anatomic constraints related to endograft technology. Treat-
ment by endografts or open aortic reconstruction can be
discussed in the context of 3 overlapping aortic lesions:
intimal defect without IMH, intimal defect with IMH, and
IMH without an intimal defect.
8.6.6.1. Intimal Defect Without Intramural Hematoma
These are localized lesions and may involve a limited
segment of the aorta. They are often an incidental finding. By
imaging criteria, they include uncomplicated aortic ulcers,
blebs, and eccentric or saccular aneurysms of the aorta. They
are treated as saccular aneurysms based on their maximum
diameter and clinical feature.212,306,354 These lesions can be
treated with open reconstruction and are the most suitable of
the 3 groups for treatment by endografts, if in the descending
thoracic aorta. They involve a limited segment, which can
easily be excluded from the circulation, as long as there is an
adequate distance from a critical branch artery. When these
limited dissections involve the ascending aorta, emergency
surgery is indicated as for other types of AoD because rupture
or cardiac tamponade can occur.212,306,354
8.6.6.2. Intimal Defect With Intramural Hematoma
The intimal defect again presents a target lesion for endovas-
cular treatment in the descending thoracic aorta, but the
associated IMH involves a longer segment of aorta than the
first category. If the patient becomes asymptomatic in re-
sponse to aggressive medical treatment, it may be possible to
delay endovascular or open reconstruction until the IMH has
reabsorbed and organized. (Of note, some writing committee
members have observed healing of IMH such that immediate
reconstruction was not required but have continued to follow
that small number of patients closely.) Two considerations
affect the length of aorta bordering the intimal defect, which
is to be included in the segment targeted for treatment.
Evidence of adjacent atheromatous wall should favor more
extensive treatment of the aorta with longer endografts,
because radiographic imaging underestimates shallow ulcer-
ated atheromas, and the ulcer typically arises in a bed of
atheromatous intima. Treatment with longer endografts pro-
vides a safety margin against undertreating the intimal defect.
The second consideration is the extent of associated IMH.
The self-expanding endograft may tear through the intimal
surface into underlying thrombosed false lumen. When treat-
ment of this lesion in the acute stage is clinically necessary
(eg, persisting pain, evidence for expansion or rupture,
compromise of critical branches), it is preferable to anchor
the endograft in the noninvolved wall above and below the
intimal defect.
8.6.6.3. Recommendation for Intramural Hematoma
Without Intimal Defect
Class IIa
1. It is reasonable to treat intramural hematoma sim-
ilar to aortic dissection in the corresponding segment
of the aorta. (Level of Evidence: C)
As noted earlier, some authors suggest treating IMH as an
AoD in the corresponding aortic territory. Others recommend
invasive treatment regardless of location or aortic diame-
ter.354 However, small patient series, incomplete anatomic
description of case material, and lack of explicit anatomic or
clinical guidelines indicating open or endovascular aortic
repair make it difficult to generalize from the literature.
The absence of an intimal defect, which can serve as a
target lesion, presents a diagnostic as well as treatment
challenge. Intimal tears can be extremely subtle, depending
on the size of the intimal tear and the amount of intramedial
thrombus, which can sometimes fill the cavity flush with the
aortic lumen. The intimal tear may be remote in the aorta
despite leaking into the chest. IMH in a normal caliber aorta
without an apparent intimal tear precludes limited treatment
of a target lesion. There are no data supporting prophylactic
implantation of endografts covering the entire descending
aorta, yet in unusual circumstances one may be forced to
propose such treatment. IMH in an aneurysmal aorta presents
a particularly urgent problem, because this complication may
be a precursor to aneurysm rupture. Although the literature
gives no compelling guidelines for treatment, the writing
committee believes that treatment of IMH corresponding to
treatment of AoD in the corresponding segment of the aorta
is reasonable.
8.7. Treatment for the Management of Traumatic
Aortic Rupture
The management of blunt TRA is evolving.3,318,319,355,356 On
the basis of the report by Parmley and colleagues,318 most
surgeons have recommended immediate surgical repair.
However, when other serious traumatic injuries are present
including head injuries and long bone or pelvic fractures,
immediate surgery may not be feasible or may be dangerous.
Multiple studies appear to show that if careful blood pressure
control is used, many patients can be treated initially conser-
vatively and then undergo operation once their other injuries
have been stabilized.3,321,357–359 In a review by Svensson et
al359 of 44 patients initially treated with careful blood pres-
sure control who subsequently had delayed open surgery,
there were no operative deaths. This approach has also been
reported as being safe by Pate and colleagues and oth-
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ers.3,321,357,358 Thus, in selected patients at high risk for other
injuries and bleeding, delayed repair of traumatic contained
rupture of the aorta may be an option.
The open surgical repair of TRA has evolved over time. In
a meta-analysis of 596 TRA patients by Svensson et al,359 the
highest mortality rate was noted with cardiopulmonary by-
pass (16.7%), the rate was less with shunts (11.4%), and the
rate was lowest with a simple “clamp and sew” approach
(5.8%, P0.01). There was no difference in the risk of
postoperative paralysis. Subsequently, von Oppell and col-
leagues360 reviewed 1742 patients and found the risk of death
was 18.2% with cardiopulmonary bypass, 11.9% for distal
perfusion with atriofemoral bypass, 12.3% for shunts, and
16% for the “clamp and sew” method. The respective
paralysis rates were 2.4%, 1.7%, 11.1%, and 19.2%, respec-
tively. The key factor in open repairs has been to keep the
total aorta cross-clamp time to as short a period as possible,
especially less than 45 minutes.3,359,361–364
The latest evolution in managing TRA is the use of
endovascular deployed graft covered stents. Although endo-
vascular stent grafting has not been prospectively studied for
this clinical scenario, US Food and Drug Administration–
approved devices are being used “off label,” with consider-
able success reported based on retrospective studies. In a
collected series of 284 patients reported in the literature,
Lettinga-van de Poll and colleagues reported the procedure-
related mortality was 1.5%, 6.7% had endoleaks, and 14.4%
had procedure-related complications.358,365–370 In a multi-
center study of 30 patients with 100% implantation success,
6% to 7% of patients died, 1 had a stroke (3.3%), and 1 had
partial stent collapse (3.3%).370 Reporting bias of favorable
results may be an issue regarding interpretation of the safety
and efficacy of this approach.
The problems with endovascular grafting for TRA have
included the need to cover the left subclavian artery; the acute
sharp angle of the distal aortic arch, particularly in young
patients; and the lack of sufficiently small prostheses for use
in young patients. The size and angle problem can result in
the “bird beak” deformity, where the proximal edge of the
stent is not in contact with the aortic wall and can result in
lifting or collapse of the stent366 (Figure 27). Similarly, when
the stent graft is larger than the aortic diameter, enfolding
of the stent and collapse can occur. On cross-sectional views,
the stent graft has the appearance of a diagrammatic heart.
Over time, it is hoped newer iterations of endografts will be
developed that are better able to accommodate the angulation
of the distal arch and are smaller. It is unlikely that a
prospective randomized study will be performed for this
because of the small number of patients who make it to any
surgical center and because initial results with endografting
of TRA, with exception of the problems listed earlier, have
been reasonable. The Expert Opinion Committee of the
Society of Thoracic Surgeons and the American Association
of Thoracic Surgeons suggested that both acute and chronic
ruptures be considered for treatment with endografts. Some
measures of caution must be taken because these are young
patients who may be subjected to cumulative radiation
exposure with multiple CT scans and because the long-
term durability of endovascular stent grafts is not
known.371
9. Thoracic Aortic Aneurysms
Most thoracic aortic aneurysms are caused by degenerative
disease resulting in dilatation of the aorta (Figure 28). The
incidence of thoracic aortic aneurysms is estimated to be
increasing and there are around 10.4 cases per 100 000
person-years.372
Risk factors for development of thoracic aortic aneurysms
include hypertension, smoking, and chronic obstructive pul-
monary disease. In addition, several genetic syndromes with
a predisposition for thoracic aortic aneurysms have been
identified and are listed in Section 5. Thoracic aortic aneu-
rysms are also associated with bicuspid aortic valve (see
Section 6.1) and other congenital cardiovascular anomalies
(see Section 6) and inflammatory diseases (see Section 7).
Some thoracic aortic aneurysms are due to an inheritance of
a predisposition for the disease, termed familial thoracic
aortic aneurysm syndrome (see Section 5.1.6), and still others
are idiopathic.
Many patients with a thoracic aortic aneurysm are
asymptomatic and diagnosed by chest x-ray or CT scan
obtained for other reasons. An aneurysm may cause
compressive symptoms on adjacent structures including
hoarseness, from left recurrent laryngeal nerve stretching;
stridor, from tracheal or bronchial compression; dyspnea,
from lung compression; dysphagia, from esophageal com-
pression; and plethora and edema, from superior vena cava
compression. Aortic valve regurgitation may develop due
to aortic root or ascending aortic dilatation and result in
heart failure. Neck and jaw pain may occur with aortic arch
aneurysms, whereas back, interscapular, and/or left shoul-
der pain may occur with descending thoracic aortic aneu-
rysms. Embolization of atherosclerotic debris with end-
organ symptoms may occur. Finally, acute syndromes
including dissection or rupture without dissection may
occur with potentially catastrophic outcomes as described
in Section 8.5.
Thoracic aortic aneurysms may involve different seg-
ments of the aorta. The ascending thoracic aorta and/or
root is most commonly involved, with the descending aorta
involved less often. Involvement of the aortic arch occurs
in only 10%. The etiology, natural history, and treatments
differ somewhat for aneurysms in each location. In Marfan
syndrome, aneurysms typically arise in the aortic root, a
process often referred to as annuloaortic ectasia. Because
the leaflets of the aortic valve are suspended within the
root, successful repair of the aortic root may require
performance of a valve-sparing root repair or, in some
cases, a composite aortic graft.
The average rate of expansion of thoracic aortic aneurysms
is estimated to be 0.10 to 0.42 cm/y.373–375 Medical and
surgical treatment considerations and selection criteria are
noted in Section 9.2.
A leaking or ruptured aneurysm (see Section 9.1.2.1)
may also present as chest pain with hypotension due to
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hemorrhage into the left or right pleural space or pericar-
dium376; an aortoesophageal fistula may manifest as gas-
trointestinal hemorrhage.377 An unusual manifestation re-
ported is a hemoptysis from a ruptured ascending aortic
aneurysm eroding into the left lung bronchus.378
Further anatomic classifications refer to segments of the
descending thoracic aorta and thoracoabdominal aorta
divided into subsections according to the extent of the
disease that is replaced at the time of surgery. These
extents have an important influence on the risk of death
and complications after surgery or stenting (Figure 29)
(see Section 9.2.2.3).
9.1. General Approach to the Patient
9.1.1. Recommendation for History and Physical
Examination for Thoracic Aortic Disease
Class I
1. For patients presenting with a history of acute cardiac
and noncardiac symptoms associated with a significant
likelihood of thoracic aortic disease, the clinician
should perform a focused physical examination, in-
cluding a careful and complete search for arterial
perfusion differentials in both upper and lower extrem-
ities, evidence of visceral ischemia, focal neurologic defi-
Figure 27. Beaking of thoracic endoprosthesis. Top left, Baseline thoracic aortography in left anterior oblique projection shows a trau-
matic pseudoaneurysm several cm distal to the left subclavian artery. Aortic diameter proximal to the left subclavian artery measured
23 mm, and distal to the pseudoaneurysm measured 21 mm. Top middle, Thoracic aortography following deployment of a 23-mm-
diameter cuff distally and a 26 mm  10 cm thoracic endograft proximally. Considerable beaking of the leading edge of the endograft
is present (arrow), with lack of conformity of the proximal endograft with the tight inner curve of the aortic arch. The left subclavian
artery was covered intentionally to exclude the pseudoaneurysm, which does not opacify. Top right, CT examination of the chest 2
days following implantation of the endografts shows collapse of the leading edge of the endograft (arrow). Bottom left, On a CT slice
several centimeters more caudally, the endograft remains collapsed posterolaterally, resulting in revascularization of the pseudoaneu-
rysm (arrow). Bottom middle, Thoracic aortography confirms posterior collapse of the endograft and reopening of the pseudoaneurysm.
Bottom right, After placement of a self-expanding z-stent in the proximal endograft and reballooning of the endoprostheses, the
endograft has been reexpanded and the pseudoaneurysm was once again excluded. Although beaking persists, the endograft has
remained fully expanded and the pseudoaneurysm has remained excluded for 3 years of follow-up. CT indicates computed tomo-
graphic imaging.
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cits, a murmur of aortic regurgitation, bruits, and find-
ings compatible with possible cardiac tamponade.339–341
(Level of Evidence: C)
The physical findings of thoracic aortic diseases may be
subtle indirect manifestations of uncommon underlying ge-
netically predisposing conditions. In evaluating the evidence
base for physical examination of patients with thoracic aortic
disease, there are no controlled or blinded experimental
research studies that have stratified patients into different
treatment categories based on physical findings.
For all patients with thoracic aortic disease, the first and
foremost issue is to identify those who are acutely at risk
for catastrophic harm as early as possible. Establishing a
set of “triggers” or “red flags” may serve as alerts to
either exclude or identify life-threatening thoracic aortic
disease.
Given the growing awareness of an extensive variety of
diseases associated with nonemergent thoracic aortic disease,
it is important to be aware of the many different physical
findings associated with extracardiovascular etiologies par-
ticularly those of genetic origin (see Section 5).
9.1.1.1. Coronary Artery Disease
The frequency of coexisting CAD varies widely among
patient subgroups with thoracic aortic disease as does the
Figure 28. Ascending thoracic aortic aneurysm
in a patient with calcific aortic stenosis. Top
left, Axial CT image demonstrates an enlarged
ascending thoracic aorta (A) and normal caliber
descending thoracic aorta (D). Top right, Axial
CT image demonstrates extensive aortic valve
leaflet calcification (arrows). Middle left, Coro-
nal CT image also demonstrates the dilated
ascending aorta (A) and aortic valve leaflet cal-
cification (arrows). Middle right, Volume ren-
dered CT image demonstrates the dilated
ascending thoracic aorta (A), normal caliber
aortic arch and descending thoracic aorta (D)
and great vessels with a bovine arch configu-
ration (INN, LCCA, LSCA). Bottom, Volume
rendered rotating image of the thoracic aorta
can be used to depict the anatomy, particu-
larly the relationship of an aortic abnormality
to the great vessels, for surgical planning.
The full cine video for the bottom panel is
available in the online-only Data Supplement at
http://circ.ahajournals.org/cgi/content/full/CIR.
0b013e3181d4739e/DC1. CT indicates computed
tomographic imaging; INN, innominate artery;
LCCA, left common carotid artery; LSCA, left
subclavian artery; and LV, left ventricle.
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etiology of the coronary artery abnormalities, if present.
Patients with atherosclerotic aneurysms of the descending
aorta are at elevated risk for coronary atherosclerosis, partic-
ularly if they have multiple atherosclerotic risk factors. While
patients with Type A dissection or annuloaortic ectasia may
be protected from atherosclerosis,383 patients with Takayasu
arteritis may occasionally have inflammatory coronary in-
volvement with coronary aneurysms (less than 10%).384,385
Similarly, an occasional patient with GCA may have coro-
nary artery involvement.386,387 If ascending aortic surgery is
being considered, with or without aortic valve surgery, then
identification of the coronary anatomy and any underlying
CAD is important for planning the best operation.
9.1.1.2. Emboli
Embolization of material thrombus, atheromatous debris, or
cholesterol crystals may affect any distal arterial bed (see
Section 11.3). Embolization may occur in patients with
thoracic aortic aneurysms or atheromas and in those who
have undergone angiography, major vessel surgery, or
thrombolytic therapy.388–397 Clinical consequences of such
embolization vary considerably, from being completely
asymptomatic to presenting with acute multiorgan failure,
including progressive renal failure or cutaneous involvement,
with a mortality rate as high as 70% to 90%.398
9.1.1.3. Associated Renal Ischemia
Renal complications of thoracic aortic disease may be acute,
subacute, and chronic.399 Patients may present with severe
abdominal or flank pain, hematuria, fever, nausea, or a
combination of these signs and symptoms.400
9.1.1.4. Associated Mesenteric Ischemia
Patients with acute intestinal ischemia have severe abdominal
pain that is initially out of proportion to physical findings.401
Hours to days later, peritonits and sepsis correlate with
intestinal perforation. Findings suggestive of intestinal ische-
mia as well as specific arterial or venous obstruction require
further surgical or vascular specialist evaluation.402–406
9.1.1.5. Associated Peripheral Ischemia
Acute limb ischemia results in pain, pallor, paraesthesias,
and paralysis.4 Noninvasive vascular diagnostic testing
(eg, ankle- and toe-brachial indices, segmental pressure
measurements, pulse volume recordings, duplex ultra-
sound imaging, and Doppler waveform analysis) may
document ischemia with additional use of angiographic
imaging when necessary.407
9.1.2. Differential Diagnosis
9.1.2.1. Symptoms
Symptoms are most commonly related to pain or discomfort.
Particularly large thoracic aneurysms may be associated with
chest discomfort. Rarely, dysphagia (dysphagia lusoria) or
dyspnea is present, usually related to congenital distal arch
lesions, such as aberrant right subclavian artery and Kom-
merell diverticulum or Felson and Palayew Type I or II
right-sided aortic arch lesions.408
History of fevers may be related to inflammatory disease or
mycotic aneurysms. Occasionally, with chronic dissection
and leaking aneurysms, the reabsorption of blood may be
associated with fever or jaundice.
9.1.2.2. Physical Findings
Most physical findings are not specific for thoracic aortic
disease. Other findings may be related to genetic syndromes
and connective tissue disorders (see Section 5) or inflamma-
tory diseases (see Section 7). Findings associated with coarc-
tation of the aorta include brachial-femoral pulse delay and
murmurs.
Figure 29. Descending aneurysm classification.
Descending aneurysms are classified as involv-
ing thirds of the descending thoracic aorta and
various combinations. A involves the proximal
third, B the middle third, and C as the distal
third. Thus, an aneurysm involving the proximal
two thirds is an AB extent aneurysm. Practi-
cally, these groupings can be combined into
proximal or distal aneurysm, because these
extents influence the risk of paralysis after
either open or endovascular repairs. Thoraco-
abdominal aneurysms are classified according
to the Crawford classification: Type I extends
from proximal to the sixth rib and extends
down to the renal arteries. Type II extends from
proximal to the sixth rib and extends to below
the renal arteries. Type III extends from distal
to the sixth rib but from above the diaphragm
into the abdominal aorta. Type IV extends from
below the diaphragm and involves the entire
visceral aortic segment and most of the
abdominal aorta. Juxtarenal and supraenal an-
eurysms are excluded.379–382 Image reprinted
with permission from the Cleveland Clinic
Foundation.
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9.1.3. Considerations for Imaging
Because most cases of chronic thoracic aortic disease are
asymptomatic and difficult to detect on physical examination,
the clinician must have a low threshold for screening for
thoracic aortic disease. CT or MR is required to adequately
visualize the affected aorta. There has been no cost–benefit
analysis of screening in these populations (see Section 18.1).
9.2. General Medical Treatment and Risk Factor
Management for Patients With Thoracic
Aortic Disease
9.2.1. Recommendation for Medical Treatment of Patients
With Thoracic Aortic Diseases
Class I
1. Stringent control of hypertension, lipid profile opti-
mization, smoking cessation, and other atherosclero-
sis risk-reduction measures should be instituted for
patients with small aneurysms not requiring sur-
gery, as well as for patients who are not considered
to be surgical or stent graft candidates. (Level of
Evidence: C)
The patient’s general status should be optimized where
possible. Respiratory illness, a common comorbid problem,
may be improved by stopping smoking, clearing bronchitis,
and exercising regularly with walking. Because other athero-
sclerotic disease is usually present in patients with thoracic
aortic aneurysms or atheroma, risk-reduction measures as
outlined in other guidelines are appropriate.409 Additional
medical management rationales are noted in Table 13.
Patients who are not candidates for operative intervention
include those whose aneurysms or other aortic pathology do not
meet the criteria for surgical intervention and those in whom the
criteria are met but who are considered inoperable, most com-
monly because of coexisting disease. Patients with large
aneurysms who are considered inoperable may benefit
from stringent control of risk factors (see Section 3.2) to
potentially slow the rate of growth and reduce the risk of
rupture or dissection. Recommendations for periodic im-
aging are noted in Section 14.
Table 13. Studies of Medical Treatment of Thoracic Aortic Aneurysm
Treatment Studies Results
Beta blockers Genoni M, Paul M, Jenni R, et al410 Retrospective, case-record review of 78 patients with chronic Type B dissection who received
medical treatment. 51 of 71 received beta-blocker treatment, 20 of 71 were treated with
other antihypertensive drugs. 10 of 51 (20%) of the beta-blocker–treated patients and 9 of
20 (45%) from the other treatment group needed dissection-related surgery (P0.002). The
incidence of increasing aortic diameter was 12% (6 of 51) in the beta-blocker group and
40% (8 of 20) in the other treatment group (P0.002).
Shores J, Berger KR, Murphy EA,
et al88
Open-label, randomized, control study of propranolol in 70 patients with Marfan syndrome.
The treated group received a mean daily propranolol dose of 21268 mg/d. Propranolol
therapy slowed aortic root dilation (0.023 vs 0.084 per year, P0.001).
Ladouceur M, Fermanian C,
Lupoglazoff JM, et al411
Retrospective evaluation of aortic dilation in children with Marfan syndrome. Aortic dilatation
was slowed by 0.2 mm/y in children treated with beta blockers.
Angiotensin-converting
enzyme inhibitors
Ahimastos AA, Aggarwal A, D’Orsa
KM, et al412
Randomized, double-blind, placebo-controlled trial of 17 patients with Marfan syndrome
taking beta-blocker therapy to perindopril or placebo. After 24 weeks of therapy, the
perindopril-treated subjects compared with placebo-treated subjects had smaller growth in
the ascending aortic diameter during systole (1.2 vs 0.3 mm/m2, P0.01) and a significant
reduction in ascending aortic diameter during diastole (0.4 vs 1.2 mm/m2, P0.001),
respectively.
Angiotensin receptor
blockers
Mochizuki S, Dahlof B, Shimizu M,
et al413
3081 Japanese patients with hypertension, coronary heart disease, heart failure, or a
combination were randomly assigned either to open-label valsartan (40 to 160 mg/d) or to
other treatment without angiotension receptor blockers. Patients randomized to valsartan had
reduction in composite cardiovascular outcome (OR 0.61, 95% CI 0.47 to 0.79) and reduction
in aortic dissection (OR 0.18, 95% CI 0.04 to 0.88). Open-label, randomized.
Brooke BS, Habashi JP, Judge DP,
et al89
The clinical response to angiotension receptor blockers (losartan in 17 patients and irbesartan
in 1 patient) were evaluated in pediatric patients with Marfan syndrome with severe aortic
root enlargement. The mean (SD) rate of change in aortic root diameter decreased
significantly from 3.542.87 mm/y during previous medical therapy to 0.460.62 mm/y
during angiotension receptor blocker therapy (P0.001). The deviation of aortic root
enlargement from normal, as expressed by the rate of change in z scores, was reduced by a
mean difference of 1.47 z scores/y (95% CI 0.70 to 2.24, P0.001) after the initiation of
angiotension receptor blocker therapy. The sinotubular junction showed a reduced rate of
change in diameter during angiotension receptor blocker therapy (P0.05), whereas the
distal ascending aorta was not affected by angiotension receptor blocker therapy.
Statins Diehm N, Decker G, Katzen B,
et al414
A nonrandomized propensity-score–adjusted study of statin use effect on long-term mortality
of patients after endovascular repair of AAA (731 patients) or TAA (59 patients) was done.
Statin use was associated with decreased long-term mortality in patients with AAA (adjusted
HR 0.613, 95% CI 0.379 to 0.993, P0.047), but not for patients with TAA (adjusted HR
1.795, 95% CI 0.147 to 21.942; P0.647).
AAA indicates abdominal aortic aneurysm; CI, confidence interval; SD, standard deviation; and TAA, thoracic aortic aneurysm.
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9.2.1.1. Recommendations for Blood Pressure Control
Class I
1. Antihypertensive therapy should be administered to
hypertensive patients with thoracic aortic diseases to
achieve a goal of less than 140/90 mm Hg (patients
without diabetes) or less than 130/80 mm Hg (pa-
tients with diabetes or chronic renal disease) to
reduce the risk of stroke, myocardial infarction,
heart failure, and cardiovascular death.415–419 (Level
of Evidence: B)
2. Beta adrenergic–blocking drugs should be adminis-
tered to all patients with Marfan syndrome and
aortic aneurysm to reduce the rate of aortic dilata-
tion unless contraindicated.88 (Level of Evidence: B)
Class IIa
1. For patients with thoracic aortic aneurysm, it is
reasonable to reduce blood pressure with beta block-
ers and angiotensin-converting enzyme inhibitors412
or angiotensin receptor blockers89,413 to the lowest
point patients can tolerate without adverse ef-
fects.88,410,411 (Level of Evidence: B)
2. An angiotensin receptor blocker (losartan) is reason-
able for patients with Marfan syndrome, to reduce
the rate of aortic dilatation unless contraindicat-
ed.89,90 (Level of Evidence: B)
Treatment of hypertension to reduce end points of MI,
stroke, and death is well established with many random-
ized clinical trials.420 In the Jikei Heart Study, Japanese
patients who received valsartan along with other antihy-
pertensive therapy had a significantly lower rate of cardio-
vascular morbidity and mortality compared with patients
treated without valsartan. Reductions noted in particular
included lower incidence of stroke, transient ischemic
attack (TIA), angina pectoris, and heart failure. Moreover,
pertinent to this guideline, there was a significant reduc-
tion in the incidence of AoD in the valsartan-treated
patients, which contributed to the reduction in overall
cardiovascular morbidity and mortality.413
Currently, beta adrenergic blockade serves as the founda-
tion of the medical regimen because of demonstrated inhibi-
tion of aneurysm expansion in patients with Marfan syn-
drome. Shores and colleagues88 randomized 70 patients with
Marfan syndrome to propranolol or placebo in a open-label
study demonstrating an attenuated rate of expansion over the
10-year follow-up. Dietz and colleagues91 demonstrated that
angiotensin receptor blocker therapy reduces aneurysm ex-
pansion in animal models of Marfan syndrome. This group
has also recently demonstrated that angiotension receptor
blocker therapy slowed the rate of progression of progressive
aortic root dilatation in a preliminary study of 18 pediatric
patients with Marfan syndrome.89 Both beta blockade and
angiotensin II receptor blockade therapy are being further
investigated in a randomized trial for patients with Marfan
syndrome.90
Lifestyle modifications of diet, weight reduction for over-
weight or obese patients, moderation of alcohol consumption,
and aerobic exercise are standard approaches to treat hyper-
tension,421 but pharmacological therapy is usually required
for patients with thoracic aortic diseases.
9.2.1.2. Recommendation for Dyslipidemia
Class IIa
1. Treatment with a statin to achieve a target LDL
cholesterol of less than 70 mg/dL is reasonable for
patients with a coronary heart disease risk equiva-
lent such as noncoronary atherosclerotic disease,
atherosclerotic aortic aneurysm, and coexistent cor-
onary heart disease at high risk for coronary ische-
mic events.422–425 (Level of Evidence: A)
The National Cholesterol Education Program ATP III recom-
mends that patients with noncoronary atherosclerosis be
treated like patients with established coronary heart dis-
ease.426 Atherosclerosis in the aorta, like atherosclerosis in
any noncoronary vascular bed, markedly increases the risk of
MI and stroke. As a result of this high-risk status (greater than
20% event rate in 10 years), the goal for hypolipidemic
therapy is an LDL level less than 100 mg/dL. Initial therapy
in these patients should be a statin. After the National
Cholesterol Education Program ATP III guidelines were
released in 2001, the Heart Protection Study reported in 2002
that patients with atherosclerosis and a total cholesterol level
greater than 135 mg/dL benefited from the addition of
simvastatin 40 mg/d.427 The RR reductions remained even
when LDL started at less than 100 mg/dL. In concert with
data from patients with acute coronary syndromes, the more
recent ACC/AHA Guidelines for the Management of Patients
With Peripheral Arterial Disease also gave a Class IIa
recommendation suggesting the use of a statin to achieve a
target LDL of less than 70 mg/dL for patients at very high risk
of ischemic events is reasonable.4
There are experimental data demonstrating a delayed
development of atherosclerosis and prevention of aneurysm
development by statins.428–430 However, there are no clinical
outcomes data that justify their use acutely or suggest that
statins prevent expansion after thoracic aortic aneurysms
have developed.
9.2.1.3. Recommendation for Smoking Cessation
Class I
1. Smoking cessation and avoidance of exposure to
environmental tobacco smoke at work and home are
recommended. Follow-up, referral to special pro-
grams, and/or pharmacotherapy (including nicotine
replacement, buproprion, or varenicline) is useful,
as is adopting a stepwise strategy aimed at smoking
cessation (the 5 A’s are Ask, Advise, Assess, Assist,
and Arrange).431–432b (Level of Evidence: B)
There are no randomized or prospective trials that have
investigated the effect of smoking cessation on thoracic aortic
disease. Patients with thoracic aortic aneurysm who smoke
have double the rate of aneurysm expansion.433 Aneurysm
expansion and rupture after Type B dissection are not
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affected by cigarette smoking.434 Smoking cessation reduces
the rate of MI and death in patients with noncoronary
atherosclerosis.435 Patients who smoke require close
follow-up in conjunction with medical and other support to
achieve complete smoking cessation.
9.2.2. Surgical and Endovascular Treatment by Location
of Disease
9.2.2.1. Ascending Aorta and Aortic Sinuses
9.2.2.1.1. Recommendations for Asymptomatic Patients With
Ascending Aortic Aneurysm
Class I
1. Asymptomatic patients with degenerative thoracic
aneurysm, chronic aortic dissection, intramural he-
matoma, penetrating atherosclerotic ulcer, mycotic
aneurysm, or pseudoaneurysm, who are otherwise
suitable candidates and for whom the ascending
aorta or aortic sinus diameter is 5.5 cm or greater,
should be evaluated for surgical repair.371 (Level of
Evidence: C)
2. Patients with Marfan syndrome or other genetically
mediated disorders (vascular Ehlers-Danlos syn-
drome, Turner syndrome, bicuspid aortic valve, or
familial thoracic aortic aneurysm and dissection)
should undergo elective operation at smaller diam-
eters (4.0 to 5.0 cm depending on the condition; see
Section 5) to avoid acute dissection or rup-
ture.81,114,143,371,436–439 (Level of Evidence: C)
3. Patients with a growth rate of more than 0.5 cm/y in
an aorta that is less than 5.5 cm in diameter should
be considered for operation. (Level of Evidence: C)
4. Patients undergoing aortic valve repair or replace-
ment and who have an ascending aorta or aortic root
of greater than 4.5 cm should be considered for
concomitant repair of the aortic root or replacement
of the ascending aorta. (Level of Evidence: C)
Class IIa
1. Elective aortic replacement is reasonable for patients
with Marfan syndrome, other genetic diseases, or
bicuspid aortic valves, when the ratio of maximal
ascending or aortic root area ( r2) in cm2 divided by
the patient’s height in meters exceeds 10.16,143 (Level of
Evidence: C)
2. It is reasonable for patients with Loeys-Dietz syn-
drome or a confirmed TGFBR1 or TGFBR2 mutation
to undergo aortic repair when the aortic diameter
reaches 4.2 cm or greater by transesophageal echo-
cardiogram (internal diameter) or 4.4 to 4.6 cm or
greater by computed tomographic imaging and/or
magnetic resonance imaging (external diameter).78
(Level of Evidence: C)
Aortic diameter is a major criterion for recommending elective
operation in asymptomatic patients with aneurysm of the tho-
racic and thoracoabdominal aorta. This assumes that the risk of
operation is low (less than 5%). Currently, aortic diameter
perpendicular to the axis of flow as measured by CT is the
dimension most often used to determine the size of the enlarged
aorta. This recommendation is based on the observation that the
risk of an adverse event (rupture, dissection, death) exceeds the
risk of elective operation when the maximum diameter exceeds
5.5 to 6.0 cm374,436,437,440 (Figure 30). Formulas that incorporate
height and aortic cross-sectional area have been developed to
establish thresholds for operation in shorter patients but are less
widely used.16,143
The morphology and histopathology of thoracic aortic en-
largements affect the natural history of aortic diseases, including
the risk of rupture or dissection, and thus can influence the
decision to intervene (Figures 31 and 32). Fusiform aneurysms
are most common and behave in a relatively predictable manner.
Aortic dimension can thus be used as an indication for operation.
Saccular aneurysms occur less frequently and may be associated
with a greater risk of rupture. Many of these are actually
pseudoaneurysms, which can develop after previous trauma or
aortic surgery, or with PAUs, and which result in focal disrup-
tion or weakening of the layers of the aorta.
Patients with substantial dilatation of the aortic sinuses
may develop asymptomatic aortic regurgitation as a result of
loss of coaptation of the otherwise normal aortic valve cusps.
Patients with associated bicuspid aortic valve disease may
have asymptomatic stenosis or regurgitation of the valve. In
these patients, the valvular disease may be an indication for
operative intervention.5
9.2.2.1.2. Recommendation for Symptomatic Patients With
Thoracic Aortic Aneurysm
Class I
1. Patients with symptoms suggestive of expansion of a
thoracic aneurysm should be evaluated for prompt
surgical intervention unless life expectancy from
comorbid conditions is limited or quality of life is
substantially impaired. (Level of Evidence: C)
Symptoms associated with thoracic aneurysms usually
develop later in the course of enlargement of the aorta and
most commonly result from impingement of the aneurysm
on adjacent structures. Aneurysms of the ascending aorta
and aortic sinuses may result in symptoms related to the
Figure 30. Effect of aortic aneurysms diameter on risk of com-
plication. For thoracic aortic aneurysms of all etiologies.
Adapted from Elefteriades et al.437
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aortic regurgitation that develops as a result of the pro-
gressive aortic enlargement. Chest or back pain in the
presence of an enlarged thoracic aorta is a predictor of
aortic rupture.336,441 Patients who develop an acute Type A
AoD commonly present with severe chest or back pain.
9.2.2.1.3. Endovascular Grafting for Ascending Aortic Aneu-
rysm. At the time of this writing, endovascular stent grafts
have not been approved by the US Food and Drug Adminis-
tration for treatment of aneurysms or other conditions of the
ascending aorta.
9.2.2.1.4. Recommendations for Open Surgery for Ascending
Aortic Aneurysm
Class I
1. Separate valve and ascending aortic replacement are
recommended in patients without significant aortic
root dilatation, in elderly patients, or in young
patients with minimal dilatation who have aortic
valve disease. (Level of Evidence: C)
2. Patients with Marfan, Loeys-Dietz, and Ehlers-
Danlos syndromes and other patients with dilatation
Figure 31. Ascending aortic aneurysm of degenerative etiology. CABG indicates coronary artery bypass graft surgery; CAD, coronary
artery disease; CT, computed tomographic imaging; and MR, magnetic resonance imaging.
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of the aortic root and sinuses of Valsalva should
undergo excision of the sinuses in combination with
a modified David reimplantation operation if techni-
cally feasible or, if not, root replacement with valved
graft conduit.134,164,442–444 (Level of Evidence: B)
Ascending Aortic Aneurysms: The extent of aortic resection
and the need for ancillary procedures are determined by
preoperative testing and intraoperative findings. Ancillary
procedures that may be performed concurrently include
coronary artery bypass graft surgery, valve replacement or
repair, repair of cardiac septal defects, closure of vascular
fistulas, and ablative therapy for arrhythmias.
For patients with isolated aneurysms confined to the
ascending aorta, resection and graft replacement is the most
commonly performed and recommended procedure. Alterna-
tively, reduction aortoplasty with or without external rein-
forcement has only been performed in very limited
circumstances.445,446
For patients with aortic valve stenosis who require valve
replacement, the choice of valve substitute is determined by
age of the patient, presence of comorbid disease, risk of
Figure 32. Ascending aortic aneurysms associated with genetic disorder. *Depends on specific genetic condition. †See Recommenda-
tions for Asymptomatic Patients With Ascending Aortic Aneurysm (Section 9.2.2.1.1) and Recommendations for Bicuspid Aortic Valve
and Associated Congenital Variants in Adults (Section 6.1). CABG indicates coronary artery bypass graft surgery; CAD, coronary artery
disease; CT, computed tomographic imaging; and MR, magnetic resonance imaging.
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complications related to anticoagulation and reoperation, and
life expectancy.139
For patients with aortic regurgitation associated with a
bicuspid aortic valve, repair of the aortic valve with or
without root remodeling or tailoring of the sinotubular junc-
tion is preferable if the valve is not severely fibrotic or
calcified.99,140 For patients with a dilated aortic root, partic-
ularly those with stenotic bicuspid valves, composite valve
grafts containing either mechanical or biological valves are
implanted.
Ascending aneurysms larger than 4.5 to 5.0 cm require
repair or tube graft replacement when aortic valve repair or
replacement is the primary indication for operation.5 In
elderly patients, ascending aortic aortoplasty when the aortic
diameter does not exceed 5.0 cm may be an acceptable
alternative.
Aortic Valve and Root: In patients with aortic valve regur-
gitation and root dilatation, aortic valve repair and root-
sparing procedure may be the primary procedure. In patients
with Marfan syndrome or with tricuspid aortic valve regur-
gitation, a modification of the David reimplantation operation
may be considered. 94,95,97–99,447 Composite valve grafts with
either biological or mechanical valves are an alternative
option, particularly for valvular stenosis.99,140,441,448
9.2.2.2. Recommendations for Aortic Arch Aneurysms
Class IIa
1. For thoracic aortic aneurysms also involving the
proximal aortic arch, partial arch replacement to-
gether with ascending aorta repair using right sub-
clavian/axillary artery inflow and hypothermic cir-
culatory arrest is reasonable.222,449,450 (Level of
Evidence: B)
2. Replacement of the entire aortic arch is reasonable
for acute dissection when the arch is aneurysmal or
there is extensive aortic arch destruction and leak-
age.222,450 (Level of Evidence: B)
3. Replacement of the entire aortic arch is reasonable
for aneurysms of the entire arch, for chronic dissec-
tion when the arch is enlarged, and for distal arch
aneurysms that also involve the proximal descending
thoracic aorta, usually with the elephant trunk pro-
cedure.451–453 (Level of Evidence: B)
4. For patients with low operative risk in whom an
isolated degenerative or atherosclerotic aneurysm of
the aortic arch is present, operative treatment is
reasonable for asymptomatic patients when the di-
ameter of the arch exceeds 5.5 cm.374 (Level of
Evidence: B)
5. For patients with isolated aortic arch aneurysms less
than 4.0 cm in diameter, it is reasonable to reimage
using computed tomographic imaging or magnetic
resonance imaging, at 12-month intervals, to detect
enlargement of the aneurysm. (Level of Evidence: C)
6. For patients with isolated aortic arch aneurysms
4.0 cm or greater in diameter, it is reasonable to
reimage using computed tomographic imaging or
magnetic resonance imaging, at 6-month intervals,
to detect enlargement of the aneurysm. (Level of
Evidence: C)
Aneurysms of the aortic arch are commonly associated with
aneurysmal disease or dissection of the ascending aorta or the
adjacent descending thoracic aorta, and the indications for
operative intervention in these patients are those for the
adjacent aortic segment. This relates to the need for hypo-
thermic cardiopulmonary bypass and an interval of hypother-
mic circulatory arrest, and to higher operative mortality and
stroke rates than those observed following operation for
isolated aneurysms of the ascending or descending thoracic
aorta.451–459 As with ascending aneurysms, a growth rate of
more than 0.5 cm/y in the absence of symptoms could be
considered an indication for operation.
Symptoms associated with aortic arch aneurysms such as
hoarseness resulting from stretching of the left recurrent
laryngeal nerve, dysphagia, dyspnea, and chest or back pain
are indications for operative intervention for patients with
arch aneurysms unless life expectancy is quite limited.
Suitability for operative intervention involves similar risk
assessment to that for aneurysm or other disorders of the
ascending aorta and aortic root.
The innominate, left carotid, and left subclavian arteries
may require separate grafting. For short periods of circulatory
arrest, the use of retrograde or antegrade brain perfusion has
not conclusively been shown to add further brain protection;
however, use of the subclavian or axillary artery bypass with
a side graft reduces the risk of stroke.449
9.2.2.2.1. Open Surgery. At present, endovascular stent
grafts have not been approved by the US Food and Drug
Administration for treatment of aneurysms or other condi-
tions of the aortic arch. For patients with large aneurysms
who are not candidates for conventional open operation,
experience is accumulating with operative procedures that
involve translocation of the brachiocephalic arteries from the
aortic arch using branch grafts from the proximal ascending
aorta, and placement of an endovascular graft into the distal
ascending aorta, the entire aortic arch, and a segment of the
adjacent descending thoracic aorta.371,460,461
Cardiopulmonary bypass with some degree of hypother-
mia is required for operations that require replacement of
the aortic arch. Brain protection can be achieved by
profound hypothermia alone, direct antegrade perfusion of
1 or more of the brachiocephalic arteries, or retrograde
perfusion using cold oxygenated blood that is infused into
the superior vena cava during the arrest period211,449,462– 467
(see Section 14.5.1). The aortic arch is replaced with a
synthetic graft. The brachiocephalic arteries are attached to
the graft using a patch of the aorta which contains the
origins of the 3 vessels or separately using a graft that
contains 3 branches. The proximal and distal ends of the
aortic graft are attached to normal segments of ascending
and descending thoracic aorta.
An “elephant trunk” procedure has been used to recon-
struct the arch and then provide a Dacron graft landing zone
for endovascular stent graft treatment of descending thoracic
aortic aneurysms (Figure 33).
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9.2.2.3. Descending Thoracic Aorta and Thoracoabdominal
Aorta
9.2.2.3.1. Recommendations for Descending Thoracic Aorta
and Thoracoabdominal Aortic Aneurysms
Class I
1. For patients with chronic dissection, particularly
if associated with a connective tissue disorder, but
without significant comorbid disease, and a de-
scending thoracic aortic diameter exceeding 5.5
cm, open repair is recommended.371,382,468 (Level of
Evidence: B)
2. For patients with degenerative or traumatic aneu-
rysms of the descending thoracic aorta exceeding 5.5
cm, saccular aneurysms, or postoperative pseudoan-
eurysms, endovascular stent grafting should be
strongly considered when feasible.371,469 (Level of
Evidence: B)
3. For patients with thoracoabdominal aneurysms, in
whom endovascular stent graft options are limited
and surgical morbidity is elevated, elective surgery is
recommended if the aortic diameter exceeds 6.0 cm,
or less if a connective tissue disorder such as Marfan
or Loeys-Dietz syndrome is present.371 (Level of
Evidence: C)
4. For patients with thoracoabdominal aneurysms and
with end-organ ischemia or significant stenosis from
atherosclerotic visceral artery disease, an additional
revascularization procedure is recommended.470
(Level of Evidence: B)
At the time of publication of this document, 3 endovascular
stent grafts have been approved by the US Food and Drug
Administration only for aneurysms involving the descending
thoracic aorta. Although the feasibility and safety of endo-
vascular stent grafting of the descending aorta have been
demonstrated for other pathologic conditions including acute
and chronic Type B AoD, IMH, PAU, acute traumatic aortic
transsection, and pseudoaneurysms, these conditions are cur-
rently considered “off label.”
There are no published randomized trials that compare the
outcomes of endovascular stent grafting with conventional
open operation or nonoperative management. Thus, recom-
mendations for use are based principally on observational
studies and nonrandomized comparisons of cohorts of
patients.
9.2.2.3.2. Endovascular Versus Open Surgical Approach. The
potential advantages of endovascular grafting over open
operation include the absence of a thoracotomy incision and
the need for partial or total extracorporeal circulatory support
and clamping of the aorta, as well as lower hospital morbidity
rates and shorter length of hospital stay.
Endovascular grafting may be of particular value in
patients with significant comorbid conditions (older age,
substantial cardiac, pulmonary and renal dysfunction) who
would be considered poor or noncandidates for open surgery.
Patients who are not considered candidates for open surgery
but who have undergone endovascular grafting have substan-
tially poorer long-term outcomes than patients who are
reasonable candidates for open operation and are treated with
endografts.471 Furthermore, intervention (endovascular stent
graft or open surgical graft replacement) for a descending
aneurysm has real risks of mortality and morbidity, including the
risk of spinal cord ischemic injury. All physicians should work
collaboratively among specialities during the initial decision-
making steps to determine via consensus whether a particular
Figure 33. Elephant trunk procedure. Left,
Preoperative disease. Middle, Stage I with
replacement of the ascending aorta and
arch with a Dacron graft with the distal
graft sutured circumferentially to the aorta
distal to the left subclavian artery and the
free end of the graft (“elephant trunk”)
within the descending aneurysm. Right,
Completion of the procedure using an
endovascular stent graft attached proxi-
mally to the “elephant trunk” and the dis-
tal end secured to a Dacron graft cuff.
Images reprinted with permission from the
Cleveland Clinic Foundation.
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patient’s pathology, risk factors, and projected natural history if
treated medically justify an intervention on the descending
thoracic aorta, either a stent graft or an open procedure.
There are no data that conclusively demonstrate that the
prevalence of spinal cord ischemic injury (lower extremity
paralysis or paresis) is less for endovascular approaches than
for open surgical repair. Similarly, there are no firm data to
indicate that overall costs of medical care are lower with
endovascular procedures. Although the costs of the initial
hospitalization may be lower because of reduced operative time
and a shorter length of stay, these benefits may be negated by the
cost of the devices, the need for subsequent interventions, and
the cost and dissatisfaction of repeated imaging studies, which
are necessary in the postoperative period.472,473
Some patients are not suitable candidates for endovascular
grafting procedures. Absence of suitable “landing zones”
above and below the aneurysm (usually 2 to 3 cm of normal
diameter aorta without circumferential thrombus) is a contra-
indication. A width of the aorta at the landing zones that
exceeds the recommended width for the largest available
endovascular grafts (generally 10% to 15% larger than the
width of the aorta) is also a contraindication.
Lack of vascular access sites to insert the relatively
large-bore sheaths that are necessary for deployment of the
grafts is also a contraindication. Severe atherosclerosis and
intraluminal thrombus of the aorta may increase the risk of
embolic stroke during manipulation of guidewires and cath-
eters and represents a relative contraindication.474
9.2.2.3.3. End-Organ Preservation During Thoracic En-
dograft Implantation. Because aneurysmal disease can in-
volve any portion of the aorta, organ preservation during
repair of either aneurysmal disease or dissection is an
important part of the implant procedure. Aneurysms involv-
ing the aortic arch pose a significant risk to cerebral and upper
extremity blood flow with endovascular repair. The need to
cover either the left common carotid or the innominate artery
to treat arch aneurysmal disease is infrequent. Intentional
coverage of the left subclavian artery is more common,
occurring in approximately 50% of thoracic endograft im-
plants. Most patients tolerate coverage of the left subclavian
artery without upper extremity ischemia,475–478 but recently
several groups have suggested that these patients may be at
higher risk of perioperative stroke and spinal cord ischemic
injury.479–481 In the Talent VALOR trial, the need for
intentional preimplant left subclavian artery bypass was only
5.2%.482 To minimize the risk associated with intentional
coverage of the left subclavian artery, it is recommended that
the patency of the contralateral right subclavian and vertebral
arteries be determined preoperatively by CT, MR, or invasive
angiography. Additionally, verification that the vertebral
arteries communicate at the basilar artery by either transcra-
nial Doppler or angiography is also recommended. If these
steps are taken to ensure that the contralateral posterior
circulation is intact, the need to perform a left subclavian
artery bypass postoperatively to prevent symptomatic arm
claudication or vertebral basilar insufficiency is infrequent.
Spinal cord ischemia leading to paralysis is one of the
serious potential complications of the thoracic endograft
procedure. Intercostal arteries are intentionally covered by the
endograft. There is evidence that the risk of spinal cord
ischemia may be greater when treatment involves coverage of
most of the descending thoracic aorta (eg, from left subcla-
vian to celiac artery).483 Additionally, patients who have had
previous repair of abdominal aneurysm (either open or
endovascular) are at increased risk for spinal cord ischemia
and paraplegia.484 In 1 study, the risk of spinal cord ischemia
was 10% to 12% in patients with previous abdominal aneu-
rysm repairs and 2% in patients who did not have previous
abdominal aneurysm repairs.485 In circumstances where it is
necessary to cover most of the descending thoracic aorta or if
the patient has had a previous abdominal aneurysm repair,
cerebrospinal fluid (CSF) pressure monitoring and drainage
are an important strategy to minimize the risk of paraplegia.486
Treatment of TAAs with an endograft may require inten-
tional coverage of the celiac and/or superior mesenteric
arteries to achieve a seal at the distal attachment site. In these
instances, a superior mesenteric-to-celiac artery bypass graft
or an aorta-to-superior mesenteric and/or celiac artery bypass
graft has been used as a first-stage debranching procedure
before proceeding with the endograft implant (Figure 34).
However, risk of the debranching operation may be no lower
Figure 34. Schema of TAA treated with initial left iliac artery–to–
left renal artery–to–superior mesenteric artery bypass graft and
subsequent placement of a thoracoabdominal endograft. Proxi-
mal superior mesenteric artery and left renal arteries were
ligated. SMA indicates superior mesenteric artery; and TAA,
thoracoabdominal aneurysm. Adapted from Flye et al.489
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than conventional open repair, and therefore these operative
approaches are performed selectively.487 Fenestrated grafts
are in development and are undergoing clinical trials. Roselli
et al488 published initial results in the first 73 patients
undergoing in situ endovascular repair of extensive TAAs
using a branch endograft with promising results in a high-risk
population. With careful attention to preservation of blood
flow to the mesenteric vessels, the incidence of mesenteric
ischemia with endograft implants is approximately 3%.482
Most instances of mesenteric ischemia are the result of
emboli rather than malperfusion owing to coverage or occlu-
sion of a mesenteric vessel.
AoDs pose a complex situation for intestinal, renal, or
lower extremity perfusion, as the branches of the aorta in the
abdominal cavity may be perfused from either the true or
false lumen. Often, both the true and false lumens are patent
and some of the visceral, renal, or lower extremity vessels are
fed by one channel and the remainder by the other. Thus, the
operator must consider how blood flow reaches vital organs
in the abdominal cavity before considering treatment of an
AoD with an endograft. In most cases, where descending
thoracic dissections are treated with an endograft, the impor-
tant treatment principle is to cover the proximal entry tear
obliterating the false lumen. However, if the false lumen
supplies blood flow to the visceral vessels, blood flow to
these organs may be compromised after endograft implanta-
tion. Stenting of the vessels at risk from the true lumen or
establishing flow communication between true and false
lumen more distally with a fenestration procedure may
prevent such compromise. In cases of acute Type B AoD
treated with endografts, coverage of the proximal entry site
into the false lumen may result in healing of the tear
downstream with restoration of blood flow from the true
lumen without the need for adjunctive fenestration
procedures.490
9.2.2.3.4. Periprocedural Complications of Endograft Proce-
dures. The acute complications of thoracic endograft proce-
dures are related to problems with access and with device
implantation. Vascular access is a substantial issue with
thoracic endograft procedures. The sheath required to deploy
endovascular grafts is size 20 French or greater and can be up
to size 25 French. Many patients have femoral arteries that
are too small to accommodate such large sheaths. Use of the
iliac artery or the aorta for access is required in approximately
15% of the patients. Infection at the access site is not an
infrequent complication. Bleeding complications are less
frequent. Average blood loss in the Talent VALOR trial was
371 mL, and the need for transfusion in the STARZ TX2
clinical trial (study results on the Zenith TX2 Endovascular
Graft for the Thoracic Aortic Aneurysms) was 3%.469,482
Thromboemboli to mesenteric, renal, or lower extremity
vessels can also occur.491
Major adverse events related to the device occur in 10%
to 12% of patients in the initial 30-day perioperative period.
Stroke was observed in 2.5% of the patients in the STARZ
TX2 clinical trial469 and 3.6% in the Talent VALOR trial.482
It has been reported to be as high as 8% in other studies.474,492
Most strokes occur as a result of atheroemboli from the
transverse aortic arch with manipulation of the guidewires
and device in the arch vessels.474 Paraplegia varied from 1.3%
in the STARZ TX2 clinical trial to 1.5% in the Talent
VALOR trial to 3% in the TAG trial.469,482,493
Cardiac complications, principally MI, occur rarely (2% to
4%).469,482 Cardiac tamponade or rupture is rare and may be
caused by either the stiff guidewires that are required to
deliver the devices or excessive afterload created by the
balloons that are inflated to produce a seal of the graft to the
aortic wall. Ventricular tachycardia or ventricular fibrillation
has been reported.469 Pulmonary complications include post-
operative pneumonias, which occur in less than 5% of
patients. Acute renal failure requiring dialysis is also uncom-
mon, reported to occur in 1.3% of patients in the Talent
VALOR trial.482 Device implant infection is exceedingly rare
and has been observed mainly in situations where the device
was implanted in an infected medium emergently (ie, mycotic
aneurysms or aortoenteric fistulae).482
Endoleak is defined as the persistence of blood flow
outside the lumen of the endoluminal graft but within the
aneurysm sac, based on imaging. Endoleaks are classified
based on the source of blood flow (Table 14).
Perforation or dissection of the aorta at the implantation
site is infrequent but usually reported with stent systems that
have uncovered or bare proximal attachment stents.495–499
Involution or infolding of the endografts may occur and has
been most frequently reported with grafts applied to a
relatively small aorta where oversizing can be substantial,
especially in trauma cases.366,500,501 Infoldings can also occur
when there is inadequate conformity of the device to the
aortic wall in a region of marked curvature or “beaking” (see
Figure 27). This leads to collapse of the endograft, gross
endoleak, and the potential for acute occlusion of flow to the
descending thoracic aorta. It can be prevented (or managed
Table 14. Classification of Endoleaks
Type Cause of Perigraft Flow Sequelae and Treatment Strategy
I Inadequate seal at
proximal and/or distal
graft attachment site
Systemic arterial pressure transmitted to
the aneurysm sac, leading to expansion
and rupture. Should be repaired when
diagnosed.
II Retrograde aortic
branch arterial blood
flow into aneurysm sac
May spontaneously thrombose. If
aneurysm is stable or shrinking,
observe. If aneurysm is expanding,
embolic occlusion of branch artery
indicated but often difficult.
III Structural failure of
endograft (eg, stent
graft fractures, holes in
fabric, junctional
separations)
Systemic arterial pressure transmitted to
the aneurysm sac, leading to expansion
and rupture. Should be repaired when
diagnosed.
IV Stent graft fabric
porosity
Noted at time of implantation and
usually resolved with reversal of
anticoagulation.
V Expansion of aneurysm
without demonstrable
endoleak, also called
“endotension”
Reline the endograft with a second
endograft.
Adapted from Veith et al.494
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after it occurs) with implantation of a reinforcing stainless
steel stent at the proximal leading edge of the implant.500
Late complications of thoracic aortic endografting include
endoleaks, continued aneurysm growth, metal fatigue and
stent fracture and kinking, detachment, migration, perfora-
tion, and infection of the implanted device. Endoleaks occur
in 10% to 20% of patients.482 The frequency is greatest in the
first month following implantation and declines over the
ensuing 5 years.502 The most frequent type of endoleak is
Type IA, or proximal attachment site failure (see Section
8.6).469,482,503–505 Migration occurs infrequently—at 1-year
follow-up in 0.4% of cases in the TAG clinical trial and 3.9%
of cases in the Talent VALOR trial.469,482,506
Late perforations of the aorta by the endograft can occur
and are common with the use of oversized grafts and/or
grafts with bare or uncovered stents.507,508 Most late device
complications such as endoleak and migration are treatable
with implantation of graft extensions. The overall need for
repeat interventions to maintain endograft integrity is 6%
to 7%, most commonly in the form of implantation of an
extension cuff. Conversions to open operation are rarely
needed (1% to 2%).476,480,505,509,510 Late complications (9 to
24 months) include stent fractures, which are often asymp-
tomatic.511 There are case reports of fractures leading to
endograft dysfunction, endoleak, migration, and/or embo-
lization.512 Endograft infection, usually as a result of an
ongoing systemic infection, or as a result of infected
structures adjacent to the graft,513,514 is uncommon, but
when it occurs, it is very difficult to eradicate without
explantation of the device and, without explantation, can
lead to aortic rupture.515
The experience with the use of endografts for the treat-
ment of acute descending AoD is limited. A meta-analysis of
609 published cases suggests that when endografts are used,
mortality is slightly higher (5.3%) and late conversions to
open procedures are more frequent (2.5%) than data reported
for treatment of aneurysms. The risk of major complications
including stroke, paraplegia, and aneurysm rupture appears to
be similar in both conditions.516 A complication unique to
endograft treatment of acute Type B dissections is conversion
of the dissection to a retrograde Type A dissection, creating a
surgical emergency.480,517 Until and unless this life-
threatening complication is understood and eliminated, en-
dograft treatment of acute Type B dissections should be
undertaken at institutions with a team qualified to perform
open aortic surgery.
In the absence of Level A or Level B evidence regarding
the relative efficacy of open and endovascular procedures for
treatment of descending aortic aneurysms, no firm recom-
mendations can be made regarding the optimal method of
treatment. Among comparable patients treated with either
open or endovascular procedures, the midterm results can be
anticipated to be equivalent. The early mortality advantage of
endovascular procedures may be lost during follow-up such
as that seen with endovascular treatment of AAAs.518,519 The
long-term durability of endovascular stent grafts is uncertain;
currently, available grafts may have a durability of no more
than 10 years. Younger patient age may be a relative
contraindication to endografting.
There are no data to indicate that endovascular stent
grafting should be performed in patients with asymptomatic
descending aortic aneurysms that are less than 5.5 cm in
diameter, because the risk of operation (approximately 5%)
exceeds the risk of rupture or dissection371 (Table 15).
Undoubtedly, as new iterations of devices are introduced,
these guidelines will change.
9.2.2.3.5. Open Surgical. Diseases of the aorta that require
extensive thoracoabdominal surgical or interventional ap-
proaches fall into 3 large groups: 1) degenerative aneurysms,
2) AoD resulting in subsequent aneurysms or visceral ische-
mia, and 3) occlusive disease of the visceral arteries. Selec-
tion of patients for repair is based on symptoms, risk of death
from rupture, and end-organ ischemia, provided associated
comorbidity does not prevent surgical repair. In patients with
lower chest or upper abdominal pain, CT or MR is performed
to determine if the patient has a contained rupture, leak, or an
aneurysm impinging on surrounding structures that may be
causing pain. The perioperative risk of death is approxi-
mately 80% with emergency surgery; a few patients will
recover without a major complication limiting quality of
life, and few will be long-term survivors because of
comorbid disease. In patients with pain from compression
of surrounding structures, if comorbid disease is not a
factor, results are considerably better with a 10% to 20%
risk of death. In patients undergoing elective surgery, the
risk of death is 3% to 10%, depending on the extent of
repair.
The extent of repair for TAA is classified by the Crawford
types: Type I is a repair that extends from the proximal
Table 15. Summary of Society of Thoracic Surgeons
Recommendations for Thoracic Stent Graft Insertion
Entity/Subgroup Classification
Level of
Evidence
Penetrating ulcer/intramural hematoma
Asymptomatic III C
Symptomatic IIa C
Acute traumatic I B
Chronic traumatic IIa C
Acute Type B dissection
Ischemia I A
No ischemia IIb C
Subacute dissection IIb B
Chronic dissection IIb B
Degenerative descending
5.5 cm, comorbidity IIa B
5.5 cm, no comorbidity IIb C
5.5 cm III C
Arch
Reasonable open risk III A
Severe comorbidity IIb C
Thoracoabdominal/severe comorbidity IIb C
Reprinted from Svensson et al.371
Hiratzka et al 2010 Guidelines on Thoracic Aortic Disease e327
D
ow
nloaded from
 http://ahajournals.org by on August 16, 2018
descending aorta above T6 to the renal arteries; Type II, the
highest risk group, extends from the proximal descending
aorta above T6 to below the renal arteries; Type III extends
from the distal descending aorta below T6 to below the
diaphragm for variable extents; and Type IV extends from the
diaphragm and involves most of the abdominal aorta. This
classification correlates with the risk of paralysis, renal
failure, and death.
Open surgical repair of TAA improved over the past 15
years, particularly on preventing postoperative paralysis.
Historically, one of the most serious complications was
paralysis, either paraparesis or paraplegia, caused by spinal
cord injury whose risk is for Type I TAA repair, 15%; for
Type II, 30%; Type III, 7%; and for Type IV, 4%.381 Current
risk of paralysis is 3% to 5%, depending somewhat on the
extent of repair.381,382,520–526
The risk of renal failure may be reduced by preoperative
day admission, fluid hydration starting the day before sur-
gery, and the addition of bicarbonate to the hydration regimen
and hypothermia protection during the operative procedure.
9.2.2.3.6. End-Organ Preservation During Open Thoracoab-
dominal Repairs. For thoracoabdominal aortic repairs done
in combination with proximal repairs of the aortic arch, the
key vital end organs to protect are the heart and brain.
Flooding the field with CO2 appears to be beneficial.527,528
When the aortic arch requires repair, hypothermic circulatory
arrest is usually required. Protection of the brain involves
ensuring that calcium plaques or atheromata are not disturbed
to prevent brain embolization. The temperature and where it
is best measured, at which circulatory arrest is commenced,
are debated but most large series have recommended circu-
latory arrest at a temperature below 20°C.211
Perfusion of the celiac artery or superior mesenteric artery
does not appear to be needed to protect the abdominal organs
in most patients where moderate hypothermia (30° to 32°C) is
used. Protection of the left lung during left thoracotomy
repairs is important to avoid lacerations and bleeding into the
parenchyma. Deflation of the left lung may be of benefit.
However, disruption of the visceral pleura with attendant
complications of bleeding and air leak may be unavoidable,
particularly if adhesions are present due to prior surgery or
inflammatory changes.
9.2.2.3.7. Aortic Dissection With Malperfusion. Renal, mes-
enteric, lower extremity, or cord malperfusion accompanies
up to one third of acute AoD and roughly doubles mortali-
ty.248,529,530 In the case of Type A AoD with malperfusion,
there is controversy over whether patient outcomes are
improved by first repairing the aorta and then treating
persistent malperfusion531 or by first correcting the malper-
fusion and then repairing the aorta.247,532 The general consen-
sus is to first repair the aorta, because this will correct
malperfusion in most patients. In the case of Type B AoD,
there is a general consensus that medical management should
be supplemented by open or endovascular intervention when
there is evidence for renal, mesenteric, lower extremity, or
cord malperfusion.248,490,533
10. Special Considerations in Pregnant
Patients With Aortic Disease
10.1. Effects of Pregnancy on the Aorta
Physiologic effects of pregnancy may have a profound effect
not only on aortic stress but potentially on arterial ultra
structure as well. The pregnant state is characterized by
increases in maternal blood volume, heart rate, blood pres-
sure, stroke volume, and cardiac output.534,535 Taken together,
the combined effects lead to greater arterial wall tension as
well as intimal shear forces. These changes begin in the first
and second trimesters but are most notable in the third
trimester and peripartum period. Whether arterial wall weak-
ening itself occurs during pregnancy remains controversial.
Arterial dissection and/or rupture may occur with the highest
incidence in the third trimester (approximately 50%) and
peripartum period (33%). In one of the few prospective
studies of pregnant patients with Marfan syndrome, 4.4% of
carefully monitored patients developed aortic dissection.534 In
unmonitored patients, the risk is likely higher.
10.2. Epidemiology of Chronic and Acute Aortic
Conditions in Pregnancy
Marfan syndrome, Ehlers-Danlos syndrome, and other non-
Marfan aortic disease may manifest during pregnancy. Al-
though clearly rare, it has been estimated that half of AoD
and/or ruptures in women younger than 40 years of age have
been associated with pregnancy.536 Most dissections occur in
the ascending aorta, although dissection or rupture of virtu-
ally any artery in the body has been described. In addition,
pregnancy-related expansion of the sinotubular junction may
lead to aortic valve insufficiency.
10.3. Counseling and Management of Chronic
Aortic Diseases in Pregnancy
10.3.1. Recommendations for Counseling and
Management of Chronic Aortic Diseases in Pregnancy
Class I
1. Women with Marfan syndrome and aortic dilata-
tion, as well as patients without Marfan syndrome
who have known aortic disease, should be counseled
about the risk of aortic dissection as well as the
heritable nature of the disease prior to pregnancy.74,91
(Level of Evidence: C)
2. For pregnant women with known thoracic aortic
dilatation or a familial or genetic predisposition for
aortic dissection, strict blood pressure control, spe-
cifically to prevent Stage II hypertension, is recom-
mended. (Level of Evidence: C)
3. For all pregnant women with known aortic root or
ascending aortic dilatation, monthly or bimonthly
echocardiographic measurements of the ascending
aortic dimensions are recommended to detect aortic
expansion until birth. (Level of Evidence: C)
4. For imaging of pregnant women with aortic arch,
descending, or abdominal aortic dilatation, magnetic
resonance imaging (without gadolinium) is recom-
mended over computed tomographic imaging to
avoid exposing both the mother and fetus to ionizing
radiation. Transesophageal echocardiogram is an
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option for imaging of the thoracic aorta. (Level of
Evidence: C)
5. Pregnant women with aortic aneurysms should be
delivered where cardiothoracic surgery is available.
(Level of Evidence: C)
Class IIa
1. Fetal delivery via cesarean section is reasonable for
patients with significant aortic enlargement, dissec-
tion, or severe aortic valve regurgitation.91 (Level of
Evidence: C)
Class IIb
1. If progressive aortic dilatation and/or advancing
aortic valve regurgitation are documented, prophy-
lactic surgery may be considered.537 (Level of Evi-
dence: C)
In this regard, risk of major aortic complications during
pregnancy appears to be low when the aortic root diameter is
less than 4.0 cm.538 Such individuals may have one or more
successful pregnancies. For patients with an aortic diameter
greater than 4.0 cm and Marfan syndrome, half will have
come to prophylactic surgery during pregnancy, will have a
rupture, or will have life-threatening growth. Optimal preven-
tive therapy in the pregnant woman with known aortic disease
includes use of beta blockers to control heart rate and reduce
shear stresses, particularly in the third trimester and peripar-
tum period. Both angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers are contraindicated during
pregnancy.
10.4. Evaluation and Management of Acute Aortic
Syndromes During Pregnancy
Pregnant women with Marfan syndrome, bicuspid aortic
valve and ascending aneurysms, Ehlers-Danlos syndrome,
and non-Marfan familial thoracic aortic aneurysm and dis-
section may present with acute aortic syndromes at any point
during the pregnancy but are particularly prone to do so in the
last trimester, during delivery, or in the early postpartum
period. Such women may have no knowledge of their
underlying aortic condition until presentation with their acute
aortic problem.
Obviously, acute AoD poses a huge risk for both the
mother and the unborn child. Optimal treatment parallels that
of nonpregnant women but with the added complication of
when and how to deliver the child. Optimal care includes
involvement with a high-risk maternal-fetal team along with
an aortic specialty team capable of medical, percutaneous,
and surgical aortic treatment. For Type A AoD occurring
during the first or second trimester, urgent surgical repair
with aggressive fetal monitoring is preferred. Fetal loss
during hypothermia and cardiopulmonary bypass is common.
When dissection complicates the third trimester, urgent ce-
sarean section followed by aortic repair appears to offer the
best chance for survival for the unborn child and the mother.
For acute arch or Type B AoD, medical therapy is preferred
unless percutaneous stent grafting or open surgery is man-
dated by malperfusion, aortic rupture, or subacute aortic
leaking.539
11. Aortic Arch and Thoracic Aortic
Atheroma and Atheroembolic Disease
11.1. Recommendations for Aortic Arch
and Thoracic Aortic Atheroma and
Atheroembolic Disease
Class IIa
1. Treatment with a statin is a reasonable option for
patients with aortic arch atheroma to reduce the risk
of stroke.540 (Level of Evidence: C)
Class IIb
1. Oral anticoagulation therapy with warfarin (INR 2.0
to 3.0) or antiplatelet therapy may be considered in
stroke patients with aortic arch atheroma 4.0 mm or
greater to prevent recurrent stroke. (Level of Evi-
dence: C)
11.2. Clinical Description
Aortic arch atheroma is a risk factor for ischemic stroke based
on autopsy,541,542 TEE,543–548 and intraoperative ultrasono-
graphic studies549 (Figure 35). In particular, plaques 4 mm or
greater in thickness proximal to the origin of the left subcla-
vian artery are associated with stroke and constitute one third
of patients with otherwise unexplained stroke.542 These pa-
tients, even on antiplatelet therapy, carry a risk of recurrent
ischemic stroke as high as 11% at 1 year, and the risk of a
new vascular event (ischemic stroke, MI, peripheral event,
and vascular death) is 20%, 36%, and 50% at 1, 2, and 3
years, respectively.550 The RR of new ischemic stroke was
3.8 (95% CI 1.8 to 7.8, P0.002), and that of new vascular
events was 3.5 (95% CI 2.1 to 5.9, P0.001), independent of
carotid stenosis, atrial fibrillation, peripheral artery disease,
or other risk factors.550 Other studies showed that aortic arch
plaques were independent predictors of recurrent strokes, MI
and vascular death.551–553 Patients with noncalcified plaques
were at higher risk for recurrent vascular events.554
Figure 35. Ultrasound image of aortic atheroma.
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Regarding the natural history of aortic arch atheroma, Sen
et al555 noted progression in 29% and regression (defined as
an increase or decrease in plaque thickness by 1 grade or
greater, respectively) in 9%. Montgomery et al556 reported 30
patients with moderate-to-severe aortic plaque noted on
initial bi/multiplanar TEE as part of a workup for cardiac or
an embolic event. Over a mean of 1 year, progression was
reported in 23% and regression in 10%. Pistavos et al557 used
monoplanar TEE in 16 patients with familial hypercholester-
olemia taking pravastatin to show progression in 19% and
regression in 38% over 2 years. Geraci and Weinberger,558
using supraclavicular B-mode ultrasonography of the proxi-
mal aortic arch in 89 patients evaluated for transient neuro-
logic symptom, noted a progression rate of 19% and a
regression rate of 18% over a mean of 7.7 months (range 3 to
18 months). Sen et al559 confirmed that in patients with
stroke/TIA, aortic arch atheroma progression over 12 months
is associated with more vascular events.
11.3. Risk Factors
Risk factors for the development of aortic atheroma include
age, sex, heredity, hypertension, diabetes mellitus, hyperlip-
idemia, sedentary lifestyle, smoking, and endothelial dys-
function. Other factors include elevated levels of inflamma-
tory markers (ie, serum C-reactive protein), homocysteine, or
lipoprotein.560,561 Risk factors for embolic complications
include inflammation, shear forces of hypertension, plaque
hemorrhage aneurysm formation, and iatrogenic manipula-
tion. The likelihood of embolization is also increased with
complex aortic plaque, defined as plaque that contains mobile
thrombi or ulcerations or is 4 mm or greater in thickness.562
Plaques with a larger lipid core, a predominance of macro-
phages, a thin fibrous cap, and a lack of calcification are more
“vulnerable” to disruption or rupture. Calcified plaques are
more stable and less likely to result in embolic
syndromes.562,564–565
11.4. Diagnosis
Methods of imaging the aortic arch to detect and/or measure
plaque include:
Transesophageal Echocardiography. TEE can provide
information of plaque mobility, ulceration, and composi-
tion,566 as well as details on the anatomic relationship of the
plaque to the origin of the great vessels69 with excellent
interobserver and intraobserver reliability.567 Limitations of
TEE in patients with stroke include the need for conscious
sedation, patient cooperation for swallowing the probe,
and risk of structural damage.566 A small portion of the
ascending aorta is masked by the tracheal air column near
the origin of the innominate artery, with an estimated 2%
of plaques being missed.568 Multiplanar probes may reduce
tracheal shadowing seen with monoplanar and biplanar
probes.569
Transthoracic Echocardiography. TTE can usually im-
age the aortic root and proximal ascending aorta but cannot
adequately assess aortic arch plaque.570,571
Epiaortic Ultrasonography. Epiaortic imaging is useful
to detect aortic arch plaque in the operative setting when the
transducer may be placed directly over the aortic arch. The
information may be used to select operative techniques such
as off-pump coronary artery bypass grafting to avoid cannu-
lation or cross-clamping of the aorta and reduce risk of
perioperative strokes.572,573
Contrast Aortography. The risk of invasive angiography
and the need for contrast injection and radiation make
contrast aortography less useful to assess aortic arch plaque in
patients with stroke.574
Magnetic Resonance Imaging. MR has been validated
against TEE for detection and measurement of aortic arch
plaque (80% overall agreement).568,575 It has limited use in
patients who are obese, have metallic implants, or are
claustrophobic. Contrast MR angiography underestimates
the plaque thickness but can identify morphologic features
including calcification, fibrocellular tissue, lipid, throm-
bus, and features used to detect plaque stability and may be
used to monitor aortic arch plaque progression and
regression.572
Computed Tomography. CT can reliably detect and
measure protruding aortic arch plaques568,576 and is the test of
choice for detecting vascular calcification. Nonenhanced
dual-helical CT may underestimate the amount of noncalci-
fied plaque and mobile thrombus that presumably is at high
risk for embolization.568 In conjunction with positron emis-
sion tomography it can be used to localize fluorodeoxyglu-
cose uptake by the plaque, identifying active plaques and
unstable plaques,577 but its clinical utility has yet to be
established.
11.5. Treatment
There is no definitive therapeutic regimen for this high-
risk patient group because no randomized trial has been
completed.
11.5.1. Anticoagulation Versus Antiplatelet Therapy
Mobile aortic atheroma have been noted to disappear during
anticoagulant therapy546 or with the use of a thrombolytic
agent.578 However, there is concern about the use of warfarin
in patients with aortic atheroma because of the theoretical
risk of plaque hemorrhage resulting in atheroemboli syn-
drome (ie, blue toes, renal failure, intestinal infarction).579
Anticoagulation has been associated with worsening,580,581
as well as improvement of an aortic thrombus on antico-
agulation in a patient with the atheroemboli syndrome.582
Cholesterol emboli have been documented on skin, mus-
cle, and renal biopsy samples in patients with aortic arch
atheroma seen on TEE.553,583 However, the risk of clinical
atheroemboli syndrome during warfarin therapy in such
patients appears to be low (only 1 episode in 134 patients
according to the SPAF [Stroke Prevention in Atrial Fibril-
lation] trial).562
Three reports shed light on the potential benefit of warfarin
in patients with aortic arch atheroma. The first described 31
patients with mobile lesions in the aorta on TEE585 where a
higher incidence of vascular events was seen in patients who
were not treated with warfarin compared with those treated
with warfarin (at the discretion of the referring physicians)
(45% versus 5%). In the SPAF randomized trial of patients
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with “high-risk” nonvalvular atrial fibrillation, the risk of
stroke at 1 year in 134 patients with complex aortic plaque
was found to be reduced from 15.8% (11 events) in those
treated with fixed low-dose warfarin plus aspirin (INR 1.2 to
1.5) to only 4% (3 events) in those treated with adjusted-
dose warfarin (INR 2.0 to 3.0), a 75% RR reduction
(P0.02) for patients with atheromas who received “ther-
apeutic range” anticoagulation.562 A third observational
study reported on 129 patients with aortic arch atheroma
on TEE performed to look for a source of cerebral or
peripheral embolization.586 Treatment with oral anticoag-
ulation, aspirin, or ticlopidine was not randomly assigned.
There was a significant reduction in the number of embolic
events in patients with plaques greater than or equal to
4 mm who received oral anticoagulants (0 events in 27
patients versus 5 events in 23 patients treated with anti-
platelet agents) (OR 0.06, 95% CI 0.003 to 1.2, P0.016).
For patients with mobile lesions, there was a significant
reduction in mortality while on anticoagulants, although
the trend toward fewer embolic events did not reach
statistical significance in this group.
These 3 reports suggest that warfarin is not harmful in
patients with aortic arch atheroma and may reduce stroke
rates. However, these studies are not randomized trials of
treatment for patients with atheromas, and the numbers are
relatively small. The current ARCH (Aortic Arch Related
Cerebral Hazard) trial is an open-label trial where patients
with aortic arch atheroma (4 mm or greater) and nondisabling
stroke are being assigned to oral anticoagulation (target INR
2.0 to 3.0) versus aspirin (75 mg/d) plus clopidogrel (75
mg/d) and followed longitudinally for recurrence of vascular
events.
11.5.2. Lipid-Lowering Agent
There are no randomized trials to support specific lipid-
lowering drug therapy for a patient with stroke caused by
atheroembolism. However, 2 randomized studies of low-
dose and higher-dose statin in patients with aortic
and/or carotid plaques showed significant regression in
plaque seen on MR, which in 1 study was related to LDL
cholesterol level but not statin dosage587 and, in the other
study, was related to both LDL lowering and the statin
dosage.588 It seems likely that statin therapy decreases
the risk of stroke. Mechanisms for this effect may involve
pleiotropic effects of statins, including plaque regression,
plaque stabilization, decreased inflammation, and inhibi-
tory effects on the coagulation cascade at different levels.
No randomized trial on the use of statins in patients with
severe aortic plaque has been published. However, in an
observational study of 519 patients with severe aortic plaque
on TEE,540 statin use was associated with an RR reduction for
ischemic stroke of 59%. Statins have reduced both primary
and secondary stroke in a variety of patient populations.589,590
Hence, a majority of patients with stroke and TIA with
identified aortic plaque already have other stronger indica-
tions for statin therapy.409 Recommendations for statins are
noted for other manifestations of atherosclerotic diseases409
(see Section 9.2.1.2). Clinical trials are needed to determine
the effects of statins in patients with severe aortic atheroma
and risk of atheroembolism.
11.5.3. Surgical and Interventional Approaches
Aortic arch endarterectomy has been attempted for patients
with thromboembolism originating from aortic arch athero-
ma. Although successful in a handful of case reports, this
procedure resulted in a relatively high rate (34.9% with
endarterectomy versus 11.6% without endarterectomy) of
perioperative stroke and mortality when it was performed to
limit stroke during cardiac surgical procedures requiring
cardiopulmonary bypass (coronary bypass surgery and valve
surgery).545 Covered stents offer the potential advantage of
shielding severely diseased aortic segments to prevent further
embolization. However, periprocedural embolization may
occur during diagnosis or interventional endovascular manip-
ulations. There is insufficient evidence to recommend pro-
phylactic endarterectomy or aortic arch stenting for purposes
of stroke prevention.
12. Porcelain Aorta
Vascular calcification occurs in the media and represents a
central component of atherogenesis, typically signaling long-
standing inflammation. The amount of calcification directly
associates with the extent of atherosclerosis, and the presence
of aortic calcium predicts the presence of coronary heart
disease.443
With severe atherosclerosis of the aorta, calcification may
be severe and diffuse, causing an eggshell appearance seen on
chest x-ray or CT.444 Also termed “porcelain aorta,” this
finding is usually noted during operation for coronary heart or
valvular heart disease at the time of surgery. The calcification
interferes significantly with cannulation of the aorta, cross-
clamping, and placement of coronary bypass grafts, increas-
ing the risk of stroke and distal embolism significantly
(Figure 36).
In these patients, direct manipulation of the aorta may
result in an unrepairable aortic injury and/or distal emboliza-
tion. Surgeons have used several techniques to reduce adverse
neurologic events in these patients: internal aortic balloon
occlusion (as apposed to aortic cross-clamping), a “no-touch”
technique to avoid the ascending aorta, alternate locations for
cannulation or coronary bypass graft anastomoses, replace-
ment of the ascending aorta, and intra-aortic filtration of
atherosclerotic debris.591–599
13. Tumors of the Thoracic Aorta
Neoplasms of the thoracic aorta are usually secondary and
related to contiguous spread of adjacent primary malignan-
cies, particularly lung and adjacent primary malignancies,
or subsequent metastases, particularly lung and
esophagus.600 – 603
Primary neoplasms of the thoracic aorta are rare. A review
of the literature between 1873 and 2002 collated a total of 53
thoracic and 10 thoracoabdominal tumors with most lesions
protruding into the aortic lumen604 (Table 16).
Metastatic disease is often demonstrated at the time of
diagnosis of primary aortic neoplasms, so that constitutional
symptoms of malaise, fatigue, weight loss, and nausea may be
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the presenting complaints. Other presentations can include
distal arterial embolization (with histopathologic examination
showing neoplasm or identified by imaging techniques during
a search for an embolic source).604–606 AoD may originate in
the area of the neoplasm or the aortic occlusion.607 Resection
and reconstruction of the segment of aorta containing the
neoplasm have been described, but because most patients
present with metastatic disease, overall prognosis is poor.608
14. Perioperative Care for Open Surgical and
Endovascular Thoracic Aortic Repairs
14.1. Recommendations for
Preoperative Evaluation
Class I
1. In preparation for surgery, imaging studies ade-
quate to establish the extent of disease and the
potential limits of the planned procedure are recom-
mended. (Level of Evidence: C)
2. Patients with thoracic aortic disease requiring a
surgical or catheter-based intervention who have
symptoms or other findings of myocardial ischemia
should undergo additional studies to determine the
presence of significant coronary artery disease.
(Level of Evidence: C)
3. Patients with unstable coronary syndromes and sig-
nificant coronary artery disease should undergo
revascularization prior to or at the time of thoracic
aortic surgery or endovascular intervention with
percutaneous coronary intervention or concomitant
coronary artery bypass graft surgery. (Level of
Evidence: C)
Class IIa
1. Additional testing is reasonable to quantitate the
patient’s comorbid states and develop a risk profile.
Figure 36. Porcelain aorta. Top left and right, PA
and lateral chest x-ray show an anterior mediasti-
nal mass with curvilinear calcifications most likely
representing the wall of an ascending aortic aneu-
rysm. Bottom left, CT scan slice at the level of the
right pulmonary artery confirms a 10-cm aneurysm
of the ascending aorta with dense mural calcifica-
tions. Bottom right, A maximum intensity projec-
tion in the oblique sagittal plane better demon-
strates the fusiform aneurysm beginning at the
sinotubular ridge and extending into the aortic
arch. Dense mural calcification extends into the
proximal descending aorta. CT indicates com-
puted tomographic imaging; and PA,
posteroanterior.
Table 16. Neoplasms of the Thoracic Aorta (Collective
Review Incidence)
Histology
Thoracic Aorta
(N53)
Thoracoabdominal
Aorta (N10)
Sarcoma 15 1
Malignant fibrous histiocytoma 11 1
Angiosarcoma 5 0
Leiomyosarcoma 6 2
Fibrosarcoma 4 0
Myxoma 3 1
Fibromyxosarcoma 1 1
Hemangiopericytoma 2 0
Hemangioendothelioma 2 0
Malignant endothelioma 2 0
Aortic intimal sarcoma 0 2
Myxosarcoma 0 1
Endotheliosarcoma 1 0
Fibromyxoma 0 1
Fibroxanthosarcoma 1 0
Adapted from Oldenburg et al.604
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These may include pulmonary function tests, cardiac
catheterization, aortography, 24-hour Holter moni-
toring, noninvasive carotid artery screening, brain
imaging, echocardiography, and neurocognitive test-
ing. (Level of Evidence: C)
2. For patients who are to undergo surgery for ascend-
ing or arch aortic disease, and who have clinically
stable, but significant (flow limiting), coronary ar-
tery disease, it is reasonable to perform concomitant
coronary artery bypass graft surgery. (Level of
Evidence: C)
Class IIb
1. For patients who are to undergo surgery or endo-
vascular intervention for descending thoracic aortic
disease, and who have clinically stable, but signifi-
cant (flow limiting), coronary artery disease, the
benefits of coronary revascularization are not well
established.609–611 (Level of Evidence: B)
Preoperative evaluation usually includes imaging studies
necessary to establish the extent of disease, the limits of the
planned procedure, and the clinical risks attendant to the
procedure. When the writing committee was polled regarding
the extent of usual preoperative laboratory testing, a variety
of approaches emerged. In some centers, extensive testing
includes pulmonary function tests (particularly for smokers
and those with Marfan syndrome), Holter monitoring, and
carotid duplex scans. In some centers, brain imaging and
neurocognitive testing are performed in patients with aortic
arch disease for whom arch repair or replacement requiring a
period of deep hypothermic circulatory arrest or low pump
flow is planned.463 Other centers obtain fewer preoperative
tests and individualize such testing as cardiac catheterization,
24-hour Holter monitoring, brain imaging, and neurocogni-
tive studies for patients to establish baseline states and risk.
In many centers, where the diagnosis of acute AoD is either
made or highly suspected, patients are immediately taken to
surgery, and TEE is performed in the operating room to either
establish or confirm the diagnosis. Most of the writing
committee believes that the delay to obtain coronary angiog-
raphy was potentially dangerous unless patients had a history
of coronary artery bypass graft surgery or a high likelihood of
coexisting CAD.
Most patients undergoing elective aortic root and ascend-
ing aortic surgery can be admitted the day of surgery.
However, some of the writing committee members routinely
admit patients the day before surgery primarily for fluid
hydration (using 5% dextrose/0.5 normal saline with addi-
tional potassium and sodium bicarbonate at 100 to 120 mL/h),
particularly those who are to have extensive open surgery for
arch, descending thoracic, or thoracoabdominal aortic dis-
ease. Preoperative use of acetylcysteine (600 mg by mouth at
night and in the morning, or 500 mg in 500 mL of normal
saline solution over 3 hours before CT or surgery) has also
been described.612,613 However, the effectiveness of these
strategies has not been tested in a clinical trial. Placement of
thoracic epidural catheters for postoperative analgesia or
lumbar spinal drains for CSF drainage is performed on the
day prior to surgery in some centers. Despite lack of evi-
dence, there is concern that neuraxial hemorrhage is more
likely if blood returns through the placement needle on the
day of surgery.
14.1.1. Preoperative Risk Assessment
MI, low cardiac output, respiratory failure, renal failure, and
stroke are the principal causes of mortality and morbidity
after operations on the thoracic aorta, and preoperative
assessment of these organ systems prior to elective operation
is essential,381,441,614–617 especially in patients with a history
of MI, angina pectoris, or symptoms of heart failure and those
older than 40 years. Patients with valvular heart disease are
evaluated with echocardiography and cardiac catheterization.
Elderly patients with thoracic aortic disease are likely to
have coexisting CAD. The benefits of prior or concomitant
coronary revascularization are controversial. Several studies
suggested that prior coronary bypass graft surgery was of
benefit to patients undergoing major vascular surgery to
reduce cardiovascular mortality.618–622
More recent clinical trials comparing outcomes of patients
with stable CAD treated with optimal medical therapy versus
revascularization have not shown any significant reductions
in cardiovascular events associated with revascularization
strategies.609–611 Major thoracic aortic surgery falls into the
highest-risk group for cardiac morbidity and mortality,623
prompting some writing committee members to aggressively
screen for and treat coexisting CAD, but the effectiveness of
such a strategy in patients with stable CAD has not been
clearly established. For patients with unstable CAD, left main
stenosis, or 3-vessel disease, revascularization is generally
warranted prior to or concomitant with the thoracic aortic
procedure. The use of drug-eluting stents for single- or
double-vessel disease may be problematic because required
antiplatelet therapies may significantly raise the risk of bleeding
with the thoracic aortic procedure and withholding antiplatelet
therapies clearly increases the risk of stent thrombosis.
History of smoking and presence of chronic pulmonary
disease are important predictors of postoperative respiratory
complications and are frequently present in patients with
thoracic aortic disease.624 Pulmonary function tests and arte-
rial blood-gas analyses help to risk-stratify patients with
chronic pulmonary disease. If reversible restrictive disease or
excessive sputum production is present, antibiotics and bron-
chodilators should be administered. Cessation of smoking is
advisable.
Preoperative renal dysfunction is the most important pre-
dictor of acute renal failure after operations on the thoracic
aorta.617,625,626 Preoperative hydration and avoidance of hy-
potension, low cardiac output, and hypovolemia in the peri-
operative period may reduce the prevalence of this
complication.
To minimize the risk of stroke or reversible ischemic
neurologic deficits and to determine the potential magnitude
of risk, duplex imaging of the carotid arteries and angiogra-
phy of the brachiocephalic arteries is often performed preop-
eratively particularly in patients with a history of stroke, TIA,
or other risk factors for cerebrovascular disease.627 However,
the efficacy of treatment of significant carotid stenosis prior
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to endovascular or open surgery for thoracic aortic disease
has not been evaluated in a randomized clinical trial.
Although older age is a risk factor for increased early
and late death after operations on the thoracic
aorta,382,441,617,625,627–630 operations can be carried out suc-
cessfully with satisfactory outcomes in appropriately selected
older patients. Emergency operation for aortic rupture or
acute dissection is associated with a higher risk of early death
after operation compared with elective operation.47
14.2. Recommendations for Choice of Anesthetic
and Monitoring Techniques
Class I
1. The choice of anesthetic techniques and agents and
patient monitoring techniques should be tailored to
individual patient needs to facilitate surgical and
perfusion techniques and the monitoring of hemody-
namics and organ function. (Level of Evidence: C)
Class IIa
1. Transesophageal echocardiography is reasonable in all
open surgical repairs of the thoracic aorta, unless there
are specific contraindications to its use. Transesopha-
geal echocardiography is reasonable in endovascular
thoracic aortic procedures for monitoring, procedural
guidance, and/or endovascular graft leak detection.631–633
(Level of Evidence: B)
2. Motor or somatosensory evoked potential monitor-
ing can be useful when the data will help to guide
therapy. It is reasonable to base the decision to use
neurophysiologic monitoring on individual patient
needs, institutional resources, the urgency of the
procedure, and the surgical and perfusion tech-
niques to be employed in the open or endovascular
thoracic aortic repair.634,635 (Level of Evidence: B)
Class III
1. Regional anesthetic techniques are not recom-
mended in patients at risk of neuraxial hematoma
formation due to thienopyridine antiplatelet ther-
apy, low-molecular-weight heparins, or clinically
significant anticoagulation.636 (Level of Evidence: C)
2. Routinely changing double-lumen endotracheal (en-
dobronchial) tubes to single-lumen tubes at the end
of surgical procedures complicated by significant
upper airway edema or hemorrhage is not recom-
mended. (Level of Evidence: C)
Choice of anesthetic technique is dependent on the planned
surgical interventions and the patient’s comorbid conditions.
For placement of endovascular aortic stent grafts, different
anesthetic (local, regional, general) techniques have been
described, although adequate comparative studies are lack-
ing.637–643 Percutaneous placement of catheters with a limited
incision may be tolerated with local anesthesia and sedation.
Extensive inguinal dissection or the construction of a femo-
ro–femoral bypass may favor either regional or general
anesthesia. If surgical dissection is extended into the retro-
peritoneum, a higher level of regional anesthesia or general
anesthesia is required. If the patient is undergoing local
anesthesia or regional anesthesia, adequate intravenous seda-
tion is necessary because of agitation secondary to restless-
ness and pain from lying in one position for a prolonged
period of time.
Retrospective studies indicate that patients having local
versus regional or general anesthesia for endovascular stent
grafts tend to have lower use of vasoactive agents and lower
fluid requirements, shorter intensive care and hospital
stays,642 earlier ambulation and gastrointestinal function,637
and lower incidence of respiratory and renal complications.643
In a large multicenter retrospective study of 5557 patients
undergoing endovascular aortic repairs,644 69% received gen-
eral anesthesia, 25% received regional anesthesia, and 6%
received local anesthesia. The incidence of cardiac compli-
cations were significantly lower in both the local or regional
anesthesia group compared with general anesthesia (1.0%
versus 2.9% versus 3.7%), and the incidence of sepsis was
significantly lower in the regional anesthesia group compared
with general anesthesia (0.2% versus 1.0%). Selection bias
and complexity of disease likely affect these results.
14.2.1. Temperature Monitoring
At most centers, temperature is monitored in at least 2
locations that estimate the brain/core (eg, blood, esophageal,
tympanic membrane, nasopharynx) temperature and the vis-
ceral (eg, bladder or rectal) temperature.645
14.2.2. Hemodynamic Monitoring
Invasive arterial pressure monitoring is required in 1 or more
sites depending on the surgical plan for cannulation and
perfusion, particularly for thoracoabdominal aortic repairs.
Arterial pressure is universally monitored proximal to aortic
cross-clamping sites, but there is institutional variability in
the monitoring of distal arterial (aortic) pressure, even when
distal aortic perfusion is performed.
Central venous cannulation allows measurement of cardiac
filling pressures, providing a route for vasoactive drug and
fluid administration. Femoral venous catheterization is dis-
couraged by current central line–associated bloodstream in-
fection prevention guidelines, but the literature does not
address the subject in thoracoabdominal surgery.646,647 Nev-
ertheless, many experienced centers use short-term catheter-
ization of the femoral vein for volume management during
surgery.
Pulmonary artery catheterization is performed routinely in
many institutions for thoracic aortic surgery. The literature
does not specifically address the subject of thoracic aortic
surgery, but the general perioperative literature does not
support the use of pulmonary artery catheterization.631
14.2.3. Transesophageal Echocardiography
TEE is safe648 and is used to confirm the preoperative
diagnoses and detect pericardial or pleural effusions, aortic
regurgitation, the extent of dissection, the location of intimal
tears, the size and integrity of aneurysms, and the presence of
appropriate flow in the true lumen upon commencement of
cardiopulmonary bypass. Current American Society of Anes-
thesiologists and the Society of Cardiovascular Anesthesiol-
ogists guidelines for TEE include the following631:
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Category I Indications (supported by the strongest evi-
dence or expert opinion):
● Preoperative use in unstable patients with suspected tho-
racic aortic aneurysms, dissection, or disruptions that need
to be evaluated quickly.
● Intraoperative assessment of aortic valve function in repair
of AoDs with possible aortic valve involvement.
Category II Indications (supported by weaker evidence or
expert opinion):
● Preoperative assessment of patients with suspected thoracic
AoDs, aneurysms, or disruption.
● Intraoperative use during repair of thoracic AoDs without
suspected aortic valve involvement.
14.2.4. Transesophageal Echocardiography for
Endovascular Repairs of the Descending Thoracic Aorta
TEE can provide views of the aorta and location of guide-
wires and endografts prior to deployment in relation to the
normal and diseased thoracic aorta.649,650 TEE has distinct
advantages over angiography by providing exact vessel and
lesion sizing and localization and can also be used to estimate
endograft size and location. Although not imaged in all
patients, large intercostal arteries have been imaged, thus
avoiding inadvertent obstruction by the aortic stent graft.
After stent graft placement, the presence or absence of
endoleaks can be determined by TEE with a high degree of
sensitivity and specificity particularly compared with contrast
angiography.632,633,650 Finally, because most of these patients
have severe concomitant cardiac disease, perioperative TEE
allows dynamic assessments of cardiac function.
Intravascular ultrasound is used for endovascular proce-
dures to visualize precise localization of branch arteries and
for measurement of aortic and branch artery sizes. Plaques,
tears, and saccular aneurysms can also be very accurately
demonstrated.
14.3. Airway Management for Descending
Thoracic Aortic Repairs
A double-lumen endotracheal tube or various types of endo-
bronchial blockers facilitate surgical exposure.651 For exten-
sive surgery of the left thorax, single-lung ventilation pro-
vides better surgical exposure, reduces the need for
pulmonary retraction, may decrease the severity of iatrogenic
pulmonary contusion, and protects the right lung from con-
tamination by blood and secretions. A large descending
thoracic aortic aneurysm may compress or distort the left
main bronchus such that left-sided endobronchial tubes must
be used with caution. If a right-sided double-lumen endotra-
cheal tube is placed, endoscopic confirmation of tube position
(to ensure right upper lobe ventilation) is necessary. Forceful
endobronchial tube placement has been associated with tho-
racic aortic aneurysm rupture. Therefore, using a different
tube or lung isolation method may be required when severe
airway distortion is encountered.
At the end of surgery, some centers have advocated
changing a double-lumen endotracheal tube to a single-lumen
tube to facilitate pulmonary toilet and to avoid the complica-
tions associated with tube malposition in the intensive care
unit. The decision to change the double-lumen endotracheal
tube to a single-lumen tube should be made after carefully
evaluating the extent of airway edema, as these procedures
are associated with significant facial and laryngeal edema.
Advanced airway management devices, such as tube ex-
changes and video laryngoscopy, may be of benefit; however,
there is no literature addressing this subject.
14.4. Recommendation for Transfusion
Management and Anticoagulation in Thoracic
Aortic Surgery
Class IIa
1. An algorithmic approach to transfusion, antifibrino-
lytic, and anticoagulation management is reasonable
to use in both open and endovascular thoracic aortic
repairs during the perioperative period. Institu-
tional variations in coagulation testing capability
and availability of transfusion products and other
prothrombotic and antithrombotic agents are im-
portant considerations in defining such an ap-
proach.652 (Level of Evidence: C)
Thoracic aortic surgery is associated with hemorrhage from
several interrelated causes, including extensive surgical dis-
section, arterial and venous bleeding, hypothermia, cardiopul-
monary bypass, fibrinolysis, dilution or consumption of
coagulation factors, thrombocytopenia, poor platelet function,
heparin and other anticoagulants, preoperative antithrombotic
therapy, and other congenital and acquired coagulopathies.
The extensive blood product and fluid requirements of open
thoracic aortic surgical repairs may exceed the total blood
volume of the patient in the most complicated cases. Clinical
practice guidelines for perioperative blood transfusion and
blood conservation in cardiac surgery have been published by
the STS and the SCA.652
These guidelines do not specifically address open or
endovascular descending thoracic aortic repairs, but the
writing committee supports treatment strategies provided by
these guidelines.
Coagulopathies in open descending thoracic aortic and
thoracoabdominal repairs mirror many of the abnormalities
seen in cardiac and thoracic aortic procedures requiring
cardiopulmonary bypass. Illig and colleagues653 reported
significantly decreased euglobulin clot lysis times, elevated
tissue plasminogen activator levels, elevated tissue plasmin-
ogen activator–to–plasminogen activator inhibitor-1 ratios,
and reduced alpha 2-antiplasmin levels within 20 minutes
after supraceliac cross-clamping, compared with infrarenal
occlusion, consistent with a primary fibrinolytic state. Vis-
ceral ischemia may be the condition that initiates fibrinolysis.
During supraceliac occlusion, fibrinolysis was attenuated
when superior mesenteric artery perfusion was maintained
via a shunt.654 Peripheral ischemia may also result in fibri-
nolysis. Within 30 minutes of the onset of acute peripheral
ischemia (with infrarenal aortic occlusion) fibrinolytic activ-
ity increased, as demonstrated by an increase in tissue-type
plasminogen activity and a decrease in plasminogen activator
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inhibitor activity. This increase in tissue-type plasminogen
activity resulted from release of stores from ischemic vascu-
lar tissues.655 Endotoxemia during aortic occlusion may also
be associated with fibrinolysis.656
To counteract fibrinolysis, the use of lysine analogs
epsilon-aminocaproic acid and tranexamic acid has been
reported in cardiac surgery. The epsilon-aminocaproic acid
loading or bolus dose ranged from 75 to 150 mg/kg, with
additional dosing from 12.5 to 30 mg/kg/h infused over
varying time periods. For tranexamic acid, loading or bolus
dose, ranged from 2.5 to 100 mg/kg, with additional dosing
from 0.25 to 4.0 mg/kg/h delivered over 1 to 12 hours.657 In
a study of 21 adult cardiac surgical patients, the tranexamic
acid dosing regimen of 10 mg/kg initial dose, followed by an
infusion of 1 mg/kg/h resulted in adequate plasma concen-
trations defined by in vitro studies to prevent fibrinolysis,
with relatively stable drug levels throughout cardiopulmonary
bypass.658 Antifibrinolytic therapy for thoracoabdominal aor-
tic surgery with distal perfusion was not associated with
decreased bleeding or transfusion in a retrospective cohort of
72 patients.659 The strong evidence derived from other car-
diac surgical studies has led to very common use of antifi-
brinolytic therapy in thoracic aortic surgery, despite the
absence of specific evidence in this surgical subset.
14.5. Organ Protection
14.5.1. Recommendations for Brain Protection During
Ascending Aortic and Transverse Aortic Arch Surgery
Class I
1. A brain protection strategy to prevent stroke and
preserve cognitive function should be a key element
of the surgical, anesthetic, and perfusion tech-
niques used to accomplish repairs of the ascending
aorta and transverse aortic arch.660 – 666 (Level of
Evidence: B)
Class IIa
1. Deep hypothermic circulatory arrest, selective ante-
grade brain perfusion, and retrograde brain perfu-
sion are techniques that alone or in combination are
reasonable to minimize brain injury during surgical
repairs of the ascending aorta and transverse aortic
arch. Institutional experience is an important factor
in selecting these techniques.211,615,667–688 (Level of
Evidence: B)
Class III
1. Perioperative brain hyperthermia is not recom-
mended in repairs of the ascending aortic and
transverse aortic arch as it is probably injurious to
the brain.689–691 (Level of Evidence: B)
A brain protection strategy is an essential component of the
operative technique for open surgical repairs of the ascending
aorta and/or the aortic arch. Moderate or profound hypother-
mia with periods of circulatory arrest and/or selective ante-
grade brain perfusion and/or retrograde brain perfusion are
the common strategies for achieving brain protection. The
experience and outcomes of the operating surgeon and the
institution are important considerations in selecting a brain
protection strategy.
Achieving brain hypothermia is nearly universally per-
formed using extracorporeal circulation, with temperatures
ranging from 12° to 30°C. Retrograde (via jugular vein) brain
perfusion is usually performed at a perfusion pressure of 20 to
40 mm Hg at a mildly or profoundly hypothermic tempera-
ture. Antegrade brain perfusion is usually performed at a
perfusion pressure of 50 to 80 mm Hg and may be instituted
by direct cannulation of the brachiocephalic arteries, side-
graft anastomosis to the axillary artery, or direct cannulation
of a portion of graft material that was anastomosed to the
brachiocephalic arteries during a period of hypothermic
circulatory arrest. The rewarming of a patient following
completion of the repair of the thoracic aorta is usually
performed at a measured rate so as not to induce brain
hyperthermia.
The reviewed literature describes an evolution of brain
protection techniques over the past 2 to 3 decades. Deep
hypothermic circulatory arrest emerged as the first technique,
but as a sole method of brain protection, it was limited by
increasing rates of neurologic morbidity, other adverse out-
comes, and mortality as the period of arrest exceeded 25 to 45
minutes.671,692 Deep hypothermic arrest without perfusion
adjuncts has been successful, especially when arrest intervals
are less than 40 minutes.693 Subsequently, various combina-
tions of retrograde brain perfusion and selective antegrade
brain perfusion were developed to extend the “safe period” of
interruption of full extracorporeal circulation. Monitoring of
brain function and metabolic suppression by electroencepha-
lography, evoked potentials, bispectral index, noninvasive
cerebral oximetry, and jugular bulb oxyhemoglobin satura-
tion are additional means used to guide the onset of extra-
corporeal circulation interruption for repairing the distal
ascending aorta and/or aortic arch. Some centers use barbi-
turates, calcium channel blockers, or steroids for added
protection, but no prospective randomized trials have been
performed to test the efficacy of pharmacological
agents.211,459
There is controversy regarding the ability of retrograde
brain perfusion to support brain metabolic function and to
improve neurologic outcomes, including transient postopera-
tive neurologic dysfunction, stroke rates, and mortali-
ty.661,671,673–675,694–699 However, this technique can maintain
brain hypothermia700 and has been associated with improved
outcomes in the centers where it is used as a primary
neuroprotection strategy.
Selective antegrade brain perfusion may be provided by
direct cannulation of 1 or more of the brachiocephalic
arteries, which permits brain perfusion with minimal periods
of interruption. If unilateral cannulation is performed, success
may depend on patency of the circle of Willis. Alternatively,
unilateral direct or side-graft cannulation of the (usually
right) axillary artery permits extracorporeal circulation and
cooling without manipulation of the diseased thoracic aorta.
This same cannula can then be used for delivering antegrade
brain perfusion immediately after the section of aorta from
which the brachiocephalic arteries originate is sutured to the
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graft or immediately after the brachiocephalic vessels are
individually anastomosed to a trifurcated graft. The time
required to complete these maneuvers requires a relatively
shorter period of hypothermic circulatory arrest compared
with compete reconstruction of the aortic arch.681,683,701–704
Bilateral brachiocephalic artery cannulation has also been
reported.705 The literature is insufficient to determine whether
unilateral or bilateral perfusion or complete avoidance of
circulatory arrest is associated with improved outcomes. A
retrospective analysis by Svensson et al449 suggested that
axillary artery perfusion via a prosthetic side-graft was
associated with improved outcomes compared with femoral
arterial cannulation.
Finally, direct cannulation of the aortic replacement graft
may be used to institute antegrade brain perfusion following
a period of circulatory arrest. The variability of techniques
among surgical centers makes direct comparison difficult;
however, most studies with some type of antegrade arterial
brain perfusion report outcomes that are comparable to or
better than those using hypothermic circulatory arrest alone
or retrograde brain perfusion.660,662,666,685,686,706,707 Further-
more, selective antegrade brain perfusion may reduce the
period of brain ischemia and permit less profound hypo-
thermia, which may be associated with good clinical
outcomes.676,687,708 –712
Our ability to create evidence-based guidelines from the
literature is particularly difficult in the case of brain protec-
tion. Changes in surgical technique, perfusion technology,
anesthetic and intensive care management, coagulation man-
agement, prosthetic graft materials, and the experience of the
reporting centers and lack of randomized clinical trials are
confounding factors.
14.5.2. Recommendations for Spinal Cord Protection
During Descending Aortic Open Surgical and
Endovascular Repairs
Class I
1. Cerebrospinal fluid drainage is recommended as a
spinal cord protective strategy in open and endovas-
cular thoracic aortic repair for patients at high risk
of spinal cord ischemic injury.522,523,713 (Level of
Evidence: B)
Class IIa
1. Spinal cord perfusion pressure optimization using
techniques, such as proximal aortic pressure
maintenance and distal aortic perfusion, is reason-
able as an integral part of the surgical, anesthetic,
and perfusion strategy in open and endovascular
thoracic aortic repair patients at high risk of
spinal cord ischemic injury. Institutional experi-
ence is an important factor in selecting these
techniques.380,382,714,715 (Level of Evidence: B)
2. Moderate systemic hypothermia is reasonable for pro-
tection of the spinal cord during open repairs of the
descending thoracic aorta.525 (Level of Evidence: B)
Class IIb
1. Adjunctive techniques to increase the tolerance of the
spinal cord to impaired perfusion may be considered
during open and endovascular thoracic aortic repair for
patients at high risk of spinal cord injury. These include
distal perfusion, epidural irrigation with hypothermic
solutions, high-dose systemic glucocorticoids, osmotic di-
uresis with mannitol, intrathecal papaverine, and cellular
metabolic suppression with anesthetic agents.520,715–717
(Level of Evidence: B)
2. Neurophysiological monitoring of the spinal cord (so-
matosensory evoked potentials or motor evoked poten-
tials) may be considered as a strategy to detect spinal
cord ischemia and to guide reimplantation of intercos-
tal arteries and/or hemodynamic optimization to pre-
vent or treat spinal cord ischemia.483,634,718,719 (Level of
Evidence: B)
Paraparesis and paraplegia are perhaps the most feared
complications following repair of the descending thoracic
aorta. Although rates as high as 23% have previously been
reported, the current incidence is probably somewhere around
2% to 6%.483,521,634,718,720 In any specific patient, however, the
likelihood of neurological complications depends highly on
individual anatomy, on whether the aorta is dissected or
aneurysmal, and on whether the pathology is acute, chronic,
or both.
Risk factors for perioperative spinal cord injury include
emergency surgery, dissection, extensive disease, prolonged
aortic cross-clamp time, aortic rupture, level of aortic cross-
clamp, patient age, prior abdominal aortic surgery, and, in
particular, hypogastric artery exclusion,143,144,721 as well as a
history of renal dysfunction. The risk of paraplegia or
paraparesis is minimal if the aortic cross-clamp time is less
than 15 minutes.722 Svensson et al381 reported a 20% risk of
neurological injury if aortic cross-clamp time was greater
than 60 minutes and less than 10% if aortic cross-clamp time
was less than 30 minutes. Although paraplegia or paraparesis
has been reported with aortic cross-clamp times of less than
20 minutes,723 others have concluded that aortic cross-clamp
times greater than 40 minutes did not result in increases in
adverse spinal cord outcome, if distal perfusion was used.382
One study of patients undergoing open or endovascular repair
of descending thoracic or thoracoabdominal aortic aneurysms
demonstrated a higher risk of spinal cord injury related to the
extent of aorta treated but no difference between the operative
approaches.724
Another option for spinal cord protection is deep hypother-
mic circulatory arrest.630 This has been a useful technique for
complex descending thoracic or thoracoabdominal aortic
repairs performed via a left thoracotomy approach.
14.5.2.1. Monitoring of Spinal Cord Function in
Descending Thoracic Aortic Repairs
In general, the comparatively low current incidence of neu-
rologic complications is attributable to the routine use of
multimodal neurophysiologic monitoring such as somatosen-
sory evoked potentials (SSEP) and motor evoked potentials
(MEP) in conjunction with neuroprotective strategies noted
later.526 Although these neuroprotective strategies continue to
evolve and may differ slightly in their implementation from
center to center, monitoring of evoked potentials during these
cases has become common because it provides the surgeon
and anesthesiologist the opportunity to promptly intervene if
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alterations in monitored potentials indicate neurologic com-
promise is occurring.524,526,719,725,726
SSEPs are cerbral cortical electrical potentials recorded
with scalp electrodes during electrical stimulation of the
posterior tibial or peroneal nerves of the lower extremities,
conducted via the lateral and posterior columns of the spinal
cord.727 Because SSEP monitoring is less sensitive to anes-
thetic drugs and paralytic agents may be used, its use is less
complex than MEP monitoring. SSEP monitoring is limited
because it is only dependent on the integrity of the lateral and
posterior columns. The anterior motor column is more likely
to be affected by ischemic injury during aortic reconstruction.
It is thus possible to sustain an isolated perioperative anterior
column injury without changes in SSEPs. In 1 study, SSEP
monitoring influenced the surgical strategy in 17 of 63
patients (27%) undergoing descending aortic reconstruc-
tion.719 Corrective interventions included partial cardiopul-
monary bypass initiated in 1 patient with traumatic aortic
rupture; reimplantation of critical intercostal, lumbar, or
sacral arteries in 11 patients; suture closure of profusely
back-bleeding intercoastal arteries in 1 patient; hastening the
proximal suture line in 1 patient; distal clamp repositioning to
a more proximal position in 1 patient; and proximal clamp
repositioning in 2 patients with left carotid ischemia. The
authors reported no cases of unexplained SSEP abnormalities.
New immediate paraplegia was observed in 1 patient with
sustained SSEP absence, and 2 patients presented with
delayed paraplegia despite normal inoperative SSEP.
In contrast, MEPs are performed by stimulating the motor
cortex (by either high-voltage short-duration electrical stim-
ulus or magnetic induction)728 and recording at the level of
the spinal cord, peripheral nerves, or muscles.524,526,725–727
Neurogenic MEPs are responses recorded at the peripheral
nerves, whereas myogenic MEPs are large biphasic responses
recorded over the muscle belly. Because the amplitude of the
response is proportional to the number of motor neurons
being stimulated, these evoked potentials are very sensitive to
neuromuscular blocking and anesthetic agents.729–738
Monitoring of SSEPs alone has not been demonstrated to
improve outcomes in patients undergoing TAA repair. SSEP
monitoring is associated with delayed ischemia detection
compared with transcranial MEPs,739 as well as high rates of
both false-negative and false-positive results.635,739 Lyon et
al740 reported a significantly higher voltage threshold for the
generation of a 50 microV amplitude signal at the end of the
procedure compared with the beginning of the procedure
(“anesthetic fade”). This increased voltage threshold was
directly proportional to the length of anesthetic exposure.
Recognition of this phenomenon is important to avoid false-
positive MEP interpretation.
To demonstrate the greater sensitivity of MEP than
SSEP monitoring, Dong et al634 reported their experience
with 56 patients undergoing descending aortic reconstruc-
tion. All patients were monitored with both MEPs and
SSEPs. Sixteen patients (29%) had MEP evidence of
perioperative spinal cord ischemia compared with 4 pa-
tients (7%) with SSEP changes. These changes were
reversed in 13 patients with either segmental artery reim-
plantation or optimization of hemodynamics. Although one
of these 13 patients awoke with immediate paraplegia, the
remaining 3 patients awoke paraplegic. All 3 patients had
normal perioperative SSEPs.
14.5.2.2. Maintenance of Spinal Cord Arterial Pressure
Proximal hypertension may increase the contribution of the
vertebral artery–derived blood flow to the spinal cord as well
as collateral flow. Other methods of maintaining arterial flow
to the spinal cord include the aggressive reimplantation of
major intercostal arteries into the aortic graft.715 Griepp et
al742 emphasized the importance of prompt ligation of non-
implanted intercostal arteries to avoid “steal” from bleeding
during periods of ischemia to this collateral bed.741 Intrathe-
cal papaverine has also been described as a method of
inducing spinal cord arterial dilation, and thus increasing
spinal cord blood flow.
The literature is unclear with respect to the benefits of
distal perfusion alone on spinal cord protection because the
technique is not used in isolation. Several studies support the
concept that distal perfusion combined with CSF drainage is
beneficial.380,382,468,714 The minimum desirable distal arterial
pressure is 60 mm Hg to ensure adequate spinal cord blood
flow, whereas maximal proximal mean arterial pressure
should be about 90 to 100 mm Hg.743
14.5.2.3. Cerebrospinal Fluid Pressure and Drainage
Application of a cross-clamp to the proximal descending
aorta not only creates a major hemodynamic load on the
heart but also causes an acute elevation in CSF pressure.744
Surgical retraction of the aortic arch may also produce
significant increases in CSF pressures.745 When CSF
pressure exceeds spinal venous pressure, a “critical closing
pressure” is achieved, and the veins collapse independent
of inflow pressure. The spinal cord perfusion pressure is
therefore the difference between spinal arterial pressure
and CSF pressure.
Coselli et al522 randomized 145 patients undergoing thora-
coabdominal aortic repair with or without CSF drainage. Nine
patients (13.0%) in the control group developed paraplegia or
paraparesis. In contrast, only 2 patients in the CSF drainage
group (2.6%) had deficits develop (P0.03). No patients with
CSF drainage had immediate paraplegia. A meta-analysis by
Khan and Stansby713 and the retrospective analysis by Safi
and colleagues523 also concluded that CSF drainage was
advantageous in reducing the risk of spinal cord injury in
open TAA repairs.
Possible complications of CSF drainage include headache,
spinal or epidural hematoma formation or inflammatory
reaction, meningitis, and persistent CSF leaks. Subdural
hematoma has been reported after thoracic aortic repair with
spinal fluid drainage.746 Introduction of blood into the sub-
arachnoid space may result in vasospasm and decreases in
spinal blood flow.747 Decreases in CSF pressure may occur
with phlebotomy, and aggressive use of hyperosmotic agents
and hyperventilation may be as effective as spinal drainage in
maintaining spinal cord perfusion pressure.748,749 In a single-
center report of 162 patients with CSF drains, 6 patients
(3.7%) had catheter-related complications: temporary abdu-
cens nerve palsy, 1 patient; retained catheter fragments, 2
patients; retained catheter fragments and meningitis, 1 pa-
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tient; isolated meningitis, 1 patient; and spinal headache, 1
patient. There were no neuraxial hemorrhagic complications
in this series.750
14.5.2.4. Hypothermia
Mild hypothermia may provide significant neuronal protec-
tion by mechanisms such as reducing excitatory neurotrans-
mitter release, decreasing free oxygen radical production,
decreasing postischemic edema, and stabilizing central ner-
vous system blood flow.751,752 Hypothermia occurs via pas-
sive cooling in a cold operating room with a major incision in
addition to cooling blankets and unwarmed intravenous
fluids. If an extracorporeal circuit is used, a heat exchanger
permits warming or cooling of the body temperature. A
temperature of 32°C is usually well tolerated by patients not
undergoing full cardiopulmonary bypass. Moderate systemic
hypothermia has been associated with improved outcomes
following TAA surgery.525 Arrhythmias, such as atrial fibril-
lation and even ventricular fibrillation, can occur if hypother-
mia is too severe.
Epidural infusion of cooled saline may be used to induce
regional hypothermia. Although this technique was asso-
ciated with substantial increases in CSF pressure, a signif-
icant reduction in postoperative neurologic deficits was
noted.520,716 A new, self-contained catheter for topical
cooling of the spinal cord without infusion into the CSF or
CSF pressure rise has been shown in the laboratory to
provide topical spinal cord hypothermia, while systemic
normothermia is maintained; clinical trials are being
organized.753
Postischemic hyperemia occurs in the spinal cord.754 The
magnitude of this hyperemia has been demonstrated to be
proportional to the incidence of paraplegia. Possible mech-
anisms for the increased neurologic injury associated with
vascular hyperemia include edema formation with the
development of a compartment syndrome and subse-
quently decreased spinal cord perfusion and increased
oxygen delivery that may result in greater free oxygen
radical species generation.
14.5.2.5. Glucocorticoids and Mannitol
Administration of methylprednisolone (30 mg/kg) before and
after aortic occlusion may result in better spinal cord protec-
tion. 717 The mechanism of this protection is unclear, but it
may be related to decreased spinal cord edema and improved
free oxygen radical scavenging. Similarly, mannitol (0.25 to
1.0 g/kg) has been used to modulate the extent of ischemic
spinal cord injury. Mannitol is hypothesized to act in similar
fashion to methylprednisolone.715
14.5.3. Recommendations for Renal Protection
During Descending Aortic Open Surgical and
Endovascular Repairs
Class IIb
1. Preoperative hydration and intraoperative mannitol
administration may be reasonable strategies for
preservation of renal function in open repairs of the
descending aorta. (Level of Evidence: C)
2. During thoracoabdominal or descending aortic repairs
with exposure of the renal arteries, renal protection by
either cold crystalloid or blood perfusion may be
considered.626,755,756 (Level of Evidence: B)
Class III
1. Furosemide, mannitol, or dopamine should not be
given solely for the purpose of renal protection in
descending aortic repairs.757,758 (Level of Evidence: B)
In a cohort of 475 patients who underwent descending
thoracic aortic repair, 25% developed acute postoperative
renal failure, whereas 8% required hemodialysis.759 Risk
factors that are associated with postoperative renal failure
after descending thoracic aortic repair include age greater
than 50 years, preexisting renal dysfunction, duration of renal
ischemia, administration of greater than 5 units or either
packed red cells or salvaged washed autologous blood,
hemodynamic instability, and diffuse atherosclerosis.626,759
There is controversy regarding the protective nature of distal
perfusion during aortic occlusion.626,759 Godet et al759 observed a
decrease in the incidence of renal failure with the use of distal
aortic perfusion. Others have observed increases in renal failure
with distal perfusion.626 Selective renal artery perfusion during
descending thoracic aortic repair may result in uninterrupted
urine production throughout the procedure and may decrease the
incidence of renal failure postoperatively.755
Pharmacological agents, including mannitol,760,761 furo-
semide,758 or dopamine,757,761–764 have not been demonstrated
to provide renal protection during descending thoracic aortic
repair.
14.6. Complications of Open Surgical Approaches
Myocardial infarction (1% to 5%): This is an uncommon
complication but it is associated with CAD or dissection of
the coronary artery ostia.228–234,250,441
Heart failure (1% to 5%): Myocardial protection difficul-
ties and ventricular distention from either aortic valve regur-
gitation or high right-sided pressures are often factors.765
Infections (1% to 5% superficial, less than 1% deep):
Intraoperative contamination or inadequate or improperly
timed antibiotic coverage, obesity, immunosuppression, pul-
monary disease, or suboptimal glucose control may be a
factor.766
Stroke (2% to 8% permanent): As noted earlier, brain
protection is important in preventing the complication of
stroke. The causes are either embolic or ischemic. Patients
who on preoperative MR have evidence of ischemic changes
and/or reduced neurocognitive function, who are elderly, or
who have a history of stroke are at increased risk of a
perioperative stroke.76,99,139,211,449,453,466,767
Neurocognitive deficit: The exact incidence of deficits has
not been studied much after circulatory arrest; however, in 1
prospective randomized study, using 51 neurocognitive tests,
at 2 to 3 weeks after surgery, 9% of patients had new deficits,
and by 6 months, all new deficits had resolved. Patients with
preoperative deficits were proved to have further deteriora-
tion; indeed, 38% of patients had preoperative deficits.211,466
Reoperation for bleeding (1% to 6%): Reoperation for
bleeding is dependent on the extent of surgery, length of
cardiopulmonary bypass, reoperative status, underlying dis-
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order, and surgical technique. Obtaining hemostasis prior to
coming off cardiopulmonary bypass and correcting all blood
coagulation defects are paramount.765,766
Respiratory failure (5% to 15%): Preoperative pulmonary
function testing helps to warn the surgeon about potential
postoperative respiratory problems. Sometimes operative
technique can be adapted to lessen the risks—for example,
shortening pump time and avoiding overtransfusion. Left
diaphragmatic incisions and trauma may add to postoperative
pulmonary dysfunction. In patients with more than 7 kg of
increased weight after surgery, delaying extubation until
excess fluid has been eliminated by diuresis is worthwhile.
White cell filtration and plasmapharesis on pump may be
useful but have not been tested in randomized trials.
Ventricular arrhythmias (1% to 5%): Ventricular
tachycardia or ventricular fibrillation was a common compli-
cation after composite valve graft insertion a decade ago, with
reports of 19% to 21% risk. Some of these events were related
to undiagnosed myocardial ischemia from coronary button
reattachment problems, which are usually apparent during
operation or shortly thereafter. Inadequate myocardial protec-
tion may also lead to both ventricular arrhythmias and low
cardiac output. The increasing use of amiodarone, optimiza-
tion of potassium and magnesium levels, and better methods
of myocardial protection including blood cardioplegia may
have reduced this risk. Twenty-four–hour Holter monitoring
studies may reveal underlying pathology, such as ischemic
changes or prolonged QT interval, particularly in patients
with Marfan syndrome, that needs to be addressed.
Paralysis: The most feared complication after these types
of operations is lower limb paralysis and neurogenic bladder.
This occurs in 2% to 4% of descending thoracic aortic repairs
and in 3% to 10% of thoracoabdominal aortic re-
pairs.382,526,724,768–773 Most lesions predominantly involve
motor function because the anterior motor nerve cells of the
spinal cord are most likely to be involved. The protective
measures were discussed earlier. Two thirds of patients with
paraparesis will recover, and about half with paraplegia
will recover to the point of walking again. Prevention of
postoperative hypotension in the intensive care unit and
continued CSF drainage for longer than 40 hours is
deemed by most authors to be beneficial in reducing the
incidence of paraparesis.380,522,523,525,713
Hoarseness: The incidence of hoarseness is related to
whether the arch needs to be clamped and whether the
proximal descending aorta at the left subclavian artery needs
to be transected. Transsection at this level is recommended to
avoid damage to the esophagus and to prevent the formation
of late aortoesophageal fistulae. This, however, may result in
damage to the recurrent laryngeal nerve as it wraps around the
aorta and ligamentum arteriosum, resulting in left vocal cord
paralysis. This can usually be improved by vocal cord
injection with either gel or collagen.
14.7. Mortality Risk for Thoracic Aortic Surgery
Expected results for risk of death are summarized next.
Composite valve graft (1% to 5%): With modern tech-
niques, death after elective repair is unusual.76,98,99,448 Addi-
tional comorbid states and the need for emergency operation
are associated with increased risk.765
Separate aortic valve replacement with ascending aorta
repair (1% to 5%)448,628: Comorbid conditions such as ad-
vanced age and concomitant coronary bypass graft surgery, as
well as emergency operation, are associated with increased
risk.76,99,448,765,774,775
Valve-sparing aortic root reconstruction (less than 1% to
1.5%): These patients are mostly young and otherwise
healthy, and thus excellent results are expected compared
with other aortic operations. Indeed, in 1 series of over 200
modified David reimplantations, there were no operative
deaths.99 Late 10-year freedom from reoperation is better than
92% for reimplantation procedures but lower for root remod-
eling procedures.76,95,98,99,448,776
Bicuspid aortic valve and ascending aorta repair (1.5%):
In a large series of over 2000 patients with bicuspid aortic
valve surgery, the operative risk of death (1.5%) for patients
who had both a bicuspid valve procedure and ascending
aortic repair (n200) was no different than the risk for those
who underwent only a bicuspid valve procedure. For patients
with Marfan syndrome or connective tissue disorders or
bicuspid aortic valves, the long-term prognosis is excellent
and reaches an average survival of 70 years.76,99 Late 10-year
risk of reoperation is not as low as for tricuspid aortic valve
repair but still is only 9% for bicuspid aortic valve repairs.
Acute AoD (3.5% to 10% in experienced centers, but
higher overall): The risk of death after surgical repair of acute
AoD is strongly influenced by associated stroke, mesenteric
ischemia, renal failure, and myocardial ischemia.337,375,765,777
Total arch replacement: A 2% to 6% risk of death and a
2% to 7% risk of stroke have been reported for these
extensive and high-risk procedures. Emergency operation
mortality and stroke rates are higher (15% and 14%, respec-
tively).778 Careful brain and myocardial protection, correction
of coagulopathies, and improved operative techniques, in-
cluding the use of elephant trunk procedure, have led to
improved outcomes.680,779
Reoperations: The risk factors for reoperations are comor-
bid disease and extent of surgery with results varying be-
tween 2% to 6% for the risk of death.464
Descending aortic replacement: The risk of death with
current techniques is 2% to 5% and the risk of paralysis is less
than 3% for elective surgical repairs.382
Thoracoabdominal repairs: The risk of death is strongly
influenced by the urgency of surgery, comorbid disease, and
extent of repair. Thus, Crawford Type I thoracoabdominal
repairs have a risk of death of approximately 5%, but this is
doubled to approximately 10% for Type II repairs. The results
depicted earlier represent the work performed in high-volume
centers and may not reflect results of all institutions at which
such surgery is performed.381,525,768,773,780,781
The late risk of death after aortic repair is strongly
influenced by age and comorbid disease. Furthermore, aortic
atherosclerosis disease is a marker for more extensive ath-
erosclerosis. For patients undergoing degenerative and AoD
repairs, usually at an average age of the lower 70s, 5-year
survival rates of only 60% have been reported for ascending
repairs, arch repairs, descending repairs, thoracoabdominal
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repairs, and infrarenal repairs.3,381 Thus, it is initially impor-
tant to identify and to treat all comorbid disease, particularly
CAD, which is the most common cause of late deaths in this
population.381 In patients undergoing elective root-sparing
procedures or bicuspid valve procedures, the 5- and 10-year
survival rates are considerably improved—better than 80% to
90% 10-year survival rates can be expected.76,139 Sadly, even
young patients with AoD have a dismal 5-year survival rate
of 50% after surgery due to residual events related to
unresected dissected aorta. This stresses the importance of
treating young patients with elective surgery, with a less than
1% risk of death, if they have aortic root dilatation.75,76
Repair of TAAs is one of the most extensive and highest-
risk operations done in patients. Hence, selection of patients
for repair and workup for surgery needs to be diligently
performed. Furthermore, the cited results are from reports of
single-center experiences and therefore representative of
centers of excellence in the treatment of aortic disease. Data
from “real world” experiences have demonstrated nearly
double the morbidity and mortality rates, especially for
high-risk indications like acute aortic dissection and thoraco-
abdominal aortic aneurysms, suggesting that high-risk pa-
tients may have better outcomes in centers specializing in the
treatment of thoracic aortic diseases.782,783
14.8. Postprocedural Care
14.8.1. Postoperative Risk Factor Management
The recognition and treatment of thoracic aortic disease
provide the opportunity to engage the patient in long-term
cardiovascular risk factor management. Conditions such as
aortic atherosclerosis and aortic aneurysm are recognized as
high-risk states by the National Cholesterol Education Pro-
gram, Adult Treatment Panel III and require maximal inten-
sity therapy.784 In these patients, the risk of a fatal or nonfatal
MI is higher than the risk of amputation or aortic rupture.
The risk factors with clinical trial evidence of benefit
include hypertension, dyslipidemia, and cigarette smoking
(see Section 9.2.1).
14.8.2. Recommendations for Surveillance of Thoracic
Aortic Disease or Previously Repaired Patients
Class IIa
1. Computed tomographic imaging or magnetic reso-
nance imaging of the thoracic aorta is reasonable
after a Type A or B aortic dissection or after prophy-
lactic repair of the aortic root/ascending aorta.74 (Level
of Evidence: C)
2. Computed tomographic imaging or magnetic reso-
nance imaging of the aorta is reasonable at 1, 3, 6, and
12 months postdissection and, if stable, annually there-
after so that any threatening enlargement can be
detected in a timely fashion. (Level of Evidence: C)
3. When following patients with imaging, utilization of
the same modality at the same institution is reason-
able, so that similar images of matching anatomic
segments can be compared side by side. (Level of
Evidence: C)
4. If a thoracic aortic aneurysm is only moderate in size
and remains relatively stable over time, magnetic
resonance imaging instead of computed tomographic
imaging is reasonable to minimize the patient’s
radiation exposure. (Level of Evidence: C)
5. Surveillance imaging similar to classic aortic dissec-
tion is reasonable in patients with intramural hema-
toma. (Level of Evidence: C)
The mean rate of growth for all thoracic aortic aneurysms is
approximately 1 mm/y, but that growth rate increases with
increasing aneurysm diameter. Growth rates tend to be faster
for aneurysms involving the descending versus the ascending
aorta, for dissected versus nondissected aortas, for those with
Marfan syndrome versus those without,375 and for those with
bicuspid versus those with tricuspid aortic valves.785 The
frequency of surveillance imaging is not clear as there are no
data to accurately dictate surveillance intervals. It seems
prudent to obtain an initial follow-up imaging study before
discharge; at 1, 3, 6, and 12 months postoperatively; and then
annually after a thoracic aortic aneurysm is first detected.
Assuming the aneurysm is stable in size on the first follow-up
study, repeat imaging can reasonably be repeated on an annual
basis. For relatively small aneurysms that are stable from year to
year on annual imaging, the writing committee believes that an
imaging frequency of every 2 to 3 years, especially in older
patients, is currently reasonable (Table 17).
The writing committee believes that the anatomical detail
provided by CT may be better than that for MR in many
instances. However, for surveillance of stable and moderate
thoracic aortic aneurysms, MR provides adequate information
and avoids the potential problems associated with repeated
radiation exposure of CT angiography.
Table 17. Suggested Follow-Up of Aortic Pathologies After
Repair or Treatment
Pathology Interval Study
Acute
dissection
Before discharge, 1 mo, 6
mo, yearly
CT or MR, chest plus
abdomen TTE
Chronic
dissection
Before discharge, 1 y, 2
to 3 y
CT or MR, chest plus
abdomen TTE
Aortic root
repair
Before discharge, yearly TTE
AVR plus
ascending
Before discharge, yearly TTE
Aortic arch Before discharge, 1 y, 2
to 3 y
CT or MR, chest plus
abdomen
Thoracic aortic
stent
Before discharge, 1 mo, 2
mo, 6 mo, yearly Or 30
days*
CXR, CT, chest plus
abdomen
Acute IMH/PAU Before discharge, 1 mo, 3
mo, 6 mo, yearly
CT or MR, chest plus
abdomen
*US Food and Drug Administration stent graft studies usually required before
discharge or at 30-day CT scan to detect endovascular leaks. If there is
concern about a leak, a predischarge study is recommended; however, the risk
of renal injury should be borne in mind. All patients should be receiving beta
blockers after surgery or medically managed aortic dissection, if tolerated.
Adapted from Erbel et al.539
AVR indicates aortic valve replacement; CT, computed tomographic
imaging; CXR, chest x-ray; IMH, intramural hematoma; MR, magnetic
resonance imaging; PAU, penetrating atherosclerotic ulcer; and TTE,
transthoracic echocardiography.
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Dissected aortas also tend to dilate progressively over
time.375,786 Therefore, those with a Type B AoD managed
medically or those with a Type A AoD with a persistent distal
dissection following ascending aortic repair must also un-
dergo periodic surveillance imaging to monitor the affected
aorta for further dilatation. When the dissected aorta is
relatively stable in size, annual surveillance imaging is
usually sufficient. The most proximal portion of the descend-
ing thoracic aorta, just beyond the ostium of the left subcla-
vian artery, is most prone to both early and late dilatation. If
this segment expands to 6.0 cm or greater or if there is rapid
growth, intervention or an open repair may become neces-
sary. Predictors of progressive dilatation or rupture of a
dissected aorta include complete patency of the false lumen787
and a large false lumen size.788 Those with chronic AoD are
also at risk for a second acute dissection arising from the
chronic dissection itself or de novo from undissected aorta.
Those with IMH are also at risk of late complications,
including conversion to a classic AoD and progressive aortic
dilatation. Conversely, in other cases there may be progres-
sive reabsorption of the IMH, and in time the radiographic
appearance of the thoracic aorta normalizes. While this is a
more favorable outcome, such patients remain at increased
risk of late complications as the apparently healed aorta is
prone to the development of “ulcer-like projections and
saccular aneurysm,” which are associated with an increased
risk of late aneurysm formation and rupture.297 Other factors
that predict adverse events are age greater than 70 years,297 a
maximum aortic diameter of 40 mm or greater, and a
maximum aortic wall thickness of 10 mm or greater.298 The
natural history of PAUs remains poorly defined. Certainly
those who present with symptoms of an acute aortic syn-
drome are likely to have increased risk of aortic rupture,
whereas those without symptoms whose ulcers are discovered
incidentally are more likely to have a chronic or slowly
growing ulcer. Those with uncomplicated ulcers are often
treated medically with antihypertensive medications and
close monitoring with serial imaging studies, similar to the
management of a patient with a distal AoD.789
15. Nursing Care and
Patient/Family Education
15.1. Nursing Care of Medically Managed Patients
Nursing care for patients with thoracic aortic disease requires
education to ensure that both patient and family understand
the disease process, the importance of therapy including
control of hypertension and other risk factors,790,791 and the
need for continued follow-up, including surveillance imag-
ing. Because some aortic diseases are hereditary, follow-up
might also include family member screening and counsel-
ing.792 For patients with acute aortic syndromes, immediate
control of hypertension and pain, as well as repeated assess-
ments of symptoms and hemodynamic status, are key
elements.345
Patients transported from smaller hospitals to larger ones
are often alone, without the immediate support of their
families, and will be dependent on nursing personnel for
emotional support and reassurance, as well as clinical and
spiritual care. Family members need to have their questions
answered honestly and in a way they can understand, to be
notified of any changes in the patient’s condition, and to have
access to their loved one(s).793
15.2. Preprocedural Nursing Care
Nurses play a key role in answering questions that remain
after initial explanations by physicians. Table 18 outlines
topics that should be discussed as part of informed consent
prior to an endovascular or open surgical procedure.
15.3. Postprocedural Nursing Care
Patients with a lower acuity level after thoracic aortic
procedures, including endovascular repair, are often admitted
to a postanesthesia care unit for initial recovery and then to an
intensive care unit that can provide frequent monitoring of
vital signs, peripheral pulses, urine output, and neurological
status including lower extremity motor strength and sensa-
tion. Assessment of the skin in the extremities and lower torso
Table 18. Topics of Discussion for Preoperative Instruction
and Informed Consent
Clarification of the intervention or surgical procedure
Length of the intervention or surgical procedure
Potential complications
Endovascular leak
Stroke
Paralysis
Respiratory dysfunction/failure
Renal dysfunction/failure
Myocardial infarction (especially if known coronary disease)
Preoperative preparation for elective procedures
Smoking cessation
Antiplatelet or anticoagulation adjustment
Preoperative testing and instructions for obtaining tests
Chlorhexidine showers or other skin preparation
Intensive care stay and environment
What to expect: monitoring, staffing ratios, equipment
Length of stay
Visiting restrictions if any
Intravascular access
Central venous lines
Arterial lines
Ventilator support and weaning
Lumbar drains
Other lines and tubes
Pain management
Transitional care unit transfer
What to expect: monitoring, staffing ratios
Length of stay
Activity progression
Sternal and other activity/lifestyle precautions
Durable power of attorney for health care
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is performed to look for cyanotic discoloration and skin
temperature changes, which may be signs of embolization.794
Embolization to cerebral vessels is another potential risk of
these procedures, so frequent monitoring of mentation, level
of consciousness, vision, speech, motor strength, and sensory
function in the extremities is required. Thromboemboli to
mesenteric, renal, and peripheral vascular beds may lead to
complaints of abdominal pain or the presence of bloody
diarrhea or vomiting. Flank pain with changes in urine
output might indicate potential renal infarction from
thromboemboli.
The initial postprocedural management focuses on blood
pressure control. Hypertension can result in stent migration
and bleeding from aortic suture lines. Hypotension can be
equally problematic with the potential to impair renal func-
tion and spinal cord perfusion pressure. Hypotension presents
a risk to spinal cord perfusion pressure and requires treatment
with fluids or vasopressors. The risk of inadequate spinal cord
perfusion is spinal cord ischemia, dysfunction, and potential
paraplegia. Any decrease in lower extremity function must be
reported to the physician team immediately as it could
represent the onset of early and potentially reversible paral-
ysis. A typical assessment consists of asking patients to
demonstrate motor strength holding their extended, straight
legs off the bed one at a time for at least 5 seconds,781 with
repeated assessments performed frequently for the first hours
and days after an endovascular or open procedure. An
objective scale that can be useful is outlined in Table 19. CSF
drains are used for many patients undergoing endovascular
and surgical procedures, and the nursing care is critically
important (see Section 14.4).
Any new back or chest pain warrants further investigation
to rule out the possibility of myocardial ischemia or infarction
as well as a potential endoleak. New-onset pain of this nature
requires notification of the physician team for further
evaluation.
A phenomenon associated with stent graft placement is
postimplantation syndrome, which can occur within 24 hours
of placement of the graft. It is characterized by fever,
leukocytosis, and occasionally thrombocytopenia. The symp-
toms, which usually resolve within 1 week, are managed with
analgesics and anti-inflammatory agents.794 Heparin-induced
thrombocytopenia can be another source for thromboembolic
events and may require treatment.
Routine assessment of the cannulation site used to deploy
the graft is necessary. Large sheaths are used to deliver stents
and can traumatize and occlude the femoral or iliac artery.
The postoperative period presents an optimal opportunity to
assess and manage cardiovascular risk factors and to educate
the patient and family on the benefits of risk-reduction
measures. The AHA/ACC Guidelines for Secondary Preven-
tion for Patients With Coronary and Other Atherosclerotic
Vascular Disease409 outlines guides to risk factor assessment,
patient education, and possible interventions (see the online-
only Data Supplement).
Patient and family preparation for discharge includes
emphasis of the importance of medication compliance, inci-
sion care, and the need for follow-up. They must be made
aware of the signs and symptoms of infection, such as
redness, swelling, drainage, and fever. Unusual or severe
pain, change in motor strength or sensation in the extremities,
and sudden weakness or dizziness, which may be symptoms
of new-onset bleeding or changes in spinal cord perfusion,
should be promptly reported.
15.4. Nursing Care of Surgically Managed Patients
Patients who have undergone open repair of aortic aneurysms
or dissection will require more intensive care. A distinguish-
ing feature will be whether the patient had an ascending aortic
arch, or descending thoracic aortic repair. Patients who have
had a dissection or an aneurysm of the ascending aorta or arch
will have a median sternotomy incision. Patients undergoing
aortic arch procedures may also have an incision over the
axillary artery site. Cardiopulmonary bypass is required for
these procedures and can be associated with fluid retention,
electrolyte abnormalities, coagulopathies, and hypothermia.
In addition, patients with aortic arch repairs are subjected to
intervals of circulatory arrest and retrograde or selective
cerebral perfusion. These adjuncts can result in neurologic
dysfunction in the postoperative period.
Patients with Type B aortic dissections or descending
thoracic aneurysms will have lateral thoracic or thoracoab-
dominal incisions. These incisions are often extensive.
These patients will often have lumbar drains that have been
placed to monitor CSF pressure and CSF fluid drainage. The
pressure used as a target for drainage varies but will generally
be around 10 mm Hg. Pressures are checked hourly or more
frequently in the early postoperative period. Care must be
taken to prevent drainage that is too rapid or too excessive to
prevent subdural hematoma formation.746 Any change in
level of consciousness or onset of irritability, confusion,
headache, or pupillary reactivity requires immediate notifica-
tion of the physician team and clamping of the drain.
Neurologic monitoring also involves assessment of lower
extremity motor and sensory function. Any deterioration may
indicate inadequate spinal cord perfusion.
Standard postoperative care of these patients includes
ventilator adjustments, optimization of blood volume, coag-
ulation parameters, and monitoring of other organ system
functions.795–799 Following the transfer of patients from the
intensive care unit, nursing care is focused on pain manage-
ment, progression to independent ambulation, pulmonary
physiotherapy and incentive spirometry, and wound care.
Preparation for discharge is similar to that described for
lower-activity patients earlier in this section.
Table 19. Lower Extremity Motor Function Assessment Scale
0No movement
1Flicker of movement
2Able to bend knee to move leg
3Unable to perform straight leg raise against gravity, but better leg movement
4Normal movement with expected later or demonstrated ambulation
Note: A score of 3 may be an indication for a neurological evaluation.
Adapted from Svensson et al.781
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16. Long-Term Issues
16.1. Recommendation for Employment and
Lifestyle in Patients With Thoracic Aortic Disease
Class IIa
1. For patients with a current thoracic aortic aneurysm
or dissection, or previously repaired aortic dissec-
tion, employment and lifestyle restrictions are rea-
sonable, including the avoidance of strenuous lifting,
pushing, or straining that would require a Valsalva
maneuver. (Level of Evidence: C)
Establishing clear lifestyle goals for patients with thoracic
aortic disease is important in improving long-term health and
reducing the risk of complications. Because regular aerobic
exercise, a low-fat and low-salt diet, and achieving an ideal
body weight are tied to the ability to effectively control blood
pressure, cholesterol, and associated aortic wall stress, pro-
viding patients with clear lifestyle targets is important.
Avoidance of tobacco is critical because it is linked to the
development of thoracic aortic disease and to aortic rupture.
Not using cocaine or other stimulating drugs such as meth-
amphetamine is important as sudden surges in blood pressure
and pulse attributed to such agents have been described as a
trigger for aortic catastrophes.800
The prescription of exercise represents a dilemma in the
management of patients with thoracic aortic disease. Because
it is thought that the sudden increases in dP/dt and systemic
blood pressure associated with physical and mental stress
may be a trigger for AoD in many patients, the concept of
avoiding such stresses makes sense.801 However, maintaining
a regular routine of aerobic exercise has day-to-day benefits
in helping patients achieve an ideal blood pressure, heart rate,
and body weight. Moreover, many patients simply enjoy
engaging in sports such as tennis, basketball, golf, bike
riding, etc. and wish to continue in such activities if at all
possible.
There are no outcomes data, and scant data of any variety
for that matter, to indicate how much exercise is safe or
beneficial for patients with thoracic aortic disease. However,
aerobic exercise, sometimes referred to as dynamic exercise,
is associated with only a modest increase in mean arterial
pressure,802 and AoD rarely occurs during aerobic exercise.
Consequently, most experts believe that aerobic exercise,
particularly when heart rate and blood pressure are well
controlled with medications, is beneficial overall. Neverthe-
less, if patients wish to engage in vigorous aerobic exercise,
such as running or basketball, one might consider performing
a symptom-limited stress test to ensure that the patient does
not have a hypertensive response to exercise.
Conversely, with isometric exercise, there is a significant
increase in mean arterial pressure. When the Valsalva ma-
neuver is used for the lifting of heavy weights, there is a
superimposed increase in intrathoracic pressure, followed by
a dramatic increase in systemic arterial pressure,802 with
systolic pressures reaching 300 mm Hg or greater.803 As a
result, most experts believe that heavy weight lifting or
competitive athletics involving isometric exercise may trigger
AoD and/or rupture and that such activities should be
avoided.804 Working with patients on an individualized basis
to streamline these goals based on insufficient data can be
challenging. For patients who are very much interested in
maintaining some sort of weight lifting program, choosing
sets of repetitive light weights appears to make more sense
than permitting heavy weight lifting.802 For example, instead
of bench-pressing 200 pounds, one might recommend select-
ing much lighter weights in repetitive sets to minimize the
hemodynamic consequences. Patients often ask exactly how
much weight is permissible to lift. Unfortunately, it is not
possible to provide a blanket answer to that question, as it all
depends on the patient’s size, muscular strength, physical
fitness, and how the weight is actually lifted. Rather than try
to define a numerical limit, it may be useful to explain that
patients can lift whatever weight they can comfortably lift
without having to “bear down” or perform the Valsalva
maneuver.
In addition to the physiologic stress of exercise, certain
sports, recreational activities, or sudden stress or trauma to
the thorax can potentially precipitate aortic rupture and/or
dissection. Thoracic stress or trauma can occur during com-
petitive football, ice hockey, or soccer or may result from a
skiing accident, a fall while water skiing, etc. Therefore,
experts often advise patients with thoracic aortic disease to
avoid these types of sports.805 Furthermore, rapid chest
rotational movement while straining or breath holding (Val-
salva maneuver) may be a common denominator in many
patients who develop aortic dissection (ie, basketball, tennis,
golf, baseball bat swing, chopping wood with an ax, shovel-
ing snow, and rapidly lifting heavy objects).
In addition to the importance of setting clear lifestyle goals
with patients with thoracic aortic disease, it is wise to
emphasize the importance of adherence to their medications,
especially to beta blockers and other antihypertensive agents.
Patients who suddenly discontinue their medications because
they fail to obtain a refill or perhaps forget their medications
at home when traveling, may find themselves in a hyperten-
sive crisis with a potentially catastrophic result.
Even patients who are compliant with their medications
may find that their blood pressure may fluctuate between
routine visits to their physician, resulting in months of
excessive hypertension. Therefore, patients may achieve
more consistent control of their hypertension if they regularly
track their heart rate and blood pressure with a home
monitoring system. In addition, by regularly tracking their
weight and activity profile, they can provide their physician
and other care members with accurate data with which to
make adjustments in medication and lifestyle going forward.
In terms of work, patients with thoracic aortic disease
generally can function normally in most types of occupations.
The exception is any job involving heavy physical and
manual labor accompanied by extreme isometric exercise (eg,
lifting heavy boxes in a stockroom, carrying furniture up and
down stairs). As with the heavy weight lifting described
earlier, this type of unusual sudden stress on the aorta may
predispose to a triggering of either aortic rupture or AoD.806
Therefore, when patients have a vocation in which such
extreme lifting might be required, it is important to discuss
the details of their daily job responsibilities and to prescribe
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avoidance of activities that might put them at risk. In some
cases patients can readily avoid such heavy lifting on the job,
but in many cases a letter from a physician explaining the
restrictions may be required.
Finally, patients with thoracic aortic disease should recognize
that aortic disease is usually a lifelong condition that puts them
at future risk for acute aortic syndromes. Even those who have
received advanced surgical or endovascular therapy must under-
stand that their aortic disease has not been “cured” by the
interventions. Educating them about what to do in the event of
the sudden onset of chest, back, or abdominal pain or the sudden
development of an ischemic complication (ie, neurological or
limb) and the critical nature of getting to an emergency depart-
ment promptly is of the utmost importance. Similarly, those who
live with or care for such patients should understand what action
needs to be taken should concerning symptoms arise.
17. Institutional/Hospital Quality Concerns
17.1. Recommendations for Quality Assessment
and Improvement for Thoracic Aortic Disease
Class I
1. Hospitals that provide regional care for patients with
acute sequelae of thoracic aortic disease (eg, proce-
dures for thoracic aortic dissection and rupture)
should participate in standardized quality assessment
and improvement activities, including thoracic aortic
disease registries. Such activities should include peri-
odic measurement and regional/national interfacility
comparisons of thoracic aortic disease–related proce-
dural volumes, complications, and risk-adjusted mor-
tality rates. (Level of Evidence: C)
2. Hospitals that provide regional care for patients with
acute sequelae of thoracic aortic disease (eg, proce-
dures for thoracic aortic dissection and rupture)
should facilitate and coordinate standardized quality
assessment and improvement activities with transfer-
ring facilities and emergency medical services teams.
Such activities might include:
a. Cooperative joint facility meetings to discuss oppor-
tunities for quality improvement and
b. Interfacility and emergency medical services team
comparisons of pretransfer care based on available
outcome data and future performance measures
developed in accordance with this guideline. (Level
of Evidence: C)
Quality assessment of outcomes for thoracic aortic disease
has been ongoing. Creation of one or more standardized
thoracic aortic disease registries may significantly improve
capacity for quality assessment and provide outcome results
and meaningful performance benchmarks. IRAD is an exam-
ple of such a registry and consists of 12 large referral centers
in 6 countries and contains information on 290 variables,
including demographics, history, physical findings, manage-
ment, imaging studies, and outcomes.227 Commitment to data
collection, analysis, measurement, validation, and reporting
should be factored into the payment structures, as all of this
will consume time, effort, and infrastructure to do it well.47
Moderate evidence supports “evidence-based referral”—
that is, limiting specific procedures only to hospitals and
physicians with experience, expertise, and capacity to take
care of complex problems, especially those requiring special-
ized surgical skills and support teams. To date, there is no
explicit evidence supporting such a recommendation for
acute thoracic aortic diseases,807 although this evidence exists
for infrarenal aortic surgery.808–811 Data courtesy of the UHC
Clinical DataBase/Resource Manager for 2006q4 through
2007q3 indicates that for patients with:
● Ruptured thoracic aortic aneurysm:
30% transferred from a different hospital
34% were admitted from the emergency department
19% referred from a clinic or physician’s office
14% transferred from a skilled nursing facility or another
nonhospital facility
3% other
● Thoracic AoD:
28% transferred from a different hospital
35% were admitted from the emergency department
23% referred from a clinic, physician’s office, or health
maintenance organization
9% transferred from a skilled nursing facility or another
nonhospital facility
5% other
Performance measures and quality metrics811a have been
developed to evaluate quality of care for many areas of
cardiac and vascular disease,5,812–814 but none have yet been
established for patients with thoracic aortic diseases. Possible
domains of quality to assess could include procedural vol-
umes (facility and operator), outcomes (eg, risk-adjusted
mortality, readmission, or complications), time to diagnosis
and intervention, and structural measures (eg, distance to
nearest referral center, services available, and contingency
planning).815 The well-established evidence base for the
regionalization of care for STEMI patients816 may serve as a
model for similar initiatives for patients with thoracic aortic
disease (Table 20).
Claims have been made that some centers either do or will
limit referrals of critically ill patients that may adversely
impact hospital mortality rates, although there are no discrete
data to confirm or disprove this behavior.817 Hence, bench-
marking and profiling efforts must recognize and account for
the most physiologically precise severity-of-illness informa-
tion and accurate and appropriate case-mix adjustments;
otherwise, referral centers may have an incentive to refuse
care for patients who could benefit from being transferred to
their facility.818
Effective medical record systems are being developed and
can enhance communication and provide caregivers with
clear documentation of a patient’s course and medications, as
well as plans for future.819,820
17.2. Interinstitutional Issues
Acute AoD or other acute problems involving any portion of
the aorta are life-threatening conditions and require placing
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the patient in a location where all appropriate diagnostic and
therapeutic measures are available. The minimum require-
ments for the care of patients with acute AoDs include
imaging with CT, echocardiography, and angiography; the
availability of cardiovascular surgery including cardiopulmo-
nary bypass and endovascular interventions; an intensive care
setting that allows continuous monitoring of blood pressure
and intravenous management of blood pressure; and physi-
cians with personal experience and expertise in the manage-
ment of patients with acute AoD.820
Transfer of patients with acute AoD from one institution to
another represents a period of danger to the patient and must
be planned and carried out efficiently. It is incumbent on the
transferring institution to provide prior physician-to-
physician communication, to stabilize and maintain blood
pressure control throughout transport, and to send copies of
imaging studies.821
Because patients with acute thoracic aortic diseases present
in any emergency department or primary care setting, there
are opportunities for retrospective and comprehensive quality
review. Typical areas of quality assessment could include the
evaluation of timely detection in centers that typically are not
equipped to manage such patients.
Retrospective evaluation of patients with thoracic aortic
diseases, especially those for whom diagnosis was delayed or
missed, is critical for learning about how best to more rapidly
and effectively identify future patients with life-threatening
thoracic aortic aneurysm and/or dissection. Independent ex-
ternal review of poor outcomes may be necessary and
appropriately constructed using de-identified clinical records
so that bias is not introduced into the evaluation process.
With the dissemination of this guideline, it is hoped that
these practice standards can form the basis for more wide-
spread use of a data registry for quality assessment and
improvement for patients with thoracic aortic disease. The
goals of such a data system would be to establish an extensive
population of thoracic aortic disease patients with the intent
of evaluating clinical effectiveness. Domains could include
volume and outcome relationships, process of care patterns,
development of standardized performance measures (struc-
ture, process, and outcomes), and facility and operator feed-
back quality data systems. It may also be possible to use
existing data that use relevant ICD-9 codes (Table 2A and
2B) and appropriate risk-adjusted methods to evaluate mor-
tality and complications.
18. Future Research Directions and Issues
The writing committee believes that there are many opportuni-
ties for additional meritorious research in thoracic aortic dis-
eases. Emerging research appears promising for the following
areas, in addition to much needed research in other areas.
18.1. Risks and Benefits of Current
Imaging Technologies
There is a great need to balance the rapid identification of
patients with acute AoD or rupture, and the relatively infre-
quent occurrence against the potential risks of radiation
exposure and contrast toxicity incurred by current imaging
methods, for the millions of patients who present with chest,
back, and/or abdominal pain. The rapid and correct diagnosis
of acute thoracic aortic diseases must not impose delays in
treatment of patients with acute MI. Additionally, screening
and serial radiographic imaging of younger patients clearly
exposes those individuals to a risk of later radiation-related
diseases. Clinical studies of safety and efficacy of screening
protocols using current imaging methods to correctly identify
patients who will benefit from surgical, endovascular, and/or
medical intervention are needed.
18.2. Mechanisms of Aortic Dissection
The year 2010 is the 250th anniversary of the death, attrib-
utable to AoD, of King George II of England, whose last
moments were memorably described by his valet.822 Al-
though a number of conditions are known to be associated
with dissection, such as hypertension and old age, the cause
of spontaneous AoD is still unknown. Is an intimal tear
followed by a dissecting hematoma,823 or does an intramural
hemorrhage ruptures into the lumen causing an intimal
tear?824,825 In approximately 4% to 10% of dissections, an
aortic intimal tear is not found. Bleeding from the vasa
vasorum is hypothesized to be responsible for the intramural
hemorrhage, but little is known about the microstructure of the
vasa vasorum walls; changes in the vasa vasorum in response to
aging, hypertension, and inflammation; and relation of extracel-
lular and intracellular metalloproteinases to protein turnover in
the walls of the vasa vasorum. Research into these questions
may shed light on the pathogenesis of dissection and provide
opportunities for prevention and treatment.
18.3. Treatment of Malperfusion and
Reperfusion Injury
Malperfusion of the gut, spinal cord, kidneys, and lower
extremities doubles the mortality of AoD.247,826 New treat-
ment strategies for malperfusion and reperfusion injury are
needed to improve the dismal prognosis of patients with acute
dissection and malperfusion syndromes.
Table 20. Standardized Transferring Facility Assessment,
Communication, and Documentation for the Following Domains
● Blood pressure control for hypertension
● Heart rate control for tachycardia
● Hemodynamic instability
● Blood volume
● Cardiac ischemia
● Neurologic ischemia
● Renal function
● Mesenteric ischemia
● Peripheral arterial pulses and perfusion
● Activation of receiving team
● Imaging expectations and communications
● Timeliness and efficiency
● EMS characteristics of transferring facility, including requisite personnel,
requisite in-transport equipment, including catastrophic resuscitation
capabilities, in-transfer contingency planning, weather conditions,
estimated transfer time, etc.
EMS indicates emergency medical services.
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18.4. Gene-Based Mechanisms and Models
18.4.1. Aortic Disease Management Based on the
Underlying Genetic Defects
As genes are identified leading to an inherited predisposition
for thoracic aortic disease, it is becoming increasingly evident
that the clinical management of thoracic aortic disease asso-
ciated with different gene mutations may differ. For example,
mutations in TGFBR1 and TGFBR2 predispose patients to
aortic dissection at an aortic diameter of 5.0 cm or less,
leading to the recommendation that the aorta be replaced at
diameters as small as 4.0 cm. As genes are identified that can
cause predisposition to thoracic aortic disease, clinical studies
are needed on these patients to determine their optimal
management.
18.4.2. Biomarkers for Acute Aortic Dissection
A quick laboratory test with at least a high sensitivity, if not
specificity, could lead to fewer missed or delayed diagnoses
of acute AoD. None currently exists. D-dimer has been
proposed as a screening test for acute AoD (see Section
8.6.1.2). A prospective study regarding the safety and effi-
cacy of such a strategy is needed.
18.4.3. Genetic Defects and Molecular Pathway Analyses
Recent studies in the mouse model of Marfan syndrome and
the identification of TGFBR1 and TGFBR2 mutations sug-
gests that alteration of TGF-Beta signaling is involved. The
identification of mutations in 2 components of the contractile
unit in smooth muscle cells, beta-myosin heavy chain and
alpha actin, has indicated a role of maintenance of smooth
muscle cell contractile function in preserving aortic structure and
preventing these aortic diseases. Further studies identifying
defective genes and analyzing pathways using human tissues or
mouse models will be the basis for understanding the molecular
pathology and will be the first step toward development of
rational medical therapies for thoracic aortic disease.
18.4.4. Clinical Trials for Medical Therapy for
Aortic Aneurysms
Recent studies in the mouse model of Marfan syndrome with
aortic disease similar to that seen in humans showed the
treatment with losartan normalized aortic root growth and aortic
wall architecture.6 Doxycycline, an inhibitor of MMP, signifi-
cantly delayed aneurysm rupture in this mouse model. A clinical
trial is ongoing in patients with Marfan syndrome under the age
of 25 years to determine if losartan delays aortic progression.
More aggressive trials (other agents, 2 or 3 agent therapies)
based on the results in mouse models to prevent the onset of
aortic disease in individuals genetically predisposed or to delay
the enlargement of already formed aneurysms are needed.
18.5. Aortic Atheroma and Atherosclerosis
Identification and Treatment
As noted in Section 11, there is a need for research into the
mechanistic aspects of aortic arch atheroma in causing
embolic events. Additionally, for those patients with known
aortic arch atheroma, a randomized blinded controlled trial is
needed to test currently available treatment options, both
medical and surgical, to prevent embolic vascular events.
The value of current imaging (MR, CT, TEE) technologies
to identify and quantitate risk for patients with aortic arch
atheroma is unknown.
18.6. Prediction Models of Aortic Rupture and the
Need for Preemptive Interventions
We need to have models or indices that are better than just
aortic diameter to predict rupture and to better determine the
best timing for surgical or endovascular intervention. Since
the advent of CT and MR scanning, a massive amount of
radiological data has accumulated with multiple studies in
individual patients that could be linked to clinical data and used
for this purpose. The evidence base regarding the clinical course
of patients with Marfan syndrome is more robust than for
patients with degenerative aneurysms and other thoracic aortic
conditions. An ongoing registry similar to that used for patients
with Marfan syndrome would be a place to start.
18.7. National Heart, Lung, and Blood Institute
Working Group Recommendations
The National Heart, Lung, and Blood Institute Working
Group on Research in Marfan Syndrome and Related Disor-
ders827 posted a summary of recommendations for future
research which apply to the broad range of patients with
thoracic aortic disease. The importance of multidisciplinary
teams and collaborative research models were stressed:
● Existing registries should be expanded or new registries
developed to define the presentation, natural history, and
clinical history of aneurysm syndromes.
● Biological and aortic tissue sample collection should be
incorporated into every clinical research program on
Marfan syndrome and related disorders and funds should
be provided to ensure that this occurs. Such resources, once
established, should be widely shared among investigators.
● An Aortic Aneurysm Clinical Trials Network should be
developed to test both surgical and medical therapies in
patients with thoracic aortic aneurysms. Partnership in this
effort should be sought with industry, academic organiza-
tions, foundations, and other governmental entities.
● The identification of novel therapeutic targets and biomarkers
should be facilitated by the development of genetically de-
fined animal models and the expanded use of genomic,
proteomic and functional analyses. There is a specific need to
understand cellular pathways that are altered leading to
aneurysms and dissections, and to develop robust in vivo
reporter assays to monitor TGF-Beta and other cellular sig-
naling cascades.
● The developmental underpinnings of apparently acquired
phenotypes should be explored. This effort will be facili-
tated by the dedicated analysis of both prenatal and early
postnatal tissues in genetically defined animal models and
through the expanded availability to researchers of surgical
specimens from affected children and young adults.
The writing committee enthusiastically endorses these
concepts.
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Appendix 3. Abbreviation List
AAAabdominal aortic aneurysm
AoDaortic dissection
CADcoronary artery disease
CSFcerebrospinal fluid
CTcomputed tomographic imaging
ECGelectrocardiogram
GCAgiant cell arteritis
IMHintramural hematoma
INRinternational normalized ratio
IRADInternational Registry of Acute Aortic Dissection
MEPmotor evoked potential
MImyocardial infarction
MMPmatrix metalloproteinase
MRmagnetic resonance imaging
PAUpenetrating atherosclerotic ulcer
SSEPsomatosensory evoked potentials
SSFPsteady-state free precession
STEMIST-elevation myocardial infarction
TAAthoracoabdominal aneurysm
TEEtransesophageal echocardiogram
TIAtransient ischemic attack
TRAtraumatic rupture of the aorta
TTEtransthoracic echocardiogram
UHCUniversity HealthSystem Consortium
Hiratzka et al 2010 Guidelines on Thoracic Aortic Disease e369
D
ow
nloaded from
 http://ahajournals.org by on August 16, 2018
